var title_f3_10_3232="Contents: Pediatric trauma";
var content_f3_10_3232=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?10/42/10926\">",
"       Adult and Pediatric Emergency Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric trauma",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric trauma",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Abdominal trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/44/13001\">",
"           Hollow viscus blunt abdominal trauma in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/42/4777\">",
"           Liver, spleen, and pancreas injury in children with blunt abdominal trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/62/33768\">",
"           Overview of blunt abdominal trauma in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Burns",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/10/44201\">",
"           Emergency care of moderate and severe thermal burns in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/19/4410\">",
"           Environmental electrical injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/38/37479\">",
"           Treatment of minor thermal burns",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Child abuse",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/13/32985\">",
"           Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/19/40249\">",
"           Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/7/20602\">",
"           Child abuse: Eye findings in children with abusive head trauma (AHT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/2/19497\">",
"           Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/30/13802\">",
"           Orthopedic aspects of child abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/19/24890\">",
"           Physical abuse in children: Diagnostic evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/54/26473\">",
"           Physical abuse in children: Epidemiology and clinical manifestations",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/11/40119\">",
"           Approach to the initially stable child with blunt or penetrating injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/32/12807\">",
"           Chest wall injuries in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/12/7367\">",
"           Classification of trauma in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/30/7658\">",
"           Emergency ultrasound in adults with abdominal and thoracic trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/31/11767\">",
"           Overview of pediatric injury prevention: Epidemiology; history; application",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/53/35669\">",
"           Straddle injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/16/29962\">",
"           Trauma management: Approach to the unstable child",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/25/3477\">",
"           Trauma management: Unique pediatric considerations",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Genitourinary trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/11/35000\">",
"           Scrotal trauma in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Head and neck trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/26/8616\">",
"           Acquired torticollis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/25/41368\">",
"           Approach to the young athlete with neck pain or injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/25/29079\">",
"           Assessment and management of auricular hematoma and cauliflower ear",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/46/32489\">",
"           Evaluation and management of dental injuries in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/29/5593\">",
"           Evaluation and management of middle ear trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/7/32889\">",
"           Evaluation of cervical spine injuries in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/9/4250\">",
"           Initial approach to severe traumatic brain injury in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/35/10808\">",
"           Intracranial epidural hematoma in children: Clinical features, evaluation, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/61/11222\">",
"           Intracranial epidural hematoma in children: Epidemiology, anatomy and pathophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/49/29464\">",
"           Intracranial subdural hematoma in children: Clinical features, evaluation, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/4/21575\">",
"           Intracranial subdural hematoma in children: Epidemiology, anatomy, and pathophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6615\">",
"           Jaw fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/38/12906\">",
"           Minor head trauma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/50/33575\">",
"           Nasal trauma and fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/34/8745\">",
"           Open globe injuries: Emergent evaluation and initial management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/35/9783\">",
"           Orbital fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/30/23016\">",
"           Oropharyngeal trauma in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/24/13704\">",
"           Skull fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/53/4951\">",
"           Spinal cord injury without radiographic abnormality (SCIWORA) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/10/38057\">",
"           Traumatic hyphema: Clinical features and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/21/17750\">",
"           Traumatic hyphema: Epidemiology, anatomy, and pathophysiology",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hip",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/42/23209\">",
"           Slipped capital femoral epiphysis (SCFE)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ophthalmologic trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/25/4502\">",
"           Conjunctival injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/8/39045\">",
"           Eyelid lacerations",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Orthopedic trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/49/24345\">",
"           Ankle fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/9/5273\">",
"           Approach to the young athlete with acute knee pain or injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/34/29223\">",
"           Approach to the young athlete with chronic knee pain or injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/36/29251\">",
"           Capitate fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/33/8726\">",
"           Causes of chronic knee pain in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/60/38855\">",
"           Causes of chronic wrist pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/20/31050\">",
"           Clinical features and management of ankle pain in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/41/23190\">",
"           Clinical features and management of foot pain in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/6/28775\">",
"           Clinical features and management of heel pain in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/8/42120\">",
"           Diagnosis and assessment of distal forearm fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/5/7257\">",
"           Distal femoral fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/9/19607\">",
"           Elbow anatomy and radiographic diagnosis of elbow fracture in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/25/22937\">",
"           Elbow injuries in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/8/22663\">",
"           Epicondylar and transphyseal elbow fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/46/19175\">",
"           Evaluation and management of condylar elbow fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/22/25961\">",
"           Evaluation and management of supracondylar fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/23/14711\">",
"           Evaluation of foot and ankle pain in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/43/32440\">",
"           Evaluation of wrist pain and injury in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/52/40776\">",
"           Femoral shaft fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/6/26726\">",
"           Fibular fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/28/15815\">",
"           Field care and evaluation of the young athlete with acute neck injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/26/17828\">",
"           First (thumb) metacarpal fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/16/35079\">",
"           Foot fractures (other than metatarsal or phalangeal) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/40/20104\">",
"           General principles of fracture management: Fracture patterns and description in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/25/9620\">",
"           Hamate fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/14/31975\">",
"           Hip fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/17/4376\">",
"           Initial evaluation and management of rib fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/14/14569\">",
"           Initial management of distal forearm fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6615\">",
"           Jaw fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/61/24531\">",
"           Lunate fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/9/22675\">",
"           Metacarpal base fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/11/22707\">",
"           Metacarpal head fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/4/13382\">",
"           Metacarpal neck fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/5/20565\">",
"           Metacarpal shaft fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/35/14903\">",
"           Metatarsal and toe fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/20/12614\">",
"           Metatarsal shaft fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/21/11609\">",
"           Midshaft forearm fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/13/30934\">",
"           Midshaft humeral fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/50/33575\">",
"           Nasal trauma and fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/35/9783\">",
"           Orbital fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/8/32905\">",
"           Overview of acute wrist injuries in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/49/4886\">",
"           Overview of carpal fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/8/23689\">",
"           Overview of cervical spinal cord and cervical peripheral nerve injuries in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/6/2149\">",
"           Overview of metacarpal fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/49/11033\">",
"           Overview of musculoskeletal neck injuries in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/19/23866\">",
"           Overview of stress fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/53/42838\">",
"           Overview of tibial fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/42/21157\">",
"           Patella fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24581\">",
"           Patellar dislocations in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/22/37218\">",
"           Pisiform fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/54/873\">",
"           Proximal fifth metatarsal fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/29/3546\">",
"           Proximal fractures of the forearm in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24855\">",
"           Proximal humeral fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/51/42807\">",
"           Proximal tibial fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/40/38532\">",
"           Radial head subluxation (nursemaid's elbow)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/51/1848\">",
"           Scaphoid fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/52/28485\">",
"           Sesamoid fractures of the foot",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/24/13704\">",
"           Skull fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/50/43812\">",
"           Stress fractures of the humeral shaft",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/61/33747\">",
"           Stress fractures of the metatarsal shaft",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/4/19527\">",
"           Stress fractures of the tibia and fibula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/46/24296\">",
"           Tibial and fibular shaft fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/3/36915\">",
"           Trapezium fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/39/33394\">",
"           Trapezoid fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/50/28455\">",
"           Traumatic causes of acute knee pain and injury in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/61/4056\">",
"           Treatment of knee injuries in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/55/36723\">",
"           Triquetral fractures",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thoracic trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/63/27640\">",
"           Initial evaluation and stabilization of children with thoracic trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/26/3495\">",
"           Intrathoracic injuries in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/38/29285\">",
"           Pulmonary contusion in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/53/40793\">",
"           Spontaneous pneumothorax in children",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-A80D153BDA-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f3_10_3232=[""].join("\n");
var outline_f3_10_3232=null;
var title_f3_10_3233="Cesarean scar preg B";
var content_f3_10_3233=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cesarean scar pregnancy at 6 weeks - transvaginal ultrasonography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 283px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEbAXYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigApyMAckZptFAEzyIwwEwahoooAKKKKACiiigAopyKzsFQFmPQAc102jeD7y9uI1u5I7RGGfmOXPXjHrx3oA5etrQPDWo63dRw2sQQMQN8p2qM9/U/hmvV/h54Z0RdW+wNp7XN47hY5JyN4OTxjoK1NdsZNC1gMW+8c/KANuCMgCgDwLULObT76e0uk2TwuY3X0IOKr17h8aPCUeqaJbeL9FjZ3VRFqKgEnIwFk9Bxwa8PoAKKKKACinxRvLIqRIzuxwFUZJ/CuhXwXrhAU20KXTYK2b3Ea3LD2iLb/TjGTngHnABzdFS3NvNazvDdRSQzIcMkilWH1BqKgAooooAfDG80qRRqWdyFVR3JrofE/g3VvDsgW8SGVdqkvBIHAJGcEdRjkdOo4zXafBrw0sBbxbrED/YrQn7ICh+eYYw/uo6fWpvF17Le6tJJIGMkh3ES8FR24+lAHkNFdbqOmwTgHCq46lcAYrnp7CWMkqMpnAyeTQBTopWBUkMMEUlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACmkqZLeRlDBSFPc1saPpcElyFu9xUjIbopoAxoYZJm2xIzH2HSrlrpryAl89cBV610RUWkW2EjaBw4HfNLbhhFJIF+bqCPWgBdP0+NXWGOEKez9Dn3rUj3W4U3G9WBG1hzg59aoRzuSCDhTw27rmta3mWeJQxVgMZU/xD1oA19Ou54L2O9gkZph83mLw3X+dd1rbx63psFyjxyTOFWQkHKMOxH1rzlFuNOaIdQx3KG4DD0rqNIurceXehm4b95ED146jNAFnwrr0mi6s9pqkYNvIPLmjcYDqQe3pXCfFP4Xz+Hy+saAwvfD8oEoaM7mt8k/Kw64HrXXeMrNob9ZWYNDMm+Jjzgf5zV/wl4svtEjaEx+fZupRlkXhlPUfSgD5xqxp5thf2xv1kazEi+csRAcpn5gpPGcZxXv3iX4Y+G/Fyzaj4Vvl0y+YjdZtH+5ZsDhem3kH169q8b8R+C/EPhx2Gq6VcxRDpOqF4jzjhxx1FAHQeN7658MX72nhdbew0O7QT2l3ZqfMuYj0YzMS4I5VlDAAgjHXPAPI7ymR3ZpCdxYnJJ9c1uaF4mutKs5NPuLa21DSpH3yWV2m5Q3ALIwwyNgDlSOgzmrx1LwU0gkbw1rSngmOPWUEee4Gbctj/gRPvQBf8DXuo+JNXs9G1VbbUtMUmSeTUBk20C8uwmyHQADOA2CeMHJB5XxH/Zv9vX40ISjSxMwtvObLbM8EmtHVvFU91pjaVptpbaVpDsHe2tgS0pHQySNlnx1wTgdhVfw94V1zxDcLDpGm3NwScFwhCL9WPA/OgDEruvh74AuPEbLqGov9i0GJj5twcbnwM7UGec9M9v0rs9D+GmieHEjvfF+ox3l4uGTTrc/KWGOHbnj271Y1/xBd6gRCnlW9rEAkUMI2rEvYACgCfxXr0c8UNjpyfZ9Ns0EMESE42j19T9a5WdmkjeSbdI56sTzVyaNvlK5KHgkj/Oaz2EhuAoUqg5B9TigCtLbFlPykBgQvfms+ayaOJfMjEjnnk9DWpPL9mdArEMxO1SRnJ61VlcsIzvxJ/dzkD3zQBkXdukkaqsasM4x6VkTaa28iI8/3Sa7BmVp4WZSRkZUDGMDrVTTrVNS1eFOFy+cjqSTQByl3p13aRpJc28scb/dcrwfxqpX01Y2t49xHY21pF5LDy5opjuVhxnPYcVx3jzwRoM2s3Q00f2dtAJKtujL7cthewz70AeLUVq6loV5YIJGQSQt0eM5/Mdqy+lACUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFWbKxub6VY7WF5GJx8o4/E0AVqcqljhQSfYV2tj4Glil/wCJrOikAN5UZySO+T/hW9eWljp9m0ej28QAXJYnLN6jJ9qAOCh0C7aBJ51EUTHAz94/hTrq0TTbtQv7xGHVhk13GnC2vdLbznZVTlB6c1k+JYN9usiIrJG2SQOe1AGBGCY5GHzRL3PYVf0GcTvBaSnGCQWHdc8H8Ku6Dpfm2NwsrbVccN/dz0z7VWtdPuLa5EyROwiOGK+lAFrVLGSyaCQ4ePJ3Bec4OQRVG7ukN08kAdYpCDtx91vSujieMsS5Vo9uVVuMGq8FlazSMu7CHlHx0b0NAGHA7PMUSRtpwSRWo6MJBslGBwWHH6U64smtbjegTYRkEHqanadLgBnVEZvvHGCaALEOrRTRi2ulyR0btV+C4kinjeOTMCnoF7e1cvK/lzhWCrt9BkNmr1ldGSMp8wZD0HQfhQB3kWowX9gtvcMJPJGIwc5HNSLJp25oZXZCR+7ZQdufxNcPDNJG5+zu4duiZ6+ta1tMJ0ZJFBkUA7W6CgDoW82NEaznIAOSEPzAevpW/o/i+/sFjjvZ2uLcceW6bgD34PrXI6deT2gcWwKgD7kibgR7H8asC5vLnIuInRG6FUGM9sGgDe1HUfBeoyMdR8K2E5zu3BDExJHJOwimQ23wvMTB/BjeceQDcuFAPTo+a567MVyjKwLypyNhHy/U96oNbN5yebHKAwG1t2KAOgNx4Us5GfSPDGm2bHGfOzN06ffJx+FQ6j441B1ZLeYRKQRsgUKuPoKwngXysYkLE8ZHBH1q3baKZPMWYRQMgySzY4/nQBmmee7JE245PzYOTV62s7aOEz3OBtGAM8cdzVsWlnBGEtrlQWGN2SzEZ7VDe2difLSOSR4+0bPwPXNAGebibVGjtrBJFjdiAyrliR6U65jtoZJIonb93jI6PnHP61di/tFp9lqYrW2iGY9i849j6060trSxeUSw+eDjzJD949zigDitQR5ZeNzyEnG7sK14NLlXT1eXaEAyDkDFbZiaCWSa2jjXfggNh2A6jnHFZOt3ovGVJrhEjiOzbHj+ffNAFSZonhJgOGjjKyOPU1qfDvR4bO+XVLxh5aMGRWOOfeuYjihnaVI3aONm4Y96szmW2t08uaTYxIXnjNAHrN34jtxouofZMI5zlnblx6149qviSWeVnkclzkA+g71Rvbq8jU2+5sNjcOv4Vk3VlcMJXweCOox+FAFxdZZyI8kIOlTy2VreRjzAFl3hd68cYyfrXOvDJE3zA7gcYqSC9lScEsSOmKANDUfDtxbBnhIkjwGAPDYP/wBasR1ZGIYEEdjXrmnWq6toouFZdkcf7wk9M9BXMXOkKTI0qh02nBPY9qAOIorTu9OCzlYGwPRqoSwyRHDqR70AR0UUUAFFFFABRRRQAUVJBFJPKscKNJIxwqqMkmt2x8K38+43K/ZVUZIkGG/KgDn62dG8Nanqrjybdo4sgGWX5VGfr1rt7LwvYWCQOELzgfM0vPUcEDpXUIsiWUEkmTGSASPQEZ/L+VAHG2ngy001N+oH7XMCQYxlUGCPTk//AF66a2lt9Otz9jSNUYEiMDpV29aPfNFG670O9Se/Y/oRXLmN45zK4AEbDcvbGeaAJ5r6RrvzJHAdh8uemCOlc39pjt55DMx2luBnpWjqabZ3RMtERlO+M9q5q6iJh2zq24HBz1+tAG1aNJHC32RsxSN8yH+E/wD16uwQzW9m7XALRsSkqEdV7EfSsTQrtrSQhjvjYD6j0P4V2+p6jbrokhUKsiANg/xAjBBoA5/SZYVgYM2+MAo4HYdj9Kr3Wti0jMSSjHTAPUVyt9fFbqQ2bOkbDGD1+lZ7uznLHJ9aAOiuteEisu35hx07VPY+IUji24VD0bPOa5SigDuDrVpeYWSRVb+H/A1PND+5fystCwJGOSp9K4CtvRtdls2CXH72AjGD1AoA6WJoZFBCnIXGD1+tJaxNah5sCTvilmurNoUmtlDxdzjJ/GpY76zlVVKuBnIA6mgCbTr6GcK0rMkyA4z1P0p8ssclyGYmPPccg/WqEbpJNiMLuXja3C1fjjZY5Nzrs6kEcD6UASpdTRlf37Ki5AI5H0q59pl+wMJJsjcMEN2+lc6rvKrorZAGRz1+lAnDLtdcMuQ27jNAGtkW0UciEEtknIz+YrTTW7c6dGY5ZIrn7rSAcEVzfks/zpLlVGSN3b2FV4Z42Pk8bzltzKeTQB1MEpkkVYl+1DG7G4Dn3re1BH2F9TW2tZ8ABVYOSNvGcGuBtiWd9rFyAACcggYrWtrkxxES7HZlwQy/d/PvQBbgtFgy7SLM+Rj5uB9atWkduJ0muUhZFYEoTtDfj1rEkmkkQrHld/p0OKhG2Dc8xVs8YVs80Adjc38AndrHZErA5WPO0Z7ZPJrn5b+KIEEspVsk1mTz37wAQhgCODToGg0y387UCJ7pvn2v2xQBqTvqN6CkSFPMC8ZxkHtVDU7KzsZd11hXQbgqnIB9KxbrxdfPO5TEaN7dB7VkyXkt1K0kkhkbHG7igDrNOkjuyxMOFTksF4Ax1qvcS2Pyb3VyDwgb361hLczx2ZWKRlU4Dgc5qaz07zrX7RNGViQ5Lk4zQBtwWNpPKr/aBljvPGBTZYLcKvlyljnPTOTWLdu80oRHAUjCgHAAq3pe+0jnnbayREAMf4m9h7UAVdQt1WR/NUqJBtDHt9KzZ9G2IzxseDxmrV5qr3dwHeMbM7zuPb0FOS5L2E7TbvPJLY7c9BQBe0vUJ7DSYrSMlgzeY4B9On867W902Kbw5pwtz5lyw82cjoGJwB+FeeabKVjBcbmbgV3Olakyaa1ug2lvkjz2z1Y/hmgDj7m0xdSFlPyBju9fSoPsojgUzEEE5INekR6dZ6jKltEB5cSgyyevt/WuR1y1ha+mjU/uFPGPrQBzMmiPLB56AoHJKDHUZ4rKu7Ka1fbIufcV7DoMFtcQz30gAtbRRGno0hHA/AZNcLrFqbi/fbwHkyfpQBx1Fbup6aIrUzkYP3j7DsKqNpFx9jFwm1l6lehoAzaKUgqSCCCOoooA+hNC0vSNEWeOzs4kkAKSSdWPoQT+HTise9aKfUJFDZDoCM1Xe5mcRyJJhipRwe5HT9KrWyS3DOYhmWEbwO/HUUAa/liawlhUlZocFCe6+hq1p00smnRW7lTGSSM9VOcGtLRbeG5tpp1H3V3g+qnqv86kk0kRXEYb5MOro46OpoA4/W4vsVwyzBkkQ4Ge61kx3m6Vg5yh4YV1nxBIGrEnEtuqgKw5yvofcVxcyRyWpkiOHHyt/Q0AWRbHLvGS8ajOB12+o+lZ4sZru5w43Bv4h6HvVvSJpbRiH+bHp2zXW6TZrNDGbVC259pXHIPtQByEXh5/OaKT5XHOMda5rXtReSVoMY2DYefvDtXsWuwxW1ilzLkTKCAwHBB9fQgivCNYbdqVwwOQWJzQBTNJRRQAUtJRQAuKKBSUAXdNv5LKXg7om4ZD0Irrre2sL21+0Wzsp/uZ5BrhKu6ZfPYXCyL8y917GgDrYJAIz50blicbh3rYsoTdxOoli2ouTuOCKzLK8s9QiBgPkyN95ev41ZZhI/zwtmMbQ44B96AIJNNeIltyMAcgKenuKguYnjJK/MWPDZzuq3/Z87HbG7KGG4knIpv2Z7ed1uNuFHAGetAFG2mJmQupG3rnrio9RSSG93x5YN0yvQVcjIJ3SFi56ZHFRS+ZuiJyjg4JAzmgB2lznLExEuvuBj3qaeWZrg7zuwOc4IqO6jR4fmRhIwzt5wTVR5ZbaTiNjIFGc9BQBemDIvDHLDIUdKkgvUgRftESysTwq4yfxrLTU5WnIEW6THTHNamlaaL25aS5/doi7sLyxNAFebXZFYpAwiYdlGTmqNr9sui7pFvdwfv5NdQljaLKbmJB5inG1gCR+NdBoNtcSBZLJYyCRgMo2j3NAHN6R4NuboDzm/eyY2oBgAfWtK/8IRWlu8NokV1Ih/ezR5Kg+hY9ce1dDO11bzTIzGV5j87twSPr2FZMlrfyTCNG8u3ZuADhT780Acomk+RMXdFkA4A6CtG+sBJtS6volQLuESAkA+n1rUv/ALVuBuSTbL8qDIBY+tZE1oXnAuQE5B+90HpigDLbT1aTdv2CLqcdak1OGJLaGOOUM6oflAwBn+tP1cLFcHyQ7qBkgHge1Ps1MrxMYi7ueSxwB6UAZVvodx9nWc7Uj7se/sKjvLGeOFg4BDdMV2NysUTGCRvnA2hQc5Pt6Cq8pRI2j8tVCIQGPPFAHCqjRqDFuJ6fStWW+lS1hY5HON3r9KvPpyRlHQlw2TgDqanOmRNaxmfIfqB05/woALfXfsln5ULEOxwfUmqN7dKysHyW/nTLqwihuCyf6pOM56mnxRxyEs546t6n0FAGheX3l6Vb2cD7YYPmYD+J25J/kKwGvGeVI0OZJWK59B3NJqBJumEj7U3ZCjv71SUMLhWQFc5JJ7LQBu3EQ1CeG0TkMdzf7opurRvZ243fKh4x6Yq14TVg899KuQ4woPZRTPFLGeI7uQgPTuT1/wAKAOFlbcxY8ljminTRlQSfUDHpRQB7B9iked4W/dyoOQfUVY0iVbXVQ+AsjLtIPQsKu6jbK2omVnKuoCyEfkG/xrFnybvcPvKct7N60AdFoWrR6bdXts8W6zmJIHdVPJH4GlOsM6PbM5eOBcKe5X+Eiq9u3k3CTtGJIAP3gx1Xv+VF7bW9vfFoXzEV3oe+3uKAOU1a8kmnZHl4c8E96oxqscQTIYMDj/CtPXbSKUyAEDdyrDoa5J2limMb7lZDuVhQB1VjAimOTJ5GM9j7GvRvB1k08JS2dGEpBweox/UVwnhuSKZ40unHkydx2PevS/Dfh2G3vomhvQIncPHKOFZT2b0NAFbx3oc2oeDZ7/TIyz2pJuISedvQsvt618030qvK4xyDwf6V9VfES9t/DiXliVk/fDdFJG3cj5lP418ua1Ei3byRLtVjyvoaAM6iiigAp6xuwyqMR7Crmj2Iv7xYnby0/if+7Wtql2+lEWcBDBRxIOc0AYcFlPO22NDuPQHjNRz281u5SaNkYdQRUst9cSSiQyMGHTFW4tZmMflXSpcQnqrjn8DQBlUVevoIcrLaNmJx07qfSqRGCQaAL+jTvb3iSJnANek2MT3cMcibdrfwk9fpXltpJ5U6Mc4Br1Lw1cmXTQIn3v1I7qKANiO38q0kZ4S8a8M+cEfSsPUZY5D+6VgwbGG6muhW3u0tGYu8ts3y8Hv9MVzZtHa4fMhR92MNQBQkMUXmHlnYZ4GMGoEeeSFGfcpU8DA5rXe2QAg5lcA7mB4FZl4Yl27UY44PzZx9BQBOWMyh8MWXjhentUgsorqJnlYM3+0cAVXF1cnysFwo4+bnNWlvJEVozGphz1OBzQAz+zIraJXR2Zz1IUD8BVmymdWEcTMjueSD1HpVEXBlkL43Mp/hJwK27NPMdCI1JbuRg/hQBuWukz3OnO6LGi9SN2SR6+wq3oq74VjlnCxLgrEgI3nPSpLa6itrCXK3CqPkUKmPMPoc9BXPz6hNcTLagpCyjA8r5iP8KAOuu0jjCmZcNL/CZPlGOwHX86wr/Ud10FkRQgXC9wKob3wLaaXZEp5IGS3rk/0q6qLfNiPcsMSY2heT/hQAmrxCW3WcHdIRndnaFH0rOmgtxFElqzSzMN0jbenvWhbRSLDM13K3ldPLPH5n0/nT7eWOGykUllSc4YIoJYDnHtQBh6xprWqQltpR1Bwpzn6n1qpEyTpGrKwOckj0HYdhWtHfW8nmJPGcgEKAMn2FVrqSKSLaIiFXgDp9SaAMW+jme5aY7UCjqW4FFtcl4mhdh5efvmi8GfugvGD931PvVWZvPaNTDtYdFUcAepoA1jepBOgjiUKqhRk9u5PuaivJZrq7kuCoRAN2TxgdqpWUDtds84Ji4Cg98Vfu5VuQYlI3FsBR3oAxbWYy3qRzkFGbOParerrHagtCANvOPf8AxqC3sn892Gd6nr6YrIvLiTzyZX3jOB6ZoAhdnuJCwUlvethbQSQ7nIAPBNR2CxLCGf77HIHc069dwrqpwqnH40AXNKuvPkW1U+XAp+Yj0HQVf1uxFtpfnyAjzSSoPoKx/CIjjvszDc2flU/zNdh4njfVp4IIsCNVywHRUHc/WgDyG5D8l+CzZxRVzXhsvGQAbc8GigD2q7uY5tYjubcBopgVdPQ45FUraBVv5GYb4uxz27f4U24i8ifMbYUnII/hYVbsZIbh2ZiFWQbHX+6aALtrJHHOEVh5T/dYjp7GodR0yWPSFnUNtiJ2EcgqTzzVnTLOORms5Ti53ZibPDH0/Gu58Bm3vbe80DVkxbTZVHPWJzn9CeKAPI3s0lg3HlcZGP4T3BrFvbKGdhJCCCpwf8DXcavoVxoPiOXTZwwQn5S3cdjXL6tZyWV3K8LfIThwO3oRQBBZWa2sUVxG2YicMvoa9H8P6ndQ6NNIEjmiU7ckdfr/AI155p22X927bAx69s9q6Dwvqi6fPNDcsRavwwxkUAcz4r1uS4unF0zDGVCsSdvtXml+wa4cqcg19H6/4f0vxtBBZabFCmrgEJIvCzjtn396+f8AxNoeo+H9UnsNVtJLa4iYgrIMEUAY9T2cBuJggIBqCtLQhE16iSttJI2nHGaANTUdPTS7OOSJnS4Ydex9q5yR3c/OxJ9673xzFMtjbpdR7GVOGx94dj71wHfk0AJRSgEniggjqKAL2mIZpGjIDKVPB4qnIpSRlIwQcVseHky8j7S21c/L2/A1l3riS4dlAHPYYoAiQZcAetegeGWuYoc4B2DOCOMV58v3hzivT/A6XDQr8yyoBjaODQB2Gj3a3HzXcAiR+u04BrNvdLmDtNFHGVYk5Q9PwqzKI7O3l+0w3asxHlrkFQPcVRm1FbSNFDyxPnpk9/Ud6AKpiijheWVi0w+XbtI49c1mXDKkJWE+YzDkbeV/Oo7vUilxhZN5J6rkD9aLybzisxJEg+95ZAz+dAFdro7YwV8tUHG89TTG1GJ3USbct/dziqgDyzEOZNi87Sc0iWG+QOXBzzlD/jQBqWxM22K1iJiJ+cjOT+NdjpWnw2No1wFjdh95ZWxj05P9K5I6zbaVbbLdw8xHOB0NZ0uuXNy5e4OMjCk5wKAOzku3upTCzKY27AnApFtrewtnlubm3jJO7aCWY/gOn41zlvLB5MbQNJLOfvgj5akeOW8fY6kof7oyB9KANGHVo7qeNba3kmVScnbwPetO71+SBNmm2IjA4LEZJPc1nR272y+XBL5cYH3VPzH8BSEyIQqKVjPTeeWPrQA5NW1HVIzbRWnl2wbdJIeC59zV62D28TyeYTjhY8cGqUN2FTY82EU5LDkf/XpJrozshWVfbcOce9AGtpTQqPIgZDdynJkbACfUmo7+28uNkWYTqM4KLkE1yetzTBgIGBjz91ep9zUGka5c2UhRyzIx+YZ7elAGr9laF9rI2SMkt6VEytFayFh83U88n2rT+0pquZosAgfNk8f/AKqz7xoyvDYVeWdj1+lAGb9onmZiUc9AMdqVp2skZ7eLExGNzfw+9WrSbzJDIAfJQd+NxqtNL80pkj+XtnpmgCH7SI0SDzC0kg+YKOQP/r1j37hp+FAROPxq3auIJ2cj534BPUe9Utcnj82OG3GFHJPegC/osImuMOfmHJ/2RU96qG7RF5wSQvp71iaZM8NyWD9Tita0eOS9L534+Ue5oAXToX+3Fl6lgB7mvSb60Wz8OrFaHzLi6bEsvooriY4wt2PL++xAB969YubSFdAtIV58sjzWHVmwMIv9frQB4V4ytPs4jbGMtj9DRXS/Fy0SytbaPgTtIHdf7uVOB+AooA6T/j43eWMhjynr9Kb5LWSvvGRIMqfWrVp5cQlglTd82Y5FOKffH7VMqXQKhuNw459aAJNFkE95bhgdrnbkdVPqK6HW5r7SdXjvgpNtIQH2jGCOv0PeudsbeS1uWRf9cpBA7Pj+tep6Dc2PiezWyvysEhxG7sM/7pPuPWgDotZ0nTPG3hawvEkUalax5SQHl0HOPr7V4F4n06S21OaNMspPGR/nivdNMjn8A+Jra3voWfS5xsEycrz3xWj4l8C2+spNeaXCjbsuEUjKnrgeoNAHzBteQoqqoYcEHjPtWjNCYLXehDpIuSp6g961dV0doL+UeWwKtyjLg8f56VVubeKWDzLOUjZy8Tcke49aAMiwub/TLtLqykZTGQyn0rtNc8Q6X8QNNSy8W28cGqRptg1BRzn+6/qPfqKxNIjW+tnSXKeVxvQZwT0yPSp00iLG5jGW5zEx2njuDQB5T4j8FX+meZLCgmgU8tGdwx6g1ysTtFKrDqpzXtV9Lc2Mxa0LKjcFW5Uj3HQ1zupaBp/iHL2W2y1Qn5ov4JD7en0oAv2F5D4t8MR6e6GW6gB8nd94f7Oe9eaanZT6deywXUDxup5DKQa0jY634bvsNbzROpzwODXSX/j06rZxWmu2EVwsX3ZHTEq+2/qR9aAPP45CjHaMg9jV+zs5bxgqRFsn+Gt37R4ZZfMFvNFJnO3dkH9OKZP4htrZPL0y2CMf4880AV9SxpVp5KBPMYYYjg/iK5onJq/eXc98xeY5P0qky8f/AFqAFhXLqTjGa9W8FpC1upUyRyAcFVyD9a8ws423qcAKe5GRXqnhExWUMb5xJ1BUkZ/CgDrb6FfscM1zOrDGNs4OM+g4rK12O2bS1ijiJdhuJ+9t+hrRvf3tv5scjSTM2VVV+7Vee3kk02aS6cDYRuiOVz9KAPN5ra58zcjKdvc4BpFRyciQkdwQK6Cd7Ahwtv5Z9dxasO/J2jEeT228fnQBXmBRyxAbA7A/LWfPcvu2Qu+cdQOv4VenKsArS7XxwBkCmR2xVcyKxbPpxigCPT4csrSg7j/EwwM111hpmnJsaYfanP8ACzEL+Yqkk8eyGD92kYIJZU5q3LpU95IFsnAT++QRx+NAGhKUjxDAIwGOBFEAT+JqzPAsARpVbP8AdVuT9fSrOg+HNOtlFxeavIZepjhgY7f+BHits3WgW2TBJPczA5Xz2AX8h1/E0Ac3falcNZmCx06K3QnO8jc5+ntVG203W9QuF+02+xNvy78Jx6810Wp6rPqbhiIIAvCRwJg/UkCu78VeH73Tfhj4W1FMfaZi5uZHODiT5o+T6KMUAeby6dJaQN9uRegCqo6VkXNk1wAMbS/YYBArdEebwm5uTI4HReVX296gvJLqByI4mV36lU5I7c0AYr28duQrQeaT1UDGB6ZrLu7NLm4cII7RfTr+Zrob5Gz/AKSzi4Y5zis29smnVTE5OPbkn29aAJ9D0CJCd1wQo+Z2b5VHoPc1Y1DT7KCXy1f7VIQPlQcZrKtHvdPcF0LqpztPIH1PrWg2purfaCFEuOgXpQAyS2eOPy/KVGznaKzb6QR7oY4y0nQs3alTVbgXbyZC574yanhikulaQIQvdiaAOc1CzdWLK54Xn1JrAKMZgvJkbpXcSCOSOQRpmNfvEdWP17VzF7G8DyTKm0njdjoPQUAZpjZZGAztQcn1rR01WSEMpILHrVBJDIBEoJx8ze596sSl44lViQp/DP8AgKAOkt2GI5weAcKPp3r2Twndw3NiLy5G2zs0Pkof+Wkh7+/NeD2d8HSNXwF6Ko9BXeeG9VWWErcSFYVHAH8I9h6npQBjfFWB5LFb6Qlmkugu4n/ZY4HtRV74u27x+HbCW5Plyyzq0cC/8s49j4J9z/SigDR06aSPbyHTI/8ArV1ckENzYqXHyN9wjqjelcbpqILkKrnySce6111ldxWkc9tc4eOQDbIOgPY+1AD7i2khSGVssVTKkjqP/rVb0SGe9Z7m2mCFeH569xmtrwzdWd7AbC/wYSN0Up6wt3HuprFbTLzTNXlFp+6DnbJGx+VgehB9PQ0Aek+GvFMOpWY0LxNC0tvJ8scw+9GR3B9vWuw8OSy+G7uSx1CRp9PYBre77BT/AHvzrwhL670S8Md5EwAbcM8/iD616H4d1XUPEN5Fb6c7zMVy4x8kfY7vQH9e1AHdeLvClj4ltZLmzWJb4dGI4cjscfzrwLUfDs0eozLa2bi5hJM1ufvj147ivoC6e38LW0USXDC6kwzMwymOm3n7o64PtRqOhWniuzS8RvsuoKMw3kB5B9GH9KAPnFPskQZ4IHWVeGU8Mw7g+9SXlq19bp9ijaRiCVVuuPT616RfaMkWpC18QQRxX+Nou4lG2Udty9D9a5PUtLurHUHs5LYrBuLRFexPcdwKAOJvYrq1tSHRSp6rIvKn0+tc3Jasbjz4UKZ6qTwD7V3upm82vHcg+nzjIP8AwLtXLyMyny41BDZ4PykH0zQBWuNcupIY4bxPOEf3S4BYD61LJbaLqgH2izXLjBIXBB9QRVLyLv7R5RQkN2AyfyrXi0aWNQkqEDGfNQHI/wB5aAMPVPAFjFIrWdxvVhnocqPcf4VmDwSshRLeZXc8c/dJ9Pau/ttNkKMm3DKuQ2Tkj1HqKoP9rtS+zbIF64YZx/WgDjH8GXMF2ILi3khkPABHB/Gt22+HEk0bGThFGWZeSn1rVlvLS+RI7dpY7gfe81sDPsaZFfi1m2zK0jqcEEkBh9RQBhXHg57JQ0sCrH1DFuHrSsti2ojPlBU6AcfkTUuss1yNyoYYz92JnJUfRqpR2wMGDIIyeuB/iaAOk02cpCTb3MqK52ksqkL+NU9cnaSNwt55r/dY8HFQq+LPy3CvH2YYBz+FY/2qS3cpEqMucnOCR+NAFMIp3ISofOd3IH41Run82QjzFD9yOKmvJw8zlY+W/utms0G2SVlm8xpeyv0FACS28nksy45P3+9R2sEslyqhhKfUk4rptJs7a5g/0icwoegbhTUtzb21sp+zzoxxj5cDH5mgClaWkcE6tN88v+wOB+dbF3rzJB5EGMDnIGcGsNJJIMsqs+e5qzDYma3DyouWOfmODQBPcX11PCC1w0hPYcAVXF+1v8vkJn+8nJY+9JcsluVQALH32tuqu8sDqQjEYPBxigDq/DH2rVtasbFdiz3E0cSKo6FmA/rX1f8AFLRkvvhzqVrDECbSATwrjOPK+bAH+6CPxr5W+EWq6fofjex1bX2lWwsw8g2JvLSbSF49s5/CvoR/jp4GuFeB5r10cFWU2xwQeCOtAHzZ9vZgUiDGRm+8MZz2H0rWttTuYQIp7iKXPXHJ/OuZuBbx3s8EM7/Z1dtrhcMyZ4z6EitCwurazKPb2wkmPIbO8/4CgDZM0V1qaJJEZTkZVgFB9vpVfU0g/tdj5iqnTZByFHoKZiS53uyBXI3SSFv0qhHbS/aW2tkgdR0FAF2FUkn8u43pb/wog+b8T2rF1S0Vr2RlbbApwEX+VaF7HPaRq7eZcSt93sBVYrdSoq7VUuMAdMD1oAdbpp+0J5OD/Ew5P0FQ385KNBGNi9Nq9h6fWiMtbSqm3IHLMB1+lLJcpM7usRRAeABigDNt4JTCI4iETdk46mmT6YZYpTIMrHyQfX3rdtrgiyIihABODJ/hS+RugSGMcudxH9TQB5xKY7KX54gT94jt7VmXMk95Kzt3P4fQV0viGzQSsBkgHJPr/wDWrGuEEMBJOMDJx29qAKseIZeGDbRjJ6ZrqfD+opZyxSY86RTu2noW7Z9hXHpuky/QLVrTrmXdtiGDn73pQB2nxFkkuvD8F1dzmS6e5X5QeFG1+vv0ornPElzLLpsETZEUbjAz1ODzRQB6hdWamb7TbgKGAdkB6fSpg0UsBDsVZRg+4p+niMkRTOE/ut2Hr+HqKj1Cyu7G5KFN8bLuTHIYexoATSrqa0u/Ldiy/wAJB6j2rsI9ejFl5FyPMCcA9wD6GuBs5t0rROhKdRjqh9RW9Z2t3qI3LDvkjHMkYzkepHegD0vwhoT+LL6OA3drJpyp+8d/9YV/uhf7w9a9t0HRdO8PactppkCQQKMs3VnP95m7mvGfhd4aaxkk8S6vKLfS7JCyhT/rXHp6qD27nj1rV1D4nNqek6jYyWZt2uG8qGVG+7GxwQ/o2OMjg57Y5AMHx7ca9B4pvr8sJrG4/wBXGpyvlgYAI9cc/U1iaf4xv7IbdKkminPBiJ4cen1FbEmn6jBZiQTpe2hX5GBzt/2WFcil3bfb2N1byRc/MucjPYg0AdJd+LJtct1t9YYw3kZzE7qQVP8AVT6VqSeKLq60xLbUYLeZIiEMh+/F6HcO3vUdhrum3kS2HiG1S7siMRXap8yezd6xvEujXmiYvNFulv8ATmHVfmZF9HH9aAL+s6bqNyWWLT47ghc5Rxll9euG/CuSsm0YXDWOtRtAN2DKgyUPuKWw8QajBhbWURRd4Dyv4Dt+FSa0bDXrY3LJJb61Hwflyk49+4P0oAXVfCtpZXsUtremSE4dGIyrj1BHQ+1bRnivAioV8+L5clsNj69x7GvKNQ8T3mlTCEmRY1PAJ+79D6Vq6J4zt5JRJcxFcja0idGH+0p4P6UAd/dpbQxeXd2qxOh3c9GB7qw4ri9Wtbee6kFq2xOoUuMr+PcVp6pqcUsML2lxbXUJ6wBicD6dR+dZCS6VLcCVoHg7YifcPxB5oAy5NMYEFQjSr95SwO4eoqzdvbm1QCNIXQfN1JP41NNb2YYhGaDJ3KzqQCPSoJp9MAYWdzMsw4KsoIJoAy8B49q4G7nO7g/nUVtBwwUsX9u1WbswLEJVkVZe4CbSKowM043GZCFOctwaAJ7oOcb1AcdiNuayr6cQKT8iEdMgnNbOq3M08Ma+YX2jAKncR+lc2ls8twwkMrqOcEcCgCjFNJJIwVkXPbb1rSt7eEwbpfKdj/eWrf2eKGEFltlQnjDEGrayaeYPMZCsiDHyY5/M0AZ1oRGGwGwvQdqkJW5QloSCP4lApN0Milz36bR/PtUq+dFEFVozGeeScUARi1lgg8xQ2CfY1IkwePErShh6DNPiniYAMY9w42pn9acfNlyqoqoOzEgGgDPu9shC7JSx/wBoc1WYbHCzMQo6A4rQNlcSOQPLCDnvg02eKJFHnmIN0A6tQAyBneMrbyED6f1qEbogcqck/fJwKttBIECxFghHJXio7iJUVfMYyP6daAEjUyEKshk3ffwOBW9ZpBBbOYXJl6KOg+pNYAEjqPLLBB/CeM/hVkXckkYj+TC9ABQB0miXUlxHKhVGiTPzHhQfX3NP0+3uJvPdJI44QeSfvP7D0FZdjMYIhGVTc/8AE56VdXUozKsUZiiijHzMueaAIL69lWXF1IqovAUHt6U+C9hjjaRYmedxhA3AHuf8KbLdWks6b41Z24TAwFHr7/WtO/g0z7Cq2kryXHUqgzt92b+lAGX9muc+ZKQWlGRnjj6elQboCDDkbe7E9ar3aTHlzII+mWPWqlrGGlZpD8oHy/8A1qAL090okAySg4RBwPrS2t4RMyofMlbjA6D61neVLPI23PHQD+Qq1Aq2iGM/NcMOVHb6/wCFAGdrUHnfLGSxzlj61z1/b5h2/fcn5EHf3NdAZd8kisw+Xr9af5McNux2gyt1Pp7UAcNcQNDDsBJPcDoBS6SC1wikEru6DvV3VCWkaNCACfmI6n2qO1hkWXag24GGP9we/vQBa8SkfZEUEH94CfyPT2FFRa6mbKOSNT5KuE3H+I4P+FFAHp2jJ9o8seYQynAPt6Gujmln01Fiu0822HzIy9vp6fSuHtLoRPlH2N39v8RWvLqspiCySEK3VScqfcUAaxijluBc22whjuU4xk+h9DXf/DrQJtY8SwSaU0tvZBfMunxxHjqvPc+n49q8ssbwWbup2tDKOR2rsvDniS6stPvre1u5I4J02TIDnK+4+nGRzzQB6p431m11bOl2EptrKzPyFF+R3HcjuvJ/nXnF9ZRPby+SNlwnLw7sgj+8p/pUGl6tG0IUykKDs83O4Ke2R1FW5sIyyXJERXlJFG5WH4UATaBfXqw+XDIrt3ic7SQO49fpSa3dWwfFzZhGkHD5ypPp/smqjSNbutxFCJY87jg7lP8AUGrGvXkNxbQ3VoA6t8stvLyG9wexoAbbNBHarcQxN5P3ZMfOv4jqK0dJ1CeCOSGFfOtuqgkHAP8Atf0NY1jNaQxYt5Ht7ojIjlHDr/dz3quLqQtIbeERr/EF7UAdO8OiXyeVcj7PKefu7WU+oI61y/iVf7IlRlRJ4h12PkSD1HcGiC2udXjMcqNmI5DD7wHt613FjaaWNDFt4hsPNhYfLfQoRIh9T60AeaXGp+GteRIdXtZkUDCTx4dk9j0JH15rGuPDFpYqbjQbyGeJvvRyDnH+6a6HXvAdjK7Pp2oJGGyYrlTmKT2bup+ted6xpWs6XN5U0uSpyCDnPuCOooAmuNGvDI88UbRheT5LZA98UK1xJ8lxI0YxgycfqKTQryVrkfbEkbHV432kfjTNY1BLaSSMMrk9PMXn8xwaANKzs794y9hqMN00YyYfMwxHsD1pJJ7qYjz7REYfe3KFb864p9TlifdbqkZ9UqR9Xu7nIklkdj/eoA6+a4sZV8uW1IkH8fmVDHHG+RayopHdmAP61zcMUqr5kkUufc/5zW9pCQPEzyiQA9toNAE1rZTXEjIimV/VMVHKlzESjoiFeuWGalkunsSfskhjVvXI/lSxQh1E91dgITkjk0AZzt5h2soKjvnbU1nMtsS0KYPcsmf51Le3FoG220wkjPaReaSGGF4zJFjjsc0AO+0WuoSCO7ZY2B+8uR+mMVDciFZPLhaV4x/ERmmvbM8gdo0hjH8Wwf41didFgMdvKHP02mgCrDIzfukRGA53MmDUV3J92NpdgHJHrS3Qizhi5k7/ADE1GAsi4Ee4joWIoAaZ7gHEbDb/AHgnSmlot++U+Y56sVyfw9KsW8ZV/wB/G+09AvSnXdpEGBjZgx/hxgD/ABoAjxG5EhaTaOinIpTOsg2CI56cHmnxI0XXc7HgZ4xU7wLa25eXClu27k0AULiHnAIGf4VPT6mnLbGMK03y+3en2oVptwjOO2Wx+NPZ0aUMMOQeq9B+JoAlhSJix8lmAGMkkVM7K0axRRov+6P60xJUlBiUMSOSV/xqR7RkjR2Vo1PIXu3uaAI7XTGMvmEmQ+rHArTzDaxbc7pDzgdPxqn9pmnO1WIHTOMAVWBBYrvJA67eM/jQBNdKJi0jOW+pqk0otI9+0PKfuj0q2nkHauQW9OwqCSKOa6PmMREvQAYLUAGmLI0TuWClvvP6ewqPZjctscu/Vz/OrcA+0N5KDYg7dTVS73RymOPG2gDNXEU5jt13OeN39afqLKkG1X+6PmI9fQev1pzJyQmT/eZeKpXb8bQNq9vU/wCFAGZCcy7FTMrdO+KsSwgRCCLGFOXfsT/WktyIY5GQfO3BbuB6Cp7GCa5dFVcjPA7fWgCHxVhNDtYkG1FkHGOvytyaK0/HECQ+GLYRjcPtK7pf7x2N09qKAGQTAJ8+Mfyq6hLwny3yO8bf0rBhcdVbKnt6Vo2qb/8AVtg9dvr9KANOzLOg+Y4B71qWd2YLhcMRgfe9KwLaWSKbA4B4YGtRJVRx5g5/vDt9R3oA27z5VE9thJT94xtw49xU9jqcz2+PNOFPKE/qK5oyxhyquyo3oelaFssax/v8sD0kQ/zoA7HSpJkfzY7lY14yp6MPpW/qwtJtOWeIIWHD+WeD9R2NcNZmS2RXVxJAevcVLfXSWu1kR0jkHI3ZVh7GgDUvpvKghSPbdQH5kzw8Z7gHv9KotIbmZfJLRs3GenPv6VUh1KJMKoJiY5II3D8v61rWdvDdyB0AZT3VsMPbmgDufh/DcWTsbtBPkYUlsA+2elek6Bch5JIsssPO+3ZFY/gD1FeX6A62iGMfatw68HKj3HcV1Wkz3FrKss8H9o2MnBeFslfy5U0AdXa6Xon9qB7bTAjycMY1wr/7yNx+VYXjj4Zabqlm8un2UYlBztjyp/Kqn/CTRW1+8Nqlw6qf9Wz7ZB9Ca3bDVLbVGJt9WuYLt+HjlXyww/lmgD591rwbc6NelBAdw7S5jbH49agbSfDV1bbNShv4br+/Gysv5Gvpa90YSWvkajJNfW7f6ozJv2H2Ydq8m8Y+ANNXdcaeZYblSS9vI3X6d/zFAHi994XsEd3tbuHjoJAcH8q5+4C2rbDFwO3UV3Ot2ktixT7EVb+9jd/9Y1yt3BK58x5Yxzyu3aaAJLW+SaJVEQCdCAallC+WViVgD/tZAqCOFEAEsYGf4l71MkUIU+XK0bf7RoAg3oqeXMfoFOaesXlpuBfb6E1LhIUJB3E/xIA1U7i68tco+Sf76gUANneNMFVck/3aW3aYsPklA96it5RKcyZ3dsDitW0VHXDr06/MeaAIJpOiqGb1DdKtxPLHF+8gCR+wH8zUkslpHF+7iO/sACahy0iDzXCKeg/+tQAkYErHygCO+8YH6Uq20qg7zGqHspoMogXER3L6kYp4ukbBeVMegGcUAWoIIlUYlXPcsQoFNe6ggDLGQ7nqwGfyqpeXEMyCOIAKP4j3qqXjtY/l3F296ALHmiPL+WzE98VGZHl+Z1VF9Wquk92x3AMQfUcflUNxMZBiYEsOwGMfWgBZnXzNobI/IVMSTgRgBF7gcVT+0KighQQPb+tI9yzrmQkZ6Kq8UAdBp948Y/dAKo5Lsv8AKrN7e/a28x3lkbGCXwBXNLeGJcuCR2yePy71pabeLcg4Vzjrgf17UADzF5AmSQeyip4mijZgVAA/Emrbwo1qfLjEZ6mRjkn6CsdIpfNy+BGD0PegDXW2iWMPGzSXL8kAcIKoSRbJDuOGPXua1Xn2RCOMMzkcIi7fxNVJrqKNBCigzOfmYDJoAZaFQjlm2RDkju1Z8zi4lZu3ZR0A9zV6/ceWttAnJ5YDkn6msplkUksQsYPQdzQBNcXLGARQqEj7ue/0rPuoCIy6qWYjAzUsbiVmdjiFOretQSXUl5OI4gVTpk9hQBHDat8qSNuPVwO3tXX+GtKS+LM5ENonLv3I9BWHFbkmO2t1LO5xgdWNd9qJj0HQBp1rh76VczyjpGP7o96APPPijqUdzBFa2cYisoJQFHcnaeT70VR8bWzRaRFI+FJnAC9/utyaKAMu2kRpyT8rH8jWtDIiNtzj29K5hH3qGHykd/StKKRpEBIzjrg9KAOiL7yGyCT1Bp8dyQ4SQbl6AnqKy7UuY/vbgOnrVguxQK34N/jQBrSReWRtw0b+vY1JHPMiNDjkdj1x/Ws2C8kjAjlAZfQ1ZuLpXRV5Dr9xu49qANLTr8qNjqyg9GU8A1oJeh1aOQqVP3kbjn1Fc6shKeZ0P8RFaNvdx3UXkTFPNH3S3yk/jQBrWVmGkLWyiZRy0e7kfQ1qxTRs6xF8p0+bh0/xrlrcMrYQurg8rnB/A1ehEzTCWR3dR1JHzH/GgD0TR9UlsrqO3a7lSReYyW/ka7XTtYvrPU1ufIS5icYlOzDEd9w7/WvJZZ4prRFt385B/A64Zf8APtXXeFvtH2eJrS9kjfOBHNJ8v0yelAHp15p1nrEDSaZAksrDIVpBlD7Z5/OuH1+w1rTlaSa1T93/ABRj5h9cHrXR2mt6dpKMdYtyk2MhvLzz7MpxXL+LPiFpurRhX0x2aPjz4icsvv3FAGdb+Lp1QC4uJQMYIDbW/HsasyfEWZ7Y2sNsLpFHWZAzD6HrXD3scF+xn0+JpR1ZJHBYfyJrInX+NJvIwegPSgDovEHiC9ntcXCxtHnKkrhl9siuH1O6SdeQrN9c1f8APmBKmdJUPGf/AKxrHnt7lZmJEbqem04oAZbXU9uh2Im30AFTJcpOMFE3Hsc1SkSaL/XxyKv94ICRTkEbjd5yv/vDBoAlmiwNo6egJFU7jTd53xAgdwzA1sWl1JFGyRGJ0Ych0B/Wql1EiIZEkVH/ANjigDF2GOQKG5+uBW1bXdxBa5SB1/20bINYcjKJg8uxsHrk5re0/XplhMMMMWzGORmgCp9tMgOZAj/7RxUayGSTLFSf7xai+AnLSNEu7r8rf/WrOiuir4Y4H4UAafmYfDMc9sEEVJO0gQKpjIPcgZqsksUYEkhL5/vCny6rGBkoij2XBNAEY06eY/u9oz3zzUyWsdmcXJAf06mmxarcTDZFCEX1OC1VZGAk/fMST2oAkuJ3eXEbkp71HIy4wx2k+gzUbnacqMjsAeKckLmMuwVVPXJyaAGPJFEyljuPYYzT5pYTtx17luarSSQltpj4Hcn+lNBSXOxMgdOaALLlCpYsue2TV/SXC4/fliOiAcflWGsZlBHlsOevSpbaU2TkohLHjI6/nQB1jTOSGlYA9lJqaCCML581yC/YAYCj61zkEks7b1+979BUjmR5Asjs7erdB9BQBsS3IiSQQOdpHzMtUrVgCz7SGboSeaVLUz4SEM+0fNI5wo+laNtZyQQDbGMN/Ge/0oAqyKIYWO8Lnknuaz5bcuge4fYh6KeWb8O1bn2dJWAA8yc/dA5x9T2rG1y6tbD90rfaLs9QOVWgCCfY0aoFwq9qfBiNTjaGPoOahsLSa4i864OxM8E8D8KvwvBCSsZ3EfxEfyoA1PBenz3mq7wdkcY3PK3AQVra1Mtxe4gGIY/u56sf7xpmjxy2ti086+XA3I3cFqiuZo/LMr9TyiDgfU0Acb8Q1CaXCu7exnDE/wDAWoo8dIX8Pxz4JBulXce52PRQBw8cjRNleRWnYyqzDadoPGKygdpGTlfX0q/ZbRKAwAz0bsfrQBt20rQOytwferSShXDupEZ79qzPNKuIpgcfwk1OLkwHb0B9ejUAXrplz8rBh1FRpMWAx82PzqnLLFKn3Cv07f8A1qRAwIbn2I70Aa0UrMxZAR6qOhqzbmCU7ST9PSs60k3uAWw3ZumKtSSeTMPPUq/98DhhQBqxO0TqYZlKjoG7VsjUSUBVQky9uzVz6ESx7igkUjll6inQW53DY5K+gODQBvm4FyFYQPE+cGSM9/pXQ6b58bhJnmkDjkJ1NcxZ3Bhk8ppdqnuw/nXaaTf2kUCQ6lEroOUkjPK/QigDYhuLf7O0Ec9xI2P9VJDuP5VzlxamaR1soRFIeCvY/gcEV6BZeRfWyNGn2kqPkuIn2yJ9c9auTw3dzEY7topMDh5Y8OB+v6GgDwu+028t5n8w7WHYfKRVFJJIJd1yvmR9wxx+teo61od/bsZQ0d1H1wjA4FcFrQVJ2LRyRA9Qw4/KgDLNwssn+iKVJ/hLDH51FOl0Byiof98fypsoRSdjKgPcjg1E5aMZaFJgf4kbmgCzbPeR/NGlpMO6ng1caOxu4j9r08Wsv/PSOQn9MVzn2qbzsQxEn0zSG5YORNG8LH3OKANWTRMbnspnlA7qvIrNdJFkKzuUYf3xjNTW9yVOFusN2G0mmagJpxvDxlh/dOSfwNAFWZdzDPlt+GP5UC2VQWMR/XFNhM8r5fjb7AValMkyYV3Qj+ItkfkBQBm3E6qpRERT7MapxyBX+YIc+lPu45NxBl8z1IXb/WqUSCOQk7OPxNAGhMhZgd4x6A05rd3wew7mokuA3DAhfUAL+lXImU42vIV9+aALdhdC0wIyrHvwKmlnWd9wWMnvnmqchiVeLZ93q3GfwqvFtViWZVHoKALlxI2DjaCOmBwKgikeTIkmLj2GKZLdIAcKrJ7GnWzpIpZIzEo9eaAGt9lBIfcf9lE/rRAkbyHDmOMfwg5P4npROWk4jQso/wCAiqV1NIQI0jX6KOPzoAu3LQ/dtWJPdic5qKBihImTf6bjgCooIDszGzSynqqDhfxqzbpMj/vVyewz0oAv2sbXB2ofLXu2MYrTg0mH7y5Yd2ZutJYWcSxLLcHC+meT9K2YLy12hX2Ii9EX+poAdZ2JnURRtFDCvJbHH596uX1pp1jaNLd3ryFRwidT9T0H0rB1PVI1fEGXPbHSsiUz3x3XGXQcAE4UfhQA691u4ud1ro0Hlq3V+px9ahstJtrJDNdSfaLx+cdl+vrVqEMkYhhVVUnkqMZrUSO3tIsvEJJiMlmPSgDOaEyhQ7sztwB6fhXX6B4ctdNgTUtZjLd4oT3Pqas+DPDZui2r6hGwto/mRSMA+59BU+p/aNbvXcMRAvEajgUAUNZvm1CVQUXAOEjUdPw9azr608pFe9BXP3Y+5rtksrPwppy3N4ofU5x+7jPLKPp2HuaxtNslvp5dS1JvMROcdvpQB5/8SBIvhS0Bj2Rm6UqMf7D0VJ8Xb9ruxhUqqIJ1Kr3A2t2ooA8vKFW2t1rSsUOByMdqrzOlwA6jZIOoFLb71kGWKc9e1AG26kxgMdrDoT0NMk5i2uAR6jtVeVp4Y88NGeo6r/8AWqujgt8spQnsf5UAXLSUhtrAMvY1qIYnjKjMb+h6GsESNDLzjd+jVejuuAUH4GgC9CwDj/lnMvYjKtWqZ0uoQuFSUfwsOKyYJlc44B9G6VfQEgF4Q6ex5FAFy1EsJDGJo27FOhrSgnjncbgkc3rjAb61VsbtVXyizBT0STkfgakPlCQhxgn170AS3xcPt3BW9G5H4GpbW6kjwsqZ9QvFZNzAQ+5CSp6j0pqSvGo2uxA7EZxQB6Bo+rx27BrPU5rKYf8APRSAfxGR+ldTb+LAYtupItwc482JtufxBx+leV2WpebhWwSOx4P4U+eZlk3hyo9ehH5UAej61q1tNGr6Y08bjnLnOPxFcVqmoG6Y/wBpxSyf7cJB/nUFrqs0CqokhlU9+jD8etXTewytmcOCfQBs0ActdjHFurFD2kXH8qhNvIY92F56FWxitjUIVmlZo7d/J/vIOn4VRTSJblv9DdH9QTg/lQBmPGYzuJG71zSbZJh80owPVq0b3RtTto+YgV9Rz/Ss6GGRZMMgV/VQQaAHPbTxKGi2SD3bFR5gkGLgOkn+wQa6G20Oa8gDNlj2DPg0yO1S3lMUkQZgeh5NAGStnbKm4yyP6An/AAFORAkZ8lCfUSOAK3Lq0cRhlQRg9nJFZs+iKyGWS7Cey/NQBjTQR7sqyK3cHJrOuYjvwNufULWpcWsCZAKt7jrWZIEjb7pU+pIoAkghMa/Pj69aN5hz5bA/hTodsgx5sY93PFWIQA3EySeuwYFAEEF60jBZSB7LnP60+ZiXAjWLb/tGpJJ4BlVVt/qTiqckzqcAKV9AuaALDLvYDam0dTGKSecqNluuxR1Lmq8c7E8x5Hu2KnjS1Pz3MhA7JHyfzoAhVpGyfMH49KhkDPkPI7f7q4FWpLhCStspiQdyMmqvmjzBuklk9FC4FAF7TFK4SMEj3NW5nCybeBjrgjNUJLgpDlysS+meaqRXkQBby949W6GgDobe6iYnJLkfiBUc908kmNuIweB0/Ssee/kWLcSEQ9lGKpi6mmX92jKv6mgDoZNQitxvmKZ7IOTUcF9JdvvfEcQ6Hv8AgKz7XS5GUTXW2JO248n6Cti2tkLLHGpdjwMDJoAsWc6xyB9pf07muv0DTleRb7WoiLcfNHbr96T6+grW8I+FLayszqOqxAMPuJJ/PFP1W+eQiOBQmThSOp+nrQBe1rxJd6ikcDRQ21pHxHbIMRr7kfxH61UOv2ehWvmxxm71RuU3D5U98VXENvaQF7lt83XGeE+p9farmieFL7xDdoYbUwQPz5jjt/e57fpQBzthDf8AiDVWku2kmuJTuK+g9T6CtnXrhLO1NvHtCRjAA6E+p9a6rV7vSPB2nNZaZIsty2VmnUZLn0UnqPevKtXvpL1mcjanbPagDiPG0pmgV2JY+aOT9DRTPGChbGPGSDKOT1PB/SigDklJU5FWUnJGV69x61VpRx0oAuJeMq4UkKe3XFQZ8xuf0qMNUiIG+4efQ0AWYBkbd2fY1oWzqgwpJx2PUfhVCMbSDIM4/OrqwrIodWJx37igC3bzBZAs0Xynow6VsQXESDbKh2n/AD1rDSV1jwQGHqvNWre8DRbS+MdAaANCaZMZt5mP+y/+NOttQEo8qbqOmetZRlDMcMuT/npSIuHycZHoaAOgJlH3UZl7EGoDO4bDIR+lVIrqaPhWIB/EUStK43d/VWyKALL3SKMTIzH1B2kfjSrqpQFVd3T+7IOR+NUC7uMDAcdmPWq7TEttljEbjuh4P4UAa0c6Od36ZrX0zVJITtFoJl/2ia45J3WXasqqf9oVv6Zd3EA/eeU+fQ0Adrp2pxpkyxNAT2BJFQXU9u8pJtvMyfT+vBrFSa5mOQfl/unNSR3MkMm1wpX0fJoAszswOVjmVf7rPkUyRLNow0+nzhv7yPTmmjIyuxh6byP51BNdgALDJLH6gnIoAW2lsUmGElx2DT7D/KtFr2yLDzFRWHTLFz+YrFd43wJCrt7x4/lWnpdtZSOFuHMPui5/nQBpwyW00iGeEyoOxZgK1NXfSG0/bbWiwSjsjM+f1qi9jonyxx6jNvPUsu1R+VaMPh/w1HCZp9XlklHO2CTb/MUAcJqFq9ypC2T7R3K4Fc/PbSwMS8SbPRSCf0zXa6lNALhksGlKeskm41h38rKpEsO4euTQBzMk0D/K0bA1JHPBEm0ysgP92p540lU4lSL2K1jTW3lOXDK+O7YxQBoiG1H7xR5pP99qnW4eRdhWKNf7qLz+tZ1tdnGCGx6R4AqT7YynESFc/nQAk2FkKr/6FVZ7iOGQbSHb0BqwFuHfOxQD/eNPnYImxIVMnqqhRQBF9ruZBndtTsqrVKa4YOerse2amRZcncQT7ngfhUPkN5nyAse7NwPwoAqsZjIDxu7Z6CrKW7lvMkuFMnZRzV220wyHLZ59Bk1dgsoreTG059+W/wDrUAV7XS2kIkuJd5/u+n1rWhgt0PUuw/hQf1q5Y6RPfMOWWAdSM4/Ouo0+0tNMKm3iEkq/xSLkD6CgBvhTwHfa8ftd48el6avJuZxnj/ZHUmuuvL7wj4PtDD4ftWv9RI5vbk559VUcCuevNSd1EmpzyFQMKrvn8l6CuekkS7uOUZUzwAeT+NAG4ur3Oq3Bku7hnY8gdh+FbmjaPdX90I9OhaWV/vPnt9e30FReHtAgeD7TeOkNsp6BuT+Nbt14zGiWnk6XElpGBjco/eN+J6UAdXbeCtN0NFvPEd7AjRDeQxG2P8PX9a5nxZ8SrIo+n+GkdbXPzTtndL9B2Feb6/4iuNVffqEz+UDkR5rnpdSXaTGuxOme5oA3b++e4lM07ZJ9+fpWdNKCCzkF/wCEfwqP61itqO98bgvv1NV7q5Z0wGKx+g6tQBS8VTrJCqLliJASx78Gis7V2/dKpKg7s7Rye/JooAyqUAk8UlKDg8UAKVIHIpF69cVZjmVgBIMH+8KZLtzhgPZhx+lAD0kbGGO5aWOV4n3ROfoar7WHI5+lIST9aANJbks25flk9jwatRTxzKQy4fvnisVRnkEip4ZmVgH596ALrSIsm2bOOx7iteytjPFmC4icjokhx+tYrhmGUKyL/dbginW8qqMAFT6UAaF0ZbaUC4R4T/e6qfxFOW7Q/MG3euRVCaZjGQJDj0JyDVESbCSCR7dqAOrtryBSCQjDupGRS31zpswAELRP6g7h/jXMrdOq5Uq47gineeJlwyf1oA1iVPAw49qltowzbSwT6isiHehBUHH+9mtqzvEIAmiwfUigC/bQSK+I5kOewbFX/Kni5meXZ6g5qiohlwcKT9cVetZLS2YGaS5iPqvzKaAK81xbodyXIZh/CxxQurYwVDKf7ysD/Orl1qFjJ8jCCVfVogDVF49PPzCGIj2O2gC3Fdm6ILmNvcgA1eifAwr4+grBzaqcwyxr/sljmlN1DGMuAfo1AHSL9rdDtkSVfRx/9aqr3Fvbg/a4ZQ3+zKcflisZdStGxgSg+zk/yp0t4yDdHGhHq5J/nQBdj1bki1jcr/tE0r3YYFrl8D+7jP8AOswX5ZefIU/QCrVoLW64uri3RT/tf4UAY2qXFvLIfJAA9hWfHbG4OBHu9hya7Y6BpEwBtr+FW77n4/WoJbO1sVKxXCSEd4yf8KAOTfSr1V+S3nRT7AZqB7RIgS6uZO+5hxXQXSi4BXzJ1H+91qrDpBZsxxA+8hzQBmQSnhGuWVf9gY/WtK3t7MoWSR2PdnarI0VWOZ2hB7Yyf0FV5tKSM5NwmP7vI/SgByw2pzh3b6HAqq0Cq5ZF/FmrRgsGlAUXIVP9lcCtGCzsbPD72nmHdxhR+FAFPSNOvLwgRqxU9xnFdLZ21hozgzpDPcns/wA20/TpWLc6tcv8kcnH+9gCoUQFg0rM7nqBQB2c+sPdKF+0YA/hRQAP6CseaR7iXy47hgncqcD86zpnBh2xIR/L86y3Qs+2WY8/wJxQB0NzPp1oAqsJp/7xOcU/SissnnFPlU9W6Vj21rbR+it/321aRu5YogsUflIP436n8KAOmvNZkS1UyMVjT7m7jH0FcdqeryTyFv4R3P8AnNUdS1AZOXMkmOST/nFc9cX6DJlIc9lB4H4d6ANK4vzKxIYOR3PQVm3N6oJy+9z+QrMub55j0wo6AcCqvmHOeKANJrsqP3YGT/FUD3snOXJPtVNmLHLHNNoAe7bzk9aKZRQAUUUUAFL2pKKAClzSUUAKKcr44PIplFAExlO3HVfftRHI6nIO4ehqGigCxLOXqHPOabRQA5WKmrMDxA5J2n2qpSgkdKAN+0mVsDKsPUHBrQWKKUcH5vQYFcsjFcMuAfUCrYvrgpgyf+Oj/CgDptPl+zSYZJAPoCK2hewOOJ4Qf7rLXAJqF0OPOOPoKZJdTP8AefP4CgD0iDULL7tzaQXC/wC6f8abcWPh27UmNfssh/h3NivOYL24RiFlYD86urqN1j/W/wDjo/woA3rvQFBJsruNvQZINZUun3duSWDkeu4EVUe+uHHzOD/wAf4VD9uuc481sehoAux6p9mO35CfSo7u8kuRuCx49nrOuJncfNtP/ARVUOVOVwD9KANARPIcl1X2LZqXy88NLD/wHNZwdnHzHNDKB2oA0Ps8rMBDIh+jnNXreCdSA8qn13GufWV4mzGxU+oqxBczZyXJPvzQB2Vjbo+A5VR69auT6iLFPLt5Fz6spNcgNTu40xHLtHso/wAKgbUrs8mY59do/wAKAOnkvriXLzXI2nsOKy5r1Q58oRsfXk1jPdzyKS8hY+9MjldfmBGfoKAN+O+mcYzJ9I+B+dSonVpyQP8Aac1grfXAHEp/IUsd3O8gLPuPuBQB01vtPMSj/exgVJLNJGuUXcfUnisWLU7rco8xcDoPLX/CpJdWvGZQ0i4Hby1/woA0Fa7uccE+y5q7Z6Vc5zIVhB68c/nWdb67qMQ/dzov/bJP8Kr3WvalLId9zn/gCj+lAHTZhsV+Q7m9SaxtT1O4k3F2Ea+rdTWLJqt6Qczf+Or/AIVmz3EszAyOW+tAD7u4aRjukbb/AHR3qo7AjAprHkmm0AFFFFABRRRQAUUUUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Image shows the gestational sac (arrow) without surrounding myometrium. Note the empty endometrial cavity (arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_10_3233=[""].join("\n");
var outline_f3_10_3233=null;
var title_f3_10_3234="Med bronchogen cyst CXR III";
var content_f3_10_3234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infected subcarinal bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows a bronchogenic cyst after infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_10_3234=[""].join("\n");
var outline_f3_10_3234=null;
var title_f3_10_3235="Polyacryl gel electrophoresis";
var content_f3_10_3235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reference gel showing proteins that are separated using two-dimensional electrophoresis. The proteins are separated first according to their isoelectric point and then secondarily then according to size. The proteins were visualized by staining the gel with a silver stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dwek MY, Alaiya AA. Proteome analysis enables separate clustering of normal breast, benign breast, and breast cancer tissues. Br J Cancer 2003; 89:305. Copyright &copy; 2003 Nature Publishing Group.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.nature.com\">",
"      file://www.nature.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_10_3235=[""].join("\n");
var outline_f3_10_3235=null;
var title_f3_10_3236="Bupivacaine and epinephrine: Patient drug information";
var content_f3_10_3236=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bupivacaine and epinephrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/22/38246?source=see_link\">",
"     see \"Bupivacaine and epinephrine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Marcaine&reg; with Epinephrine;",
"     </li>",
"     <li>",
"      Sensorcaine&reg; with Epinephrine;",
"     </li>",
"     <li>",
"      Sensorcaine&reg;-MPF with Epinephrine;",
"     </li>",
"     <li>",
"      Vivacaine&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sensorcaine&reg; with Epinephrine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before dental care to numb the area.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701661",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bupivacaine, epinephrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat while your mouth feels numb. You may bite your tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11242 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-199.231.185.123-894C5EFDCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_10_3236=[""].join("\n");
var outline_f3_10_3236=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142997\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142998\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025855\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025857\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025856\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025861\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025862\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025864\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025859\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025860\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025865\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025866\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/22/38246?source=related_link\">",
"      Bupivacaine and epinephrine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_10_3237="Phendimetrazine: Patient drug information";
var content_f3_10_3237=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Phendimetrazine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/13/8406?source=see_link\">",
"     see \"Phendimetrazine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bontril&reg; PDM;",
"     </li>",
"     <li>",
"      Bontril&reg; Slow-Release",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bontril&reg;;",
"     </li>",
"     <li>",
"      Plegine&reg;;",
"     </li>",
"     <li>",
"      Statobex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming; avoid long-term use. Use this drug as ordered by your doctor. Tell your doctor if you have a history of drug or alcohol abuse. Misuse of this drug may cause unsafe heart-related side effects. Tell your doctor if you have any heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat obesity.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702722",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to phendimetrazine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703434",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Both attention deficit/hyperactivity problems and Tourette's syndrome or tics, high blood sugar (diabetes), drug abuse, glaucoma, heart disease, high blood pressure, nervous state, overactive thyroid disease, or structure problems of the heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698413",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often if you have heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699005",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad problems with how you act.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug early in the day to stop sleep problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695212",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fast release products: Take 1 hour before meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695323",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Take 30 to 60 minutes before breakfast. Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11825 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-190.102.30.19-0FE0C5A6F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_10_3237=[""].join("\n");
var outline_f3_10_3237=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208783\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208784\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020927\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020929\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020928\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020933\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020934\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020936\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020931\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020932\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020937\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020938\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/13/8406?source=related_link\">",
"      Phendimetrazine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_10_3238="Female pattern hair loss 3";
var content_f3_10_3238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Female pattern hair loss",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF7AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwaU4XgY9hVRtwfYAdzDr6VE10zTYDHaB1q5Y3iQRtJMFJ7FqvY60h0NuSVQDaO7NVx7qw04FFHmTHvWXd6olxGTh0xwAKzrKEXF0q5Y92JpXKsdRpt0bt2mkiwq/cX1NVLyabZcjdhm53f0FWRKtrGNg4PygenvWPNd5ExPGGrPdlpWJZ54obGOXgykcZGcVmeZLNFK+SzvjJ9qiAeVWLEkVovGY7OO3iQmebnjsKq4blZCFGMnyuPMYdT7Cr2lXRe8aJeIWVgiHoB2FNuoCxWzhT5Ydobb/E561u+G9IhgvJ7u7I8m3B+X+82OlLcZdlsM2O1FK3E0Q3/h0H1NZskLzaLEjHAIySexzV3UJprm0WTcTIw3qffpj8qTIls1jOCU+d1HekwSK1uYzYsrAghhhs8se9XrpTDaR300WSoCKpHX/a+lVrW3jMkpkbbEib2brsX/E1LqdwJ76NIwwheDC+wzwKALTIZEKjLbwAHA55rR06xhs5Bcud00Q3CMfw+hPvUW37LpjMNwvJMKik/cGOPxrStbcJp0cs0ojaUhmJGTx2Hvmi4GLA8n2i5aIACQjLY4I61FePNHNayxS7Np4KjJya24LUBZP3cjO5wit1wasLYCKPfdFFQKWTb95T6GhjWhPa2Dy2aLMJWd16E8mrdrpiWqCRIladFwC43BT9O5qezvRDBG1oI9+3kud3Pv71BcjU5jGWnVUzvwqcn2qWxanO6vI8TDbtjlzumfq7KPf0z6U2KdrOOFpIcXV5kkkf6uPH8z1otbWS91OWWUPIrSGNQR9454H070urTBtTFvv8ySM5kx3PQKPbNJstLUj8PiGxtJJCpQb2IXP32q/p1ovlKbvJZmeTd33Z6/hS2tirXFtEULRxDcT6tmr0ig36LwAgOcVPmJ2JBBFcKySzMSn3ie/esa+jSDU4sMG8yIt+VbttayPBJMVQBzknv7VVuNOf7eGlkUny9q8YwM1VxIwpJfLuljjBTcD17/5zSxwlYftg4ZHCRKONx6f41DreorZS2YmhkbcCFcjqc4/wro5TAtvbGLYQm5yQcANjoPf3oG2Z625sYbm3nIjSTAQFuWY8gfj/ACq2tsHhMDXMTNEN0jEd8VXZRJqEt45AWGMgZ+bLk5LfXtVhdsd2uxVMTg+Yw6ZPP4ipAasaWkKTyh50MewnoGB5rM05IZPtCRjEcmWBBzt9QfcVpWschtLxYfuCTfGucjpzxVSzhSwe7kTc6yjlCeV6ZzTTsBz9xi21SK0BdWdgSy8Bj0249O/FXABgeYymCIlWkU/Kx6HP8qfqkbf2rF5Sh55QqROOdg6Ej0NW7W3Fy8ieYY7GM4ZxyGIPr396L3KeiCxszqWogxKy6XaDMUf/AD1PqT6ZrUv71LSIqxC3cny7x/AT0AHr6D8asXN3BZwyJEChWMMxHYHt9fQVmQ6UDeR3M5BgjzIpPRjjLP8AhwBQmRa5N5IjsjJKm541JiRj1IH3iff1qn4a0xZriS7vPmwu7LDAPsP9kdh3rSsE8/7RcSKdr7VWNsjavqR+HSnTXMUEH2cB/NlbBLdwepP4CncRW1h/tk3l3M/2eyiwxQcs5zwcDr7elAkW3jH2WytYgG2h7gebIRjPA7ZqhdR72uCkpR5WUBsfNjrge2MVrR2axW0J3gsR95jwAOM470JlWRbt5riNGku72WUrgLjEY9doA7VM9zJLI0spIhCgkN39R9KyxEJQk8cI+yxcQ+Y2Nxzy7VavjEtsBLI01wzA425HPTAz0oE0WFZru8WYRJOiJtK/dVG+noK2InCKIp4lhRsFRnLH346CsSyhKW8sDbtixAkuQFBJ6nHesy/1mLTVRILaaeXJVi0gA3D0Hf8AGlYlps7NokWTEEkikgEBO/51I0Zkj2zOsit1Ujb/AJ+tc/Z3s1xpsZuGIyeA55U45GRxUJmW/RYrGTPHJVsge+fT60WJszdNr5TeWDujOcZfOD6e9Qz20MLlkYPIBnAPyjj2rOkvPJXYs55Hzybfv+qrUtgYrm2KwyFIEbLSHhgf6n1oHqU7ea1NzJDLHm4VSWkReoPGcVXi0y0uNNuEh2XawyZMbn5kzwVPvW+trliFgaQjpIWBZjnPUdPpVO203T7WS7nghkjM5bzFUNtZupJHrTuFzkV0SCC/hK6e7BWyHKHhR29sVzktjYPG8gsNgJOMyAE8+hNex3FtBd2wMty6tICqSKcHJH5E15/4k8KXtsy3Npa2+pKARLG67HXjsPcVSYc2mp57rVqXKSQ2ssaheSBkfpWbp1wbW/tpiMiORWI7HBq/fGe0ZZbRRHGc4wmGXHUN9KpSXxmU+dHEXwfnCAZ+tUtDnqNSlfY9sL2HiDSxp87bkMjGKVzmS3ZflIB/iGCDg9Qa84v9Pmtb248P6wux1bNvO3ARj91x/sPwD781qfaVjEx8pAI5LaZXiyuDLDsb9QDXRSxWnjXwlbPevImoQFrdJcBnWReqn1VuoHYg4psb1VjyzTr+60a/YHchSTEkfQhlPUehHrVrxNZCRE1e1VBaXLkOqAgRydSMdgeo/Gp/F1pcmVLm7TF2v7i5OOHZR8rj13LjPuDUfh27SeK6028JMNwnHrvXlSP5ULUz5ejOdoqZoGEzxHG5c55qDvQZi0UUUAFFFFAG5Z24lYNJxEv6modQlEkrbc7F4A7VJf3aMFhhXaq9hUUELzOsZyBTbudy1K6eZKcdvTtXR6bZJbW377gvyze3pTNLsVklMr/JbQHLf7R9KnvbprxGMUYVC2xMVLXQaRXWbeZGQ5UDC5qolmZTmQFVX5jkYrStNPELwrLl3kOFQdvc1tJYrd+dGyhII+WI/i9qexZztvZvcXIjiULGmfxrYvLEW/yxb/tHl5LdlXvW3YWccCCTA81xlQePpURiWaWVxIHIYB2/hUZ5B9TSC+pS0fR287Y52xsRLJKxxtAHT61pXLRNIrMAIlJRYx192P1rL1O9eWRIEOEV9wQDrjuaufY38p2I3NtwPmwCSec0C5Xcg8pZbaCVARGkpIyfSmBDDeXMoXBC5xjrngAfjVueLKSRRBTFCQi7TyWPWrNvbvHbSXU0TOwIKr2JHQfnUodrGbeRCKGWzi3F96vNjnnso9hWra2Sie3vpAFEcI8tTyN2OpHtUGmaXcTiCGdoxPK7SuAwJC55relW0nUMsjmGMbCyLzgdqGDMXEkpldm3lpNw3cdf610g095YVw2FhCqpYYHuaisrWOKeR4ox5KjzQW+ZicVbQXF1KhkLCPPCjoTjvUthuRxpb7mW0kd9uQZGHVu5pktuJIisILyEby7ZwCOlWYYpI7cxRpyzck8k5P8AKtVNPlVJHfcqAY449+KVxGRpT3EsEaQwpEFG5sJwD75q1qHnTO9v57y8YbYR8o71Xt7iOwd4djTXEhL+WxJCjHGamvZHCpD8qpjzJRGAv4fnRcb3KCxx2bMkRZmjQDI6KW7D3x3rE0+NvtpaEq8m87SR1Hf+VXIpd8EzsrBIyXbnnJ4A/LtUWjL515cSLlFQeWme56f4mk2UtDZ0qL/WyyciPJHue1V48rHGzjM0ykkHsMmtK2iEemyrH1BCqCc5J71WiljnuoyqkrnylVR6f/qpXJWpYa6TyhFFGGzgAqPSqQhmmv3L7wFCrnPTjNbBjRHQJGMLyepIqrAr7He6dOZGbj+72oDYyZtMhv7e5a5AkVNyRgnofUe9QadbGLT0tyFZYQAxbuP8a25i0Vv5MKksxLsOn4VnTRdbdSWwpZ2HUsT/AEp3BK+pXiiwJNhGBGXB6jk4GfX1pbqKU2logHyA7mPuOcVc5N5Mp/1McYQhB1Y8AVPPbH7O6sOcYC56Glcd7FGzjYNujACFtxP94dhVXUgiTXNwo+b5QyY7Y7e1XbKGWN4wits8pfvDuDTrWyU38xu1DRwgrGGOVz1Jb1z6Urj8zMjtLm6NoIk2iRSJZsY8pO5Huelab24t7bZEEgt4hlVx9xf77D1PYVrxsywKWYqv3kQf+hEenYCnagscUfltl2yCcHJ3f7R7t7dqZO5hf2dHBcQ3uos7Khza22fmkLDq9WGhluWkhcLydzjsi9gKixLJqZlfJnaMqQBxGueMe5rXjxBbn5S0mPmOOp7j6UXGzO2hWjt4kbax8yR+pUcYB9zVW9hF9cxJDGSZS2D6Dua1bW3ZUeZiWmc8noMmnXCmNGjZSnyBN4HJHv7UNjWhjRQwW4PlKXndydzcgL0H8qtzIrbGugG2pyp/i9B9BVkQLDEJSAVIAAA6+g+lS+QPMVnBeSTGMev9BQBj+XJdyLJcRt5OchCcLirkdhHskf5izHK/7J9T/hV5Y5JWZMDylO0kH7x9B7e9W/sZljfzDsh6+w47UXFJmZb2SvbXSJIJGVNgL/xY6j8O1Z0mkKzG4RRJct86K5+6e5PqK3LeKG0j3KjEHvjlvaobm2heLh5413biSOcHnFUSYqWks0c0TMygMrFjwAB2+nXirsNjDpkOyLEbyn7o4+Xtu9K2UWOE+ZK5Yk/u0cZPsTWbqET3kvl2joXY5k7hfc+tMV7kStbsgh2rMY+ZD5eFjPY/WklvnjnszbbfszuImRY8mUnP5fWmM8VlE9miF5FIEkzdSTn5s+1UvDX76VZmWUq82yAvyWIUkvjsKNB2Ne+uZLFI44suwfaXznI9fxNV5r7UYrO9mtV811kCqMcHj0749alaHzkhdskR5BOMZHYU14547K6mWQLNJHswCflXPBA9cUkBnDXpvM0qCFcSzzSZeFQUYjA6Nk4yT+VbM2slldozbeagySxIUANgjPY46VmXcVrHbw2byR7wfLDvwwP8WCPqcn3rLZVjivJbu4Cm8m2iPl18sdAD9BxmnZC3Jb3TLbxCJLvTmht55ELy274KSEfxKR19DjtXmfijw5c6Xcb1gYW8ilgQcqpHUbv5e1dja3D+GtWso7aGSexvXymWwoJOPl7fhXWXUikFLi3hudOd9ssMiEFc8q+e3pkiqTsROCluefwSJJaeI4YiSlvZ2xQ45LoVP9DU/h69e2vxbr01FJdoB6TKQ6N+YI+hNdFc6dp0VlczaW8IXUAUZbiMxleDlWdSRnPsK53U7RNO1DQ5jbXlq0LB1IImjwX4547VVyORpGl4hmh1a0ZbrEEV/B9ogk28pOn3lPoPX2z6V5qVn06/OVaK6gcH6Ec17Bq+nFpb+MNj7PN9qtvLOSoaPdg+nV6801cLf6Na6rCoWWEi3uFB6cfIT+RH5UE1Frdj/F3kyanDewoiW92iuDGuNpxyMfjXOTxGNyPyPrXU3tmb7w3p89uSwYlGTH3HAIH51nvpMssBfa2QAwH16j86Upxjuyvq8p6xMGlq1c2UkKhip25xTrKze5kCqMn2o51a5l7CfNyW1KWDRXWR+GJnQEryfaisfrVPudH1GfcytNtgzNNKeF+6vc1qWUbSymOMFJCD83XAPWotPjdNhePLMMIPrXRW1jJABEkHzyj97Mei10XsWo2VihefPHFpmnqzs33cdWPcmujttG+x26q215YU5A5w1R+HbD7As9zIQ11kqsjf8s19ver8kv2XT5TG5eZhhB1LE+9Ie+hV0mwFxeYjDbsHcxFXdVMVqosVXaMg8dSKz7LWFsrWZg2+4VcM46Kf8ax4pJLq4keRiGYBmlYklQe31NDY0i9LcyXOoecW2wR4BI7egHuau+QZokCqER/m8sHoByfqTRb2++0im8srbxZIDf8ALRunP0oWeS4LlVXJBVADSuNInFpbxu8zlZLlgMg9EBPAB9atwQpcqfJY5UFmibq7Y4ANV47aRYoI1VmdDgejP6n1FSxwt/aMUQb5bbMrv2LY/wDr0rjZm2tputIIsETvKZST9ehq7fxPdXDWUWPIhHLH7oI6/lWxZ2ZlkjllIURku+OM56Ckgh+0T7IV2KX4Uemec/WgncZZWKpZqbFCDcZUueuwd/bPpV6CwWW3FvGFSGNi8rngE46VYRJHuzFGpULhVGPlx6n2FWnERCwD96rPgD19TUthYhghi+z7mYgN83yjPy9AB9atRkpChUFBnao7/jWbdXMtxcyw2uwlEwu0cZ3dKvxxeaqiSXOz5Rjue5qLhyk9ltE25SAv164purXjrauDIzSOwSOPBGSf6VIw2AbAoUnHC84pLwGNFkm5lJOwHt7UXGlqZ8ds0TeeymSWSXazr0Ve5/Sm6w4t4GbyyZHXHueeBV6ZibAKWBwRuxwPU/Xmsa8lM90S7BhbAERj1x60XBJtmdeyRWlnbQMuZi287e7YzV6ztBaaXnbukbp/vH/DJqvLai8uYpI8bQmMr65Gf1radD9pggZD8gycdCelIcnoTQhYrZQVwvzSHHt0/lVHRkfKyGJUUDjjJGeetXdXP+jNCpw0qmMGtCGBLa12smcKFA9OKCVojObc7M3zbVXbxwNx6fjUkcClYUcgbcuwI4wPWppgQiRBRtJ3Nzjk0lyTJGkSKqg/KeT93uc0r2GUJGMdq1y+WeZsr/u54qKND5wIwQvOB1J9M/WpbwCa9iQErHDhgMduw/OiMgO0iL8pzgAck+tF7jIooHN4kKnIBMjehY9Pyq5eKjSeVISuVKkjjj/E1LZja8jnaoUbdx5zUbbpjJNPt5IKAdRj/PSmIh27bny40AQIDJI3XaOiihYQweW4VhbxncF/vH0PtVqCEBQuSDkEkjkt3P4VFeuZCtvEfQkegoAZFLJKDIfllfO0/wBxexp8VqBGG2lQgbZvPXPVvrT02qqcZXcdq+tWjHmNndvnzwW/U0rjKEMJhLZH70jaN3Un/ACrUcUbQ7C29Qe/U+9If3iRTSRlVkIWJT97b3z7nFWrEqsSyFBux0B+7TbERmFpJFRG24XLccL9fekksnkXkq6sQNu7H86tpHK0I3R7SzZbJ59hTrhlWdFwDsTdgHv0FK4rGXPBIZSZ/mKkKMDof61KIWU+XEA00nVj0Rf8asIHWVFbbv8AvMyn7o9vetOBMh3iJjH3R5gBAHrTGZvlLGY1XBK88Lwv4VFIZ5wF35ycZ6Vpqk0kpLRqy9OBg0+K3RptsaZCcADv3zQJme8YiT94ysT0GPvHHaoolaOJnkG+c/cj6hfStKd4hIZSQ7Y7cY9KzJbg7SFJeaQYGBgD3piM65SaRGRNr3Mh2lvSnTQrY2QjiOzORmM/M/rk9qkYyKjx26EsOXk6Z/GoHtGWaOGSQGbAYjGQnu39BTQyjDFFKkZjhKwgcqSSG5/x71K7NDKmwKsgGyPnAUnqfyrWICXOy3UMiqQGZflYj0HoOST61hyXZcPKGJ6qrDjPYke9FwV2TyjzQZYmJj87nPYAdB+NSW0fl3MrO3zFhwT9wY6fWrVtEY7CNHPQDbk55z1NU72QCNvMcqFkLZX7zYH/ANemmLyOb1O4iuLsSXS8QKzk7fur2H1P9KzdY82O3t4VuIZbmNRI4Y7TzyuPoK20t0uZ2l2t5O4F17FRyR+PFczP502tSXNxtWInJwfXhR+FO5oom9ZgpfWsc8SPZyOH2N8wQjByD2IOa045gLuee0Z5snBhYYBVhhgM9eOaxNBhnBtypywQ7gOmC55/HFdApVrxuApgXdkdCTjH+FFyWirFpjWry2jJ/oLxl8E47ct9e1YunWl3Frvmebtt41V5FJJRhngY9TxXWzM0un43bZ87zjow7iqqqs+xMBWDbnP06CjmFYsNaJLdC4kOwvEoYoCQ2NwHHbg15la6VFa6hPpU0sstvfp5BlCgKJAcqeT1yMfjXqGoSG1smVVLElI19uBmuDETLrUEcUi7/tJIRxtZTu5wTwRSV7i5bx1I/Cclvb6Zb20iyG3nZ9yvg5AOM8dwea6e80uK2OzOUKna2OozmuS11v7P1GFoU2RIu9o/7hYnt6E5wa6nTb9NQ0SRQx82HLruOcjHIrnqwcm0bxXLFNHGeIYI4S+FHln5WGP1HvUPhKzU3pDjkHik1SZtSE4t3UmPkoTg1F4bnnTUYkWMmRM7lPXA/wDrVkoS9lY6Lx5j1iCzh2AFR8vGaKxB4giQMuQCrEYBorjdk7E8ktzn7KG00+0+1SlirL8m8Afjip9GsZdSna5mdjCMOQT8pI6Cqmp2s2s6gYFB8lMFcfxc12sot9K0hLUAKQuG28kV73mcD00MfW72GJGjtysQPJLetcZPqT3EaRw7s5OGIwSPWpNS1BLvURarCkke7O5iTgUsBgmdStv5UbHYm3ug6t+NK5rGNinAshg2kgFsHaehPb8BXXeHdIF3D+/JFrA++Q/3z9an8NeG1uHN5fxHym+VUzjCjoK0tf1L/RzYaVH5cZwpKDAb/PrUthzX0RhaneXFzcLDZIyW2Ngb0z1rS0zTSFEMWOuN3cj2qLTrR57nyiGUKuB8v3ie49h611tnp32RB5WGmxtHcIPSku4pO2hXmBsoEhjjUXDjbGAMsF9TVWw0sWkypKGkdzv2E8ZPqa14LIW9w/lyF7l8Gadjwo9FHatCCBZow7owRjgIepX1P1ouRexl4lNsfk3NN7dQOh+lWLO2+xxKiDdczHBYD+Hua1obEkpHK20KAz+w9KjumKXyQWwDOeWY9vTFJuwJdipfh2Js7Mli+FZl64/wqvbWgt4GcEGY5jzn7p9BVxwbcZt28yVzsaQdSfQVVukEcih3Y29vwQB95vrUcxfSxDFaiCLAKxnG3IXt657mpbZYxJjzGyPlCr0A/wAajkjuLudURdq7wHz0AI6CtVbSKFI44OJCgBbr19vWgNiaGIQKJZRvdsFIz2x0zWTeXAkv5TJmV0IChf7w5x9BmtC+la3g2lSFUAAufmY571kxpIkDRI25pnO+YjBYZ5A9Fz+dJsIrqySaT5o03l2QNI5UcZ9B61jSx7HSJcMZXLFuhAPJNadt++WQhiVyUDkcY7kY7UyMLLdSsy5TOxRjk9h+HU0MpaMSwh2mMgYTGVHt61oWkW+eafjj5RimRRYSZlOD0X2Pb8AOavKnkWA80lBgc+uf/rcUrkPUjgsZL25t3QYSNixJ9O3NX2tx5kgkZpAVwFX19zUliV8tGKI5bJIzxjsMVJNcRpIcfO6HBHQZPY0XAqi2JRQxRQ/JPUj2qq8aJMVU7VUHPtVyWcJDI45/hHrnuazZPmhbGQMBW+p7UXuO3crpb7oZLlwxM4Oz/ZQcL+fJpLWM72ZzhIiM/THT+VWZDsg8tjwvJb09B+FJKCz28OAAcO6nqq9ifc+lBRC8Yu7tLdOIQN59Cc55qzLhduTtROBj+dPhiwJpN2VLbePbtUsECzTorgiJQXdjxgdaAehBcMscQZxhmTIHcL/9eq9khbfI2FZz6c5xwPpVjb9pDzOm0zNlB6IKlkby1PljYTkD8qLitZFO3iMt821cxx/IB0z64q+8SEDKghRz6Cks4GitlaQnL8ICecetTXSNFEiIMvncw9fQUAV1G+eBm4VSzA9cADA4q1DEixxRgbcnnj86LeERTN5pztG0DsT3q7FEqwo2Oo7nJ/8ArUgGCIOpbJYZJ59aoxItxdy+WTt4JbHoOlasuRalANiFcBO71BZQFbZVA+djvfHAUdhTbEiCO3Xzl2gkBvmJ9AKseV5p27NwByoJ6mn+ViUqoLDk49farMVszv8ANkKT8zD+QoASJFSM4Z8E7UAPB96dLtiTCbTIW27R1LEfyFTsuZAkG1TjJPUItQmNppzHbLtROGmPb1/GmmTYyru03MIvOBVRl8L95j6VLFp3lhyojDnA+ZufZR71sMsbKEgG2JT9/HQ+p96qXkfkr5udp2kIuOY17sfc9qYX6GLNG3nY3fukIVkRCQ3sKrramFHu5gzNvJRSPlkkPf32+9biQAwhnVI41IZiR9xe31Y1Wu28xiCixkDAGOI07D6nrRcaMVBJv8ycln2naPQd6pRQxzOJfKBw2xVxgD3+lW55hITHErO8jDGeMKP8TTvJxJJ5jbFIwAP4uP0ouNIq30zMMj5VBycnqO2Kqm0byUaULvmVgUznAPp+lT3VtugV9nzM4VfYU6Sy2TRTEM/lJgYB4NMFoVJhFbxxwxYaSTgq/Ge5rlNc0q8kMULW7Z38uvKtn6dhXU/Z7hppZXbyvmwhdgfXkCltbWOP55iXIPVMxj6e5p3KUrIoadZSRvcGBss6rt7AYGB/WrU8ZUi3t1BmI2vKegb0H0zmtAzEFY4ziSTkIB0GagvCURo3Vd3O5h/eJ4FNtErVkVrKg2CPHlxfJGevtk/WpJrQpdI0S/6zbnHb1qrp2nyyRxxEYwSSwGOPWt7aXtZ+Pmydp9x/Sl0G9GU7uM3TRQRso2tkk9sn/wCtWNcWNtaz+ekaeYHMjySDccDJPsM1uIi+aZk+baOfTpgVV1C0W5sZkQkbhjPr6/pQpWG10PLtTu5Hhhv5VyS753DOYmPKn1X+XatzRbWe1sJbqzk822kKyQkHoMFWU/QH9Kv3uhtHa20Xy7VJUjHUFTSeHLR7bSLuCDDkOJYFJyAw+8PoRxWiSepLdkea+Jg8GrtMh8sudxx05/xqx5k39mLqdo4aSCRTKFPMbD7rjvjsa2PiHpcEMzfYt5csJhGedsbjIC+uDu+lc3ou6yvC8irNbPAxlVTkPGeo+o/mKdlsc8pOMtOpN4luXTVZZoiTDcYmRh0O4ZP65oq7r2kpDYEIzMY40nhJOQychsfoaKXJHsKderF2ueiQw29mIYiczyIGJ9PSsHxPqDyblBVQP3Y5yS1OurtrdSsriS9kHmt/0zXtn+lY2mWdxf30kZbanLSTv0jHoPUmnI6YRvqylpmnTzXBtY/4z+9lXnjuAa73w9pMEsq3GA7jAHGVjQdAPc1V02yXaLTT90aMQJZCOSMc4rpVuIdKsBDbRsIQdibP4mxggeuO5qRzl0QapqPlwSQWvlxjGGcnhB6f7xrFghe6kjEMIJU/eYEZPar+j+GZJoFvta2xW6MGjgzksRzkjufety1El3cEWqmC1Pt8xHYZoITtsN06xFkhSQtLM5ySDnHtmtu3tJAWkKoeeg5Cj/Grum6Xsm86QAYGFBPCjH86kvNu+OytGG+QbpXUcKPpSexm2Zwt43jcEFEByWPerVugG1wMN1UPxgepqzMPLk8vADKc4b+Ee/vVe4m3vu6qR8qE849alspK5BcvLIGWLbmQ5JxyQO9RWsMO12OV7NITk4x0FJIjeXvLFATyAck/WiziadQFjkDlsDjt61DdzTlsiSC2ikm8xFCBV2qGboO5qJbEXUoEJZYEOcMPl3eufWtkQW1tGBcDz5ugiHf3Y/Wqt8zIzvKwG3CJFEBhD659aLE82pmXoEEf+irIVDKA38yfx7VPHEtu+4sz3BGTg5IqK/WQLBGAzBeTGOAM9M+9aSRw29tsiXfcyNt4PC++e9Md7GLd2rXcqGUHauMrnjFLIUHyMG+ZdoQD5mA7ewJ71v3EZtoAsW15fmO4jqfp3qhb24giBc5lKh5Xbr6//qFKwKWhnlAICTiORU3bVHypmqFmrTTSJGB8gx5gOQxPFbF0QtruOFTcXPcNUdhC1npjzjG5sEZHOTzSKTshsVuGuVtkJKoTv9z3/wAKuzBbm4hVMlVJx6Z6UtpEsMDuuGYYQY7setWoEVt7N0GUCjjOBzzSEBxFKdobCDpjpVSQblLbc4ycf41PueREVjxIxZsdAB0x71FcYLIdxVCxJI9B0FAyo+I4QHGQOPqaiJSMpvbC5MjsfXoMepq1IgEm+VgVjXOPU9qr2kZm864lIKCTKZH3cf8A16YxIVO9RIMxtghD6+9LawvJLLK+dspPzY6KKsbj5fmBctISVyOcZ61YtUwmBwgAGPU/4ZpXAdHbBgIYlCwRjjLfiTUN7GXtlhBVGuG+ZvRB2q0VbDL2Y4zjrUMuPt7tnMcSCNRTTJ3dhphR7pyknyxAJx0qBIfPuvLXG0j5j681PbIPscr55lbOfrU1jHsBmwGLcIPb1oBsesBE7SMBkDCjqFUdPzqPYPPGS2TyTjoPSrMzMiLFAp3Hg47VNGhRAJcmRvm4HOPSgBhhWOBC5DSvk4I5GT1pyWmyQBmUkYwAMZPvVoRobgyDORwB3oaNss2cuOeOcegxQFyrdBS7tyWjUlm7A4wAKkt0xbqvOEUZJ78VI0G2zkLZy554xUpiOwxxgnj5j6UguVIgkchZ15ZjgL3q9LthhILKoUZJxwvtTREtsfOcAzZGxV528d6S4ClXDZYhdx749qdiXqVZS3kqihkLNkg9XPqasLkxeUG2woMu/XP/ANeo4oHk2uQdzD5f9ke9WY7dn/hOwdM8c+tIp2GtcqsaCGIED/Vx+p9WqFLJ5pd92/fcR6mrqAoMhFOD8vYE/wBabM7R8GMmdv4j29/f6UxWKk7K4XcAI1OY4/7x7u1ZV7/qiZF+ViTjufc1rqiopZ8s2Oc9azrsNK53cP1YnsPSkUjLggCGSYqPNf7oJ4A/pSwr5suO7EAE8jHerbICoxu2DkHH3j704RiM4OQVGOvtk00DM6eLddDb9xTjjvmoLuOaZZ0LFo1+Yndn2wK11hDRmSRdpYjr6VSkgDY2AkZwFC4FUSkZUVk8qLLMpVThsCmJFNPJJcSL+7iG2GID8M/WtmWOMRLFHKSzMQSgwFHf8qkCkyBIlbjlRjP50Jj1M2wtdqvcBQJypCs4OR71CmnvKiG5Ygl95VFySO1dIsWxGaSVs7dv4nviq9zcCBY1AkMjEkKMbiB61RPM7lR4kgiQBSCg+RPTPc+/tVW4Xy4oGb+LjHoM9qvOXdlMoVWOGI6gVDqiFY0WAk3Pl43nouT1pFJalPy8RPAnUNuz6+34Uu3y3G37oGMGkZzbgxSKdhGC3YnNXGUZHAbgDjvUGi2Kt1aefb7l256g46VhrbfY7Z0jTGWdi3c4Xv7c10kYZIz168j0qPUrMNbtjq0Z/Mmqi7ESRwXjy0TUNE+3WQaO4t4EuEI9M4b8jmuA0aKO/tb1lAjbZiQDojsQA4/2T0Ydq9jWKNtHSzdCztbyxDjI25z/ADrzFLGPRZzJO7LBNPu+QEgKvGHHUockHFbLYxcdbl6BTdaFp80kYX7PO9hcdwoYZT9QRRXUaVpUN/d3NnA3+ialBvhkVwyGRDuXB7kEfXBopqSW5TscZapJLI0t62yW4PnStj8lH4Vo6Osk0hLD/RY8MwX1P3R7k1WnEl3OLWNhubaowMkFv/rCu70XQk022ja53b1YtGnTe4+859hwBSZo3yokjs1toHWRvLunAwAM4B6gY/KtiwsNiSyvF5bKmF3HO32x61Pptqy3M8jRb5QoBdzk7zzWuLeKGHfOykFsyM3TPoKVzFu5kf2a94m2Rmjj4yM9R6Y7fWtCHCfLbIBPIcBewHYCoX1BrqUiDhs59Mc4/lWXdSSfbWitmLtJ8u8HH/AV9Pc1LYJXOhuLzySLWBw1wRmaXqqD0HvUSXqaegih5vbhsnA3bfSshF8qVLWL59mCzjqT6n27Ctu3jitnZ1O+4PygDklvb2FTe5XKkRyMUi8ssd/Q855I5Ymq8dm0hOx3dsZJI6j2rUisO8/BPOO5NXo7VUjB2oiLkuew+vqfYUbj5rbGXb2E0skX2sLFE5wqJ1wOn41pSSxR7lgZcq20KDjHsTVeZ2Nyv2UsNy8FjyVHU47Cq6xtdTCKNMA8IE5Le/8A9c0WJ5m9WK8nlsTEqzXDHG0NhRTprFtglmJkcnaE9W9QP6mr1tbQ2gbzBGJBkbE5Cn1Y9zU9mNsrzu3my4xuYcDPp60JA5LoYL2YVwZz5cccgJAPzO2PWtmxt1YteXIQ8ARRgcBff3rNB+0XDTyDfHn5FBxuIPHNXmeaYjyyDN90Y4SMd8Z/n1pid2NuGXZI+0tMwIUfwov+e9UMeeQAQ0b9WA4AHXHtnvVm5t1vg8DM3kRj7g4Dn0+lOhi2Q7h93aFVT0UDqTUgmZeohZFRSDgnG0HGVFJd7TLFCBkr8yoBTomS4nkuH5iVgE9var+m2ji5eQRkyNyB1wPWpRpsPFv5EUcS4+QZKgZyx64qW4QRWvl7GUH5Rzz+J7U8JLK37o4DYwqdQB1JPuar3MbSXgiOSifP5YOQWzjn1osCZEyRvGXZgo6ALx+A9frTUhSVmMyALEvC+hq/JEkYRpsNOPmAA4WqM8blZpGOFcnAHT60g3M+Ueayuo2AcomOGI6Z/GmIhjt0hJ3SZwxHcmppcyTRW69SMnHoKmkCpKdmPlIUD3oKKczfOpZv3ana3GTgdvxrQgZ5EhZlCljnA/hXsKLez+1XKxqCIoxvY47e9aSWrD5pAMEcKeuMUBdFaIeYw25znJJHbpVCaPMrPwCwAGOfb863bCMySiNAMDdk/Qf41VW0LzQH+AnGPU4qkiL6lS4ixbxxhSqkgthelTxwttVfUfd9AKuXUebkR7d2/LHB6gdM+1OEGz94Rhm+VeOi96Gh3IVTM6q3HysxI7VPEjGYzMxyMBQOw9qlsYt0szOMIFzk1ctoGeUfLtYkBF/z7UWFexXt7dt0jPlmJ2gdcetPmiKqcKuVxj6mtKeNbeFghAJbA56VnTKwKRq43sdxY9B2pNW0DfUbdZ2RJuOSASafCWViCwGeAcdPrUssLNOwByQvX26fnTUgSMDLA5PPrSvYaRAyHzSoKccAnGc0iKzMQWUqOpAxmnOwR3kVWBGOSc1HaJIWDsd6AliR3JpcxXLbclhjZQFVl3HqSM4FTtEFQl2Yg/dIHSljb5dxX8aJrhGZQO34/hTuIZ8u1RHE7SY4BPb1NR7XHzHedvbFWi0rKWBZB3wMfhUMiMqorD5mOeT0FAmVZvMA5Tk8njtVCSFZCoZNvdiG456CtK5iZm8uMbWbrg8gVE1vjCIhwDyfU0wRSlt1Qjsg6EH5SahmiAC5b5yPT860wgGfNwVP8A6ACo2iV2QqhK/3mHA9vrQBQlRUAJJb0zzn2qvJAfulJXY9ccDPpWo4DXKsq4JGVz/CO5qvKrYKqSCx/wC+R6/WgFsVIbdRn5UAYhcZ7f1qeIKqPKSoOdqgDqT0qxbW5aVio3dlA9akaIRyIqqMJ0A/ib1prQGUL3bCEJY7h+hrNmhKwxJGoVGHLHrknnmtKaN5bjcANvdmGeaREWV3crgdAW54A5PtSvcdrFJ0XdGAfmAOOMkDp+FUblmadowTnhAD3q1ZqzXJUKwXJOSf4aIo1nuAzZyX6nvii5S0ZDcxIZCemzjntVeFdsgQEjnhuxNbFzaGZg4ONueP6Gs64i8rK8leq+1IaJfKaT5Co3dz606+URxlTwSQo/AVb0nDoFc5ccZ7k0uoKpnWNhnb/M9ab0Qr3ZkwWn72BAAuY3GevXvXmF+Yr3ULhZUEaqfKQjldoPcV7BGgjfafvKmAfrXnWvaZHb3ZOw4JJOK1hLoJLUwfAzXWj669k8zR2okE8RwG2nHDL9eQaKvaPZtJfu6ruUHMZ7qxGCPoaKpkygma3gDQU+2S6tcMEhhLyZfoOwyfpW5FOdQWe8crGJWEUCn+4OSfpROippK6Rb5CMqGU+oB6GmSu1tNbRxqBGsZf6DOKL2Ifvam6tykI8vILPyD3+prHv9TOoXq2MGHjhPRe7epqpcu/kvtZS7DG7PTJqfTbD7Bp7zbNjzqSJDyUQd/qazbuy1FJEqycm3t1zKSS5B4Hbr+lacUENnA00+1ZiAq+i/Sk0NIkg3McgDgNwxUetWY4hcXJu53UWqjdsA+/6AUgYWcYjgZ1PzMOvc+59qsWqKCC/GRhdo5Ue1Hmrnz5IdvbYe/oKgS5N27nDbVI4Xnn0oFuasdwiYP+vYAbYw2f++j6VKJmuXUyMFSMku2Pl6fdX1qlaoq4aUK8u0l9v8PqCe/0pjvLKyvL8sa/djHAUe59fegWwsCSXNwWVSqHqSOXPt7CtTJg+SD5QTyVI3E98t2/Cs+2ujJG21JFUggk/eb2A7CkjIiyJHjUKp+TO7A9T2ApkvUsXEqyJEgQBAciNDgfUnuaQuxgcM4ZEBMmwYGPTNQWf+lKfKyI2P8AF6Dvira2sd1L9ln3C1jId1UfM5Hb6UDskUNKtJb2V5XkCwABV2DAA9M/4V0SWIWJYwGEKrjav3pfrntVzR7ZIrUjy1MgyUQj5Yh/Vvap9S3W1sgBzLIRuz95vr6CrtYzcrmCYljQyHAkJOfQDPQe/vWdeTqbfyoSAWUAZ7nv9a0dQYMJGyBGeNuOvv8AzrFtLT7TLEmWX1I6BRx/KpZokty5p9vG6LIFOxOQvbOMc+verVu0ayyQ5Z2YhAqjLY9+3WrLJGsIDZRB92Pvjtn60ROkagxRDKgltvJJPvSsFya3s2LfvHMMYJAjBzkDu3+FUZyuZjboqBiSGPHA6ZrQvWYWgGVUSD5uxPHJzWWUkupAAm2EKAM8BaJBHzFgjaSRmOWUHknoR6fWqV2jFESH7ucdOgz/AErYmmVW8qBSM/5z/wDXrOLG1WPoMITjruNQUtyoIVV5XGS6/Kpzg9P5Uqx4fzXXA2lgPerIRpEywPzNzgc89q0I7DygZZGRY1IHr09fenbQGyG2VrazVpAA8g3HI656CrpjdFjaU5mk9fzqxZxNcxidoykW4iJWHX3NaQtl85HlxkjAU9Bjv7/SqUCHJGbploIkDOf3i53/AImkmtXiPydVYgY7c/8A16vWjCZ5iuMB9pYeuKkZzI0LE4VmL8+wxVrYi5jbV8+VgMlOGJ9fSnuuVVSuTuwDninI/mSMGAG/cfwBoukCXEUS5LO3XPQVD7lokt498RwRgsWY47CrlltEsssv3VAIPuaoLN/pD24yAmF56ZqV5AyvHGWKq2WOMk1KZXKx94POEfyhgzE4IzioGkIlkcAg/dUY/lUrH5wnJKr+tRRHqTkn9Oalu7LSshY0kYYA5J7nGaekDMMttU5+YkelTqmcJjcAMfjUc6/MSI2IHHWgEQPbb3O4bsnaAP61YigCybIzgLTIFYTuyMQAveno21hgEZ681NkNjZo23synAUdRxVNFYzeZj5uuf4SavzIzkRoxXdyfU1K8aBAvOwDBY9T/APWo5RX6FVZtxAlOFHOQfvUL80jSyAc/dGajmi3HDH5D1YcMfwp6lftEcYwCOvbAqkJk8dthS7H963Uk4FRywbucjYOme9Es5ubgRBiFJ5I7AU64lBDCPGTwM9hTuhJMqSqFDvsA6DI/pTNu0gHPIwqHt7/WnFgiBWYn+In1oQFsOxwOX564ouNoryqFlYAAs/AY9ABTTGREx6luM+1WLULtHyktJyN3Ue9XraCMOztnyo/mbP8AF/k0JNhexTjhNrAvGJCD8vc56VVnRhGf73XJ4xV25ncyM5GJG52+gqrbwvO4kfJj9DQ9dECVtWVreAyK7ynaoG5vYVFcsoiOFxvwDz0FaUjhgy7tkY5Pq1Zl2PtDt5YAUfeYdBS+FWKWurKxjMCltuCw+XHU/wD1qrWMam4SMkb05J9K2JE2QAtyQOM9RjoKpRhYbV5Cv7wtjp29aYCwyKXkR+M8g+9MngSZSTxkDBqnIZElL5GCRgA9K1bREufKCH5TwTjtStdlN8upH5X2aJWUfPtJ4/vHj+VVFkMjsdvzDjNaVwG81v4gvQ47msm6DQBm5Vj8v1ptkxROiB4XcHBLEfgK57xBa+ejED5u1b3meVHEjA4C8mql4FkYHjB6jFA0jh9EQwz3MYzlULc+ooq/NA8FzM6KR5ny564zRWvNcTJbJnneSf5kkf8Adkeue/5Ul4u6aeGIHazbPwFW9HizqEz4by7dC2D03H/P6Uy1gaa5SVD8sgz79amTJitS7Z2Qit0lZf3hB2Ajjjv9KtrG11IIULBOMsfQcD8zU0kZkkUNkADy1A6bV6/rViHZDIoIId23cf3AOB+tJA3ZCJax58uRNyZ2EdS2O3vTJ5JrmVIxH5cNucHHR3J4UH0qF5pXcwxuTcOSSF4Cr6f4mreyX7Nb21r8hIYA56g/ef6noKLiaMu+YznyhJIc/KDGMsxzyQPTt9BWjb2xt4oraIRrI5G7Yc59MnvinSxfY1dYTH5pOPMPQY64Pt0qe3tJIIlJixdzDAwc+Wh/qaAexBMwSXyYPnck/OxAHuc0sw3LmQslunAc9/p6fjWh9mtrCORpmzK4/ebRk/7o9Pc1QkgaZXPILDlVHCr6fWhsFrqN+3rPHi2jKwgcY7+5qWysDdQPAAXR/wDWPjhvan6daRzvl1MdrEAT6knoo9TXWWdqYYo/NUI7/diXjy19/fvVRVyZSS0RQs7PyvkjTlFyz44QegrQgtPItjsCLJOeXPXHekvZkG2Mh9hPYfePbpUBvWknG0livynb91fbPc/pT0RnqzSe7jhCpjDZ+WNf5k9vrWJLdNNLLKNuduckcL9KnlBER3uoVuWJPvVa4ZfKYQryTge/uc0m7gkZs0Us7NAhbLYJz1Ue9X9Ptz5bBSdqtyM43Y6Ln07mnW8cdpaSXEpO7aOW6+1ZiXd3P5q26hYT/F1OT2zSbLSbLxVZL2QXBLwp0UHAJ/wokuTLLHHGhKx9IohgZPTmm2WmNGscl5MGEYLOi9MnpV9Mu5itlVF6yN6egoSC9ipGrzPK0zHLDsM7R6D3NR+YgiaJThSSQo/i+tXSwKk23yRL96Rh19TT4rWNEdo/MkbG0SkcAHngf1oBMoosZWSRUbzFG088dKgW3dnVpEXecBSeDitRkjRRuBdweEHPJ/SpLRGe5aTaFBPG/wB+poSG5divFaSPPBFGCGLb5GI4AFaH2dJLlY1H7tGzj1Pqams3MkcjrlgQScnGR/hVeKd1iEafNMRlu2BmnoiNWaMtzBapJ1YoOmMn2ArMuLqUNvlYRkKSTnPljHb1JqFSYVJBMkzksxLcA1Svdwgzs3BUxuJ6kn9aHLQtQ1LmjzB4PulFflfU9+ferl9KFZo1GBGPmHqTzWbYkxGFnIx91QPTuaSedptZVTwmTvHtS5tA5dR5AjsLiYckAqmKlhY3FxatjAZAzfWklHl2kcQAEbuwAzz6VZs48qoI2FUxn3xSbGlZXI7hGNyDj73APpU1pZ7HKsxwSOnb3p8yNhFjbBXnnnNT2M26ZX9e6+oqN5F9Bklv++mcEBdx5xTEgAjRcAZ555qdhvViTu3Fj+tTvbgCM9wB/PpQtSblV1VI8oFODzt71WdmxgRNu5xg561enjbBAIUbiaiBkVhgg56HPNJvUpbFK2lYSyBoxgcD8BToWDS54PGD7HvTjlAwcAkZwc4OaYkICEgMGPfNK1x3J4ZFeR2YcAcH2omkAXLA7ewHJxUckaxRIHxhufxqGNTLLlmVQPmYgkACmxeYRkFWlYgYOAf60wn5HI+6T1xyaiMpupCygiFThQe9TgMQHkO30AOaTfQaQkJaKMmXl27jsPSovMEsvAbA9BQ6uc4G+Mnn1/Cn7VVM4bHQClq9B2GFBI20LnnaBUs5XZIDwXIUY7CnRptcueijgnsajunEU6RgFvKXJPoT3rTbUm/QkKgAlhnjAA7+1SXNwViW3jO5x80gHTPYZ9qrq7BPOdthAxGpHf8AvGoVARPlZ3LHjjGT3NO4uUfBbmWQyXHCAHCj+L8akuZxGoRQAO4HQD0H+NEayAs7Lt+XGM5NN8ocPKMH2peg99ylJHJc5RyUGMkfTsaRUQFEQBFQ8AdWPrVi4PlkEcjPb+tFuCWZ2ABA4NJKw76EMx2uUI3H+tUZJozIylXUMNox0NacrhiSGBAHJPf2rLnLIMgEYPOOwoGkVTEpXgMxT+FmFaemgw2bs6BcKWxnOB2qGztVklYEZiA3sPT/APXSanO8ckMcfUsGkxx+FUhS10GRzshGTlX+Yg/pTfkuJVDAFBwM96ZciKeYxoNpU4JPp6VOI08sOBkYwMegqdxlW4TdG5bscCsmbLoFf7w5ArUnZUY7hleuDWVdMPNaWMnYvUHvQUjJvHd5oFUAh5RxjrRVy3GLky4BZANgHqelFWmZtamlpyRw28+5SXnO7jjhR/iaZpsISbkfLGM+mTjj9adauTfueSFQBQfcAVMCWXcAOWyQPQf/AKqUmCRKFLXA3cBV25A49zUUBM4uJ4yVJBC5HbOAfzNXL8hfLhU4ZkDP+P8A+up7SFMxtyI1JyB/dXoKQjOsLFITJuUhm++5OTtFXQjQTrEFdbu4X5yw4gj7Ae+KtW5Cq5dCSf3regX+H8c0sETvbu8zMr3J5A5Oz0HuaaE2V9Ms4r68SZFYwx/LAjDgkfxH275rSvLqDTlfYyz3MpxvLcufb0ApftK2du8NskZkYYdV+6ij+Eew/nWK1u01zgIDOf7zcJ7H2FVeyEld3Y2MyTtmXdJIeoA2qBVqK3ubtkhhOyAEZ9fcmkhgdikEBZ3k4YgdfU/SukSOOxTy0iUyqNz5PPShIJS7AsUOmxwymPzJRnyI+2e7t6VHayO5aRmEjkne2OB3IHqaqyMud9wxdz/D/Co9vU0mpTG3tVgKhZZcKFH8C/3R9e9NyM7aCXG65m3yuyQnPI6Y7kn+lWYpIY9pV1AUEFscD6e9VJTFa2wa6+dk+XYDwO+PYVJapysskZYnmOMDgd8n2pXKtoEubmQIRt/hSNh/48anjt8qJCSIAMDd1btn/wCtVlLQATO5y7rj256/hVS+mS4uGiBGxcbic4HsKb0RK1YXIglKQyB5iSWKoCce3pihZGmmNutulvCgAIGC2MdPQUtzIYYhDFndgDOOnsKnsLV9xQkq2AzFuw9T6GluytkQtGz3EVvArbnG92HIA7A1fW3Ecaw4GD/CTgsc/wAVT2kkIWRsle7v0z7CornVEgVxawBGIwJCMsT/AEp3SFZseLe2BZ7x12qPuEdvYVV1W6e4RRCTEjAZ4wcdqpxOx3yspZvuqT1JPXmi4zcShpNxQcBVPDY6VLndWKUEtWS2VuY44gUX52LHdzx6k9jV1wUtwcEzS/KvoBip5EVGCPuyqAkjtUDyk3EZLcRxliuOpPaq0SFq3cRI/KtrmNRyFAY57+lV4UyXYKcDIGO9Tq2EKNkBvnc/WozKWT5Fwg6HFZtlxRFPHiIFgWbHHpTLiGV1CHgKeMgcADtUnmIzRgnI3AmlvSZtsUec98f1qb3RdrGXbszXdwxXCKm1KfbZRpJZBiWY42jkgHip7bDTEeXtjXndng+1WFiLuGOB+83EChA7Iq6wrCSMBjmNBkVqWvMHH9zJzVLV13XbORxkr9a1Ldk+y7R1CBapbsl7IjZlAzjn070kMrCQgAgjPb1FXIoEV33LxkYA70j24RmMZUAkc9zSa6gnpYjhjKwwqDyxAPr1rT8lWL7eNo6+9U41G+Hvj5iau26nyiNw+ZscVpEiRnSo2SBuJzxjtkUgR1yWiUYXPWr5UGRyD82cVEVBDsRwazKuZhV2TIVct0HpQYJIgqYOer4q26hpVAAwP5U9SJJZDxtAAwPWi1hlAI9wmCASDxjrTLuJF2wq2BjdJz1PYVsmNY1AGOnWqaQozs2ATnJYjmh6AtWUlijZUUZKAcDFPWBTxnnsDV5YgOxH41HJb5GWLZPU+lS0UVWtlZuEGeg46VE6YlWOPnZ19jV6FFiVpWJKjjJ65pkYEjlx2/ix1pxWhOxFHCfNQPtAXLvxVJ4w8zyuByc/U+prZkCw2jOQxZjgZ9KzzjIbAB96qTtoKOupReLdKGYls9+cVMqRFs8jspVqsBMuWBdsdj0qGSNFYnYmO3BxSKJFCDjKq3fJqrKZG4hUNzy2ev4U4lAvI644UcEUpkJQHaQxOOc0BYqMWSQ4ZjIeMleaWRxgRlTj+LGBzUxgZzvj3RgcBScAn1qFYEXJI8wn0GB+JoGis672DRjkcDef6VVuoMnazsW7hBzWlJGpTax2r1IWlgiESKyA7jnaCc7f9qiwXsVlItEjyW65bB6t2H4VSuY3mLOW4OVB/iPqauTAjKRct1Hue5oaVHTDYYAYz0/GgSuZ7oiQ7QNpAwSRyFpttMCjbCQBzj2qa8VWchc5K5+X0qrEPJfyhhy33iOwo9CkR6lh41253H5j7VhXshXhFJXH61t6jIFJRSd5OOBUMunfZLyK1u7mETSY8wjJ8jP97HfHOKEh3RlWo6FWx1JPp2H9aKvarb3A1V7fUDvb5QXQgBlwAuMdRjH50VotCGyvpzM9vNKH5AIPHv1rU01i0sKHa+5wvHYVixW+1SInJXPIPpnOav6azDUFkK4CoWDA9azKsWtQuvOvZZiABvIGPTNax2pZKckZwn1HVv8ACsdNs9wCcfLgkEdR61eZ8lZmc7APlUe/ekLyLO0NcLDuwrjdKex/yOKnmuSZt4OH+7GAPuD1+tUzcC1iMswyzcEnv6Cqtmk9wBNOxT5jww7dgBVJ2JWpaurhdOiWOLMs33jtGWHp+OadpyHypbidsDGAB39fwojiKEkIQzHlu5NWULSMkW0rGgG4D0HRfqTyaFuD20NLT1FqslyVU3AAWNScDPY/59KbO+21nlYg9cyE/fc+ntmmXzpGsaggkDdIfc+n8qhuI4roRxS48mMbiewJ7AetU30IS6shshsT7bPukCNiFM8M/wDWpl2RrJdXDFroklT1w3sKY7xvN8wAVB8kYOdo/wAafykqb4w84ztT+Ee9TcoZZ2yje80Z3Nh1Vsnn19/pWvZw/vTv+aTq7dvYZrNed4Y5ZN4a5YYLHoPYVo2kzQ2QjbBuJMsxz0Hpj61UbESuya6kYDanQnJx6dABWdAhUNJM4UEkIg6j1OfWnRzIlwqbwSOin0Hr+NVYma4mDK3C5y2MAeiik3dlqNjXs42nuy+QQM7B6dtxPrVi4Rf3kURwGIMjA5yB2/pUSzeVCiJk8delRwz7t+8AAtwuev1quayJtdjpl3BYoUyF/i7A0RwRxkFsux/MmpXuc/LApHqcdfwqOON2YnymaRu54x/hWbZaQswRFB29ORk8A/40lrbf6XGpG1Rjj2qYL5U+8gNjgH0NJE7B9xOSxy1CGx94+8O75Aklx+A7U2WNPMdmwsfc55zRPFLNcW6cKiEu2e/YU+YIGCHkDAyeh9TTZCKipG0ZIZiz8nnNEliZwWKsFx34rWhRQMooIIxx3FTI2dq5AHTpSsnuVdrYwE03Y4yqqB8o9q0XtSsWIyAT1q3vTLAkMzN8oqREKsS38A6+9Cj0BtmVHA6JgKAg4yRgfrTo4lUKFQkg5yen51rybdqI65wM+2ainjP2c4OFHAAp8thc1zGlg3XG89Opx0FXYIVZHXBGCMY9qkRCYxkgIFwfU06zUoxO7GOT7Cmgb0C3YlCJMHPQ08p95t2Rkf5FaCxRNDuPPHWqU8TjGOgHPpT2JUrkEWEjO3JzwKsx/JCeRkLn8TVRBtUbcEBs1Y6wEDuRSTG0LGpZQc898dajfDOEw2FOTxT3fZEzDgng1C1wASEJG75Mn1pDGDmNiODJwMdcZqW0tylu0meXcnk9KiWRGmIU/LGOTirkTLhEZsADn60LuNkE0TqDtYHjnIpohKIvUMTkmrc43rhep5PFNLM5wMBQaBEAxjO7HsTUUrMTtBGfStArlMMy9fXNVXUxkkEEexHFIdynMkhjCK+3n+EZNS28OxAqElVOMdSzGpVyMucZxxmnRAxje4XC8jHrVRXUTeglxGrERjJ2jnjiq/lwKBlI2I6jdg0SHc/BKCgqFQADPqc5pOQJDJIVlU7VIz2DZ/Q1UMIVsLI2ewJq+oBXDISp6Fe1K0W0Er84Hq3IoAoSwHAU8gA596Zhg4Cj5iOlTzf7IB7ZJ6VEXMa7dgPfr0o9R2ZWlcsdowpA6HnFQPMJMLuO4cHB4qZ2hY7QGVj25/nUHloDkZ3e5GKlpvYa0FjChgWBLH+En/PFPMygAKoIJwSDxUM0chGQhJxkleuPaoVifJ37gvpjvTC4TSpFIDsBkYELVQTKIwuMLnGBzirUlv5pXM5VumAM0W8EEKNgPIwOR83SnysG0V/IkedSh+Ug4UDBPufaqNwvl71gAeUfxDp/n3q1qV4EULu2qTyoPX6mqF1cM8TBVG3OeP8APSjQFcp+cV2eThpn4LHkL7j6VpzLa3Ty3UtlqYuJCDKLeLekzgclSfWsVGzIw6YIyTxn2A7D3rp9VstSvL7zLbUUjtTghEuguFx9zAPr3pxFLQw76SS9u1nlt5LUKixpEwO4IBxn6jvRSaw15FeSQvKJLplXDK3mbR9fWirBGXboUkA3HOT2q1CpWCUxsCSAF+hNMIH2ppAxbKcjpg9KsCEC0wBlVO/pjn0rF6o1aJYR9mDN13/KAfQVaiUPIg5IA6noqj096rxoUZI5DgFBk++avQQuUaOQ9hu9qaIYJAZ7nzmGVXhAa1IkTYTINgC/M3X8qYzhIAifLkdT296ro8l4dqJgLgoGGASO5/oKLha5bRS0gdlCOeUVudq+p96UbYtzAnAPQDnPvSMTHG7c7zjcx6kmmhySI0XeMZY+tArDpG37SwOGy3Tt71R/fTPlMpH13df0q84fO1SWYptJx8vX+QpywllWJWJZs8ngAetAJWK0WyBAVHmzscLxwPU1NIsdpC0ty7MT/AvJY+9aDWy29s8jJsXGAcZP4VSaLawldSTjPz9FHrQMrjMMqzTKQI0zHGT1Y+tT6ek0iyzc5wACecHP+TTEie5UGUk5IZiODjsPxrorO28q2T5R1z7U0TLQx7TSm88zT/McHavtjFX4IYyRt27V4AHAzWpNCERmQZJFEUKCHOxAOvTpTsK5lyxYUnaeflwG71LHbxmQqq7QvZB39zUptpJ5U8pdqn5gDyMirsdmYkVXYsQcnHc1I76EKpxtjyi5wdo/rT3Ty0Xy+M8AL3NWBHKmSShXvx2qKPIkLMrk44OcDFOwr3KwTygS5XOOV9qr2rEguqgyHO0ZOB6VLesZHaNRg5AyvXB96mhtxwsJcY7UIe24+BNqDcWYjgknk1Nbxs0g3qV7AYzx61P5BUKmRjPJx0q7BDlw59OAOKtIzcijKI4yVMfBHB6fpUDRPKgEZb0ya2541YKBjKnOfSmAqxK5wyn05xRygpGSlosMa+WCCByD396UpIkYYPubkkE1oyAKST83HpzVaGFNwct+871PLYpO5FAkhw8wA9BninzkeW3y5+hqwEJLBG6etNuAEQIF/GmloTfUoFT52SpTPAXt+NSWseN4GN2e/Q1bEYbc5BOTnJpIQvnuAMUJDuS7Cq8Kcd8etQXjINxBwRxzWjtyhwOR71n3sOWBIHP8NNrQlblQx5g478jjmmwqcgjr3BqaFGI2rxn1qW1iDBiBvOeKlItuxFNCH2Z43epqmSDKQBhVyau3aBQ7MRkDoO1VDHsjBBJLjg9aTVhoIX2wysBuycDjk1d2gIA+dx55FVoUjdkjbCgHdkVNKuFy8hx6ilYHuOZjuAdiR24p2/av3fpmmKrsOXBHbNMmDxD5iGPQHNMB3mhV7A+1VpiScnJB5Jp5yACwGAKb0HGT9aQDAC7ckDHbFLcbQqxq5XHJwOtSx9D0z1470NCH5P3qd9LAVw0oUCN8/wC8Kd5hUYMIJH93IpXgKcoWz37/AKVWkd+gHPvlaQxJZ0Y8bg3oaR5kUKQWz6CmuzZBcfmu6kZ1IGSw/UfkaB2G+YGY/e56g85odUZMIMZ7MM4pQqPyj8jsAP50j+chGUOPVR1oEyMqUOFICkYxjIH41WKISQrwcjoGwf1qeUOx3Jwv8QzUTR45OBg8f5NAyCW0fIG3b9H/AJYqIWoVcmM8dPMf/GrEhVckvjnpmqbSLuyoBP05o0DUe3lLtJRCR/eyRWbe3ZW6UNISrDAVRgVZmDOh6he+OtUnhBlG7Cj82/8ArUw0RTvTnDMqxp6nlz9KYyouHucqGHyoT1Pqanu2SNsLmWQH75Gcf4VVdRgSXDfP1Ck8/XFFh3JbCSItKb6x+0R4AUl9vTtx1q0NU04ssf8AYigdP9ccL7tWNM7NcIwJTAyAvX6n0FS3rxxrGyjJI5A4y3pVIlruN1KWBr3/AEWMwCUrH5andtHrk+vWinXNkI2VxcwTvjEwRj1IyAMjt7UUDJru38xyW+ViACwGAfrTJUkjt5FKsMjbkdDz2rYFuJIVKsSxyQPWol+cmHaAy8kH6Vkn3Hcgtk8zJYcZzWtbAPGOAWJIz6Cq9qhDR/KNh9K04YE5G3Ge4NMGVJIJZJhEHKJjJ4yW9vpWklrEsWAGQKMjn1pY4FW5VmZsgY69qfeI7xcYz90bfQ01ohN3KLozHcFG7O4emO1TJbkhywxnksOp9sVNHCS/YjOc9h9atyxYjKAYB6nvQFykigozyfKrdQPT0q9aQxrmWQEl8ZUjnHYCmyQKiwpyecY/qanWN3HJOWO3PoPajYTdxvl75Hlky0akgDsT/gPWs2ffdTEYLJtzj3zwK3bqIJHHGOFzgD29az7UMp+T5mYluRj2FNoExlpEiyEy8gEZHqRWuMkKByhPOO1QWtuiAhjnDZP41eCqE5UgA9+9AmyIIZJuCNoPI9ParrWyMm1SOufSlt4lAdiepqRyq5GBj171ol3M27sqwxgSS4JVVGBmpoopAdxG5jyKrRhw5557Z9KnUytj0+tTcb2FkZnzvHC9VzwarTiYhlj2qh6jGaueWflLdug7U92woG1Qvt1oBOxjJbYlRFyx3ZyeO1aMcYiOQBjtj1qNQXl3dEPQe9WAjeXlsDPAA9KLDbHRsoctISTngYqxETtDAkE/pVdRlueuDTjNsRApG7+Yp3J3HK2AwPAzzSEgOJOdzfKCP0qN23sQvTvVpEG1Q3O3k+9CB6DQRjY3LDrVa4jBAZQOOTVkqVIIwSOue9QxZefY2NnoO/40hxG27SLuB6Hv6VJcL+6dG547c5qyhCjaPXIzQV3EkcqeMVViW7srqp2gjITjrUXlkXIx0K9fxq/HFszw3PAFQlG80F8AqcBB6e9OwJkilkwMZyPzqCRTIwZwG28Yq+i78hACc85GQKiW2xN8vzD0oaEmU3gHljaQjZ4JqONZEjZcgbTjjvWl5TSMVH8HXioLmEo5AJDHqBQ4gpGVekyPGiAHJxj+dOMe0jJxj0HSrEMEfnFjjKjAz60kkpw21c5OOaixfMU0jQszBwBmiQleBjb65q3FDGFwdvv9aSWEBQSoJ9aTRXMioCR0+b6U/nOcNu9OtKFPTr7inD5VwAFPp3pDIjJ1ABYn1qIYJIBPv7VYkGRyuA3QjvTBEyEbV3eopBewwnEY56dOKVSwUEY5qTy8jKkg+h5qAu6MQyDvjmgCSNiep+buKZII5Cdw49etQkSYJCke6ndUZEgyfND89MYoGh7xNjdGRgdMGqsjyEYdCefrTpJyGG+QqQe6f1FI8p2bvNibnOelIY0Krcj5T7ioJJZIjgSnPoWz+hqQu5BYsg98kVBLKX4PluexJ4P6UANFxMWxth/4HxmhxxlpIU78EnBqFi+0kqmP9k1BKrEDcqke5zimBIzxhvnk355wox/Oo5pGKZA8tf7zHP8AOkDMpGyMZ9QtRyRSltxADHufmamkDGTOMD5t4/vNwo+nrVSaLzSCWORzxwDVtocHJxkcFmOWrPu7lI3ygBI4+bpTsiVrsLOyxruUDHUk9KypmAJKrvkPRup/D/Grjq821w2ExlmPQfQULsWFxEBu678df8+tJsu1ioLcRx5m4LkDZkkkn1rcnsbK3utRmntmlgtAkUcchOJJSOvHt6VjiItACSxONuepJz0Fa+sSG3tg0+p3DSafJFvUICqE+h6lgKqJMjI8RRLb6gbe1Ty0MaS7W6xkgHbRSaxbSW+rG4lmM0T4kSUnl1YZyPeik2UnodHBNbBNykKQAOlMX97J5gVSDwzfyqnE6yHDZLZySOhrWgbkhUDHuAaz3EJbW5U7QnBH5VaVTG2OVB6A1JbFvMG7GPSrc6hgoxiqEytvTbggbj61NEyPsJAbKkcdqawCgYByeCTVi38sAncAF7jvQhDFQqhVmxt5APpUu5X2g8nGahMYkYuzNg9Pap44d43M3Qdcc0wJURZzvZSCDnB71OsHyhlypBOBmo4irjhmYDgY4p43H1AFUhPyHSBigVVO85waqpblAjFgxxjJ6VYLrHuJyePWo5HWeM+XgtjGMUmxRJoEC/vCcv0XHSpjtIJlOCOo64qnDMufLjYjZjdkUSzO8jJHgZ6nqaLg0XopIwCmAQeQFB/WhZQWO04I7etVwrRKEXO1iMZPWrSqFmjLKAeRgU73E0kh8kBV1YDO7n6VIoYHI69qa04ZgE6H9DRl4xnOeeRT6ivoNeTy5EZ87CCpz6+tTRgMTznjrUcjeZExKn2FRQSk/KwKspKkU9hpaEzhMfLzgdaTJCPv5K8ACh1Uuvln5etRyoyjP3tp6DvUsNB9s+1vmHzE9DQSpuGB42881FG3mZXowOR7VHK535YYU8fQ0rjS1LkYUEMDndkmpoiRtyO+CaqW0oJ2N9/qKsGdQQSMgHt2qlYlomuAUQleSOaoIxaZPmwC2SR2q5dHJyDzjFMggBBxgP1xQ1qCZcVFcg8EjrU6oqMPlAGapwN5W4sCDnGff3qysokA39fatIkMsoAS2eMGmSQ4csxH1o3hTu7jqKIwXYFuVPIzTIDO1Nigjvhe9KmdwbO1ccjHIpxOJgXTZt5zUpiV2Z4+jfeYnpigLkGCijLtkg4B4zVWeNlBK8yEZc/3RV24g3DeAcLwoHOfrSFfNkULhU28gdc+9DQJ6lC2tliSNp2JzkjPP0qF4t0ysMqcnpWizKIgV+8vyk55qrJuWf5UYkDd0/nSaKUgWKPcxwD3yDVWdFLcKeO+elXmVNq+WcA9aY0SoRhQR7UmtCrmXIirwCxpsexyVX9TWhKFKleg96qywAfwZHXris2i0xRb5yN2c9M0hBiG1149RVdJGBwrkgdmqRrhsfMvzelA7MY80QwQCB3461CJY3QYIcenpStMpJAwM+opP3ZwduM+lSPYgkeIkkDB/wBk4NVnUFsu/U53N/8AWrQ2AkgYYDnn/Gqs9urZwv44p2YyosCKSRKBu6AAgH60jQEEhDEP1pzwBeEVwx75qNonbr5n13AfpSC7Ee2JOSu5scbeKQQzFhsRSe+WNKVAGMLj1L4qPzyHyqqQO3pRoJ3JXt5CMl0C46AZqBxDChLyjI/z0qOedXTDtJj+7uwuaqvIETrkH8v0quZCUWyQ3UZJCxuTjO8/KPyqvLeKicyKueu3kkVVlYbSVTaxPXOKb/pAH3liUj7wAU/40uYvkSIblZZWUkBUP8TnaPypk0aIuBieT+6Pu1LlE5ZnkJ7u2M1VlmZlIDiNP7g5J/GkHoSOWkiAYLgDBAPAPpVYkKpJwcdd3A//AFUguAYAEBAU9T0+pNVg0csnzAuVOQW+6D9KCkhtv5ly7bX4yMnoB9K6O4i89J0utF1GRrgo8zRcK7L39s1gW8ih5RIN23DhV78810moRXl1qCXNheRtBgGL9+E8oY/iU+lNCkjnteF3cPHJeW0tuwZAkZUhUTgBVz1xiiti9uIp7TWH+1JNA+1Y1zndKuCzgdhRVDiroy9PkmJO3bycLnsa3IbkLtQLgnqfWsmySOFFUfMoHU8mriny8uT05xWQM1obkrJgcg1N9ocue+Ky43z5bE/e6AVPYzlhIdvzE557CgVi/wCYxkCkAnHSnWUjyLscY5LMfaqCTYSSVjyV4/OpoJCsK+rH9KLhaxp71Lg4OCcD0NWt2E4xkdvWqcRCyPvIYqOf/rVPHtYCRzwTwKpXJZNA7RsgJ+VhyT2q8pUneo25HU1kwM9wpVfuKcc/WtJX3RsRgMO1VFkSIbkhvlBzvOCfan2yqkRZeCOKpi53SsMZIFSs5wwzhQBg1JVh8TAj58b25xTY5ijyOUwrNtB7USKjtszx6jtUJDKZMnkP8wHr607hYvyPmKN1w23mmzTLhNrblyG/Cq7sbfbIv+rb7y+hqsrEZjVsEHKn1FPmFymzKqyjcr7STnIpHuOFGMkH5hUMLRy22zowH3gecVAVK8hixAwR/eH+NJgkXBOA4GRycUyeQRTh8jaeDzVVWzH8uDnofX/69OkEc8J6bsdPei47GjYuoJBPCjJqxKA5GOd3pWFp8xLtGx+Y8E1qQuVIyTtpp6Cas7ipEinJ+Xmq0uPmjI4JzzVydCRvVs8YKnvUW2KaPBPzfyoaBMz0lKNjkunI+lTiZZFVh0Y4I9KS4gGNpHzDgMazJGeCUgA47qP51L0KWpt2825QGB6881oQENlsjK8mudhuASrZwpPX3rXhuFADqOR1xVxdyJRsSztmRcMQG7/41PEx8nJ4PbFUb2TaAwBw3SmxXHTHAzkCnfqK2hozyEkO2c4596tWkwP7nGeOtUsKy/Me/enQEhwRwc7Qw7j39KpdyWjXiCvFluSCVbPeozOdisiggZ4qtvdQysx9c56Gnh2VAMAk9MVdyLF5JUyHYjcOqr6H2pkzRtKDgJtySwPWs+WRX+aMskhJBYd/ao0WbeMnKjqopOQlAt/vdzk7QccA9Me1VwxDKpdjuJz9KmeVccfJ2OetZ0sqbWzvBByM0m0UtS8CI4mVBkdcYyag86NxggBwehNRi4ViAjF/fNRyqrfOR856HFJtdB2C4KqA0bqCOoPeqcl4F/1ilc9x3p8jspGCCR26VSuJCW3OcDsueKybNYokEodcjle2KjM7jIXP86rGQ7s5AHsaBMkf8XP+1/SpuXYmWSU8+UoP86c820gmMgjvnNQMS+dpY8dqajsvQ/XNMQ9rgl/vPz2HSka4Yjbx7ZU1KJcrtKcHuM02NoXU5STPsDVJPoxNoqymQEsAv/fFQNNKR8xH4IKuSLFu2gkZ7kkGqtxAACyAt7b6TiCkV5C55BH/AAIiq0xkYLly2TyQKmKKBloUBFRtMqYDCJc9mOM/rSsO5C8e0ZDn128YNQZIX/UoDnlg2akmul2kAKB/vAVE0ikfL8+f7pzTsh6kDT7CdvmEk9cZx+NQtdDblmwT+JNPmicgMMkDsz4/QVA1m8pIkA57KRmhsditcSs/CDAxz3IqrLF8h8wqgPdua0JbOWPG1VUdir1Xmt5ipBYZP97B/SpKKgSI24cMSezMf5Uljayl3JUncM8dce/pVuOLyYlWNPmPQtwPypuLhmaP5FQc7T8ufx70x30HWZiimkUspPCkDt+Peti+awgOqL/ZUUjWOzcXJ3SIeCxNYUKuElzFEwZsD5+9bExFldkT62y3UKCJ1+y7129dpz94UIl2KOqRxw3MrRLFBDJErRpGuMIVB59/Wim3/nTvNced9pV1DebIPLJ9tvYCihgiWHCsVXhQeaZczEeYqks7EL+OaryT7nxGSzkkD0pxTywuT85JAP8AtY60gNKwmKn5zg/d/Cp4pSImP8WOO3eqsCpGRGD935frSufkK5O7eDj2zUdRl68ZFt8HhtpHXnPan2Y8xoFY8bM1nX+57SUq3zdj+NWdPlHmEZ5AIPqRVJ3BmwgDXDKxOOv5VcHG09ATnFZo3GZyh+YLx7irJcuiEAZVhweCKd7EMsW03kmZMdWJHvVpJAXd34VgCAPWsoyFbkjBOWBBHuMfzq4JA21AcfKOnqKaYNEcrCO6Crzg9R6VciIkjKucAms2ZwzIy8NyrE9asRSjyGOevOPxpAy1CjB5FibgcgHuKJmHnso4ZhnA7+oqeFATvY8ZwD+FVbuCN2OwbSg3dTkGmSVY52cSRSkjYOmOozSxDCmMnJjOY29RVe63giaIl3x82f4hVe3u0d1QkqCfkfPQ9waRaRqQXLwygqPl7f7J9PpVh7rzVJiHOelZ29nYhlUSZ69mqOWbyckHofnX0/8ArUBYvxOzupTgH7y+vuPelYlPnTJ2nBB6iqFnchmwjByDkY65q8GaV88BujZ7+x/xouFrEV1IYiJYs5bjB7e9ammXa3ahg3Xg1k+asjbeQV52H/PNRxhrW4LW/KMcsvalsDR1MjlUAYcdsdaoSMNxYuOT19Kda3ySLnAz0ye1E0YkG/ZkDrjnFW2QtNxpkJU4Y89AeQfpUE8edp3bTxg0s0DwqskPzxn+Hv8AhTo5klA3D5wenal6jKIj2OARlWPUHhqtB2Q4BIJ4B7H8Kle3P34wGHeMng1AkhDBRyB1V/vJQgZZFz5kJjf5XHPzdx7VFbT5JB+8vH4U+5hWeLIHGMjB6GswiRJcMuG7ds03oCszolm3QN5bEyKeQaWG4MQBAyAQT9c1j2tw6yjPQjDGrkTl1YqSecMvpVJ3E4o2JpSc/KRg9zkULOqFNzdcj1OapQzkcDlTmhXGMk855Bp9SGi+0rxswyAQQckU+OXYcKWUydecjPpVF5CIAM7kGevWnxzZi/Dv1p3YWJZtyv8AOw49B0pJInkAJPBHc051UxhmbjrgUIxMjcgeg9qkRX2GNtqxNgdCO/4VHcNcMML8vtgVbkO1+C3T1qlLNJ90jn1FJlIjCuo+d2Y+hOOaqzrvYkxy5HXa2RVwlf4yR9aYFRT8r9akpGZui5LSqB6FSDSEwOw2kZ7Zya1WUEYBy3pmoGtAykbU2mlYq5nlYkb5SysepBp2HxkOjf7w2mrItoYzhVDHvkYpCiK3MOf1oBkBlkQfx59EOQKDeXGOAV+tTbo1JyhUew61BOy7fun8QKYiCS6nbqcN67QaoyXc24ht/wCBq3IyMmR8vuB3pqlSNrcjsTjrSuUkjOQtOjBmncehbik+wQBtxix6fNV0sjcSKyj0xx+lKIoNmUkYD/Z5H60DM57FC2RECfV2zTDYOrEjco6EB+Mewq6Yw2FWR2bqATtpyoFXcU+bP3id1MDMa2wxUO5PoGP61XmgETLmdl/2RW3IgYYMqMRzjHIquUUHCohBGfmPNIDMSzDfO800RJyAW5P0qKeB1Y+U0kYHXJ/rV/BXOfkPbvioWPmAKxDZIHrRcZWltcKgM0jNjuaha1/dPuIYk9T2FacsaPIg3bMdO1Q3CJEhbYz5GeWwKAK9jayi3JleILnhguT9a19cuLeGWRZdLS62qMSvIwMoxwxwMVFZW/2u2AFxFbkAY8w4z9Kusb92EcWuWvJxjfn+lNEt3ZzF6/y74rYW6uN3krISBx6nmirWs73v5TNcJcOFUB1PB4ooLi1YzLaLEjM+77vHtWgsSlQo+ZoQGOeh71nXDvDKiqCXdlXB65/+tWxpoRjIgBLtwW7AnNStyXsRA+WYy3Mh7fhUKtnUk+YgPlfxxTWkKJlskgYYZp0pLCJgAHQZH6Uraj6FkEsu1xzjt6UlriG7cLkcAgeueMVHd7lBI7DcMdTz0qeHa11GRyCqtz64zVITNqCYJJ2KlduTUo+fdKTtAGQf8ayopN8Ide7ZX2zV5JVEbqfmK9B/ShiJWuFZlIUgfdyPpwfzpIHfzo3jB44Izx160z5Z4TjgDoM8gg0W0pKOX4ZWx/vCgZO/yu6HqfmGOhzTmz5YdcA46evrVcOWlGSPkIB+hq2ig4B5x6/r+tAmXbCYSxmNg27jj147Us5aPzPMBz0WT1GOhqvbJlyd3lyAY3HnpVgTgzFJD5UpyjI3Kt6NT3Je5UwPukhWI6Z/lWXc2x5eNeG5Kn+la01upbYVGV78/L+NQywSxKCiksoyVPpSKTKNvcLJH5UjEMB8rH+tXiuEBAHBxken9apOylSyp8w6qeOas2siXEeY2IcdVPUf4igZSntjFL51rw2eU9PcVoQXWIT5yqXkHIPXFSxhJf8AXKA46EcVDc2u1CW5GeG9KQXuJGyMRHICB1XJ5X8alRvl2XBDrj/WDt9aq4ZFBbJB5BPX/wCvT1YoOhA9ufzBpiZJIGtfnQ5XqD6ir1reSFTnkjkg9RUVuVMRikUbD0PUUptXikBLY77h6fTuKfK+hF+5ow3ZVcMV8s/w+lV7m1R/30JVWyM46NUaReYucgc8YOQ1RCKSNyFyV7YP3abT6j06EqMQ7DLcdR3H+IqR4xMNxbn+93qIlWAZyynsQen41MjLtGX4H/LQDIH1HpQtRMW2aSCUhSCCOVzVkRQ3gKsAuDjGeQf8KpTrEZV8yT7PPjgg/I/pimvLcWcu4qWXr64H1q07EuN9UF3ay23bOOMjnimRSlguWIc5Bx3NbUNxBc24jVtyY4buDVObTxLG6KQZPvAjjP8AhQ4dUEZ9GQQznG4+tXPtIZJUKqSSHVu/vWMwljmYbQCuAQT+tOFwJowTlcDsf0qL2L3NtJS6FTwCarrP5TFDj8ao21z8hQ8dPw+lSGUGQbSMNxk84pNgkadtcs0W3IK7asAvuQ7gCR1NYMFz5ZMbAjrj39qtC/K+WcEKDwCM0KQOPY1WaTAZ/u554qCTczFgcJ6ioI7+U8FSc9jxTBLdZx5aAem6hyTEkx7Fwx24Yj14NJI7dB17g9PwpFaV+X2Z71FJ5mQAgx6g0i7EgkxwRtP+1T9rYBGPzqDMzDDquCaVy8Y5CsR7mi4nuSMMH5jz24qMwhju4J+hpvnbhwvPekM+Aco6j17UCI50dM7WZc9eKpOJDkGU/iAatfb0JIZ+R2P/ANeo2lgcg4T0zUtlJdyiyMGOePcDrUZRgCyZX35ANXMxF87nHOARyPyodG3EIyupGSF6/rRYZTkWVCpOcH2z/KoxJnO+NG/2k6irpkCRqsqjIY9RzUMhiIO6MZzwVNFtQK8cycshDc9OpFOM38QG4c5yMYplyFjUOyNg8eYvX8f8ajBCbSspYEcBhg1QxWmTaXCYOO5psZDISmAwOMdQabLImcYIPp6U1shBgLg88UgsDEZO5CGzgAn+tMhJ+0Jx6nFSbyIgssYZSPU8VDEczOYVV8DBU5BH0osBM7IHJLcDjaBmqlxHnAVWAPAOama4VInJGznGAcGq9tMk1yGckhR6ZphZl0WkzoVjiMzqADtB4qrLp17EqbbG43c9F6Crk1zJGw8uRkdsBdpIz9at3ttAhnE2pX++EospQnALentTsK9jj7hZ0d4pYTCc7jvGCPTiitXW7dYLyVC8sowuxpDknjrn09KKC1qjI1Ni91bSxrkneCc9GH/1q1NPjEMajcckgnJ6kc1nWsYn89gAZiiyLj0HB/Sp3ZvKRUPOcJ9M8UrWI3Vh+tRKl9G0YOGGTgcGog2FUrzuBAJ9O1X7siaGHAO7G0+zL/8AWqmXO6FCBgtj/db/AAIot1GtizdgzwQOm1ZGjIHuRS2BLXGniVfvxMM9uBQVAskIA/0afn/daraRiO3wSC8bOv0J5H86aRm5aEGnMJIvKJJ2qR6ZwattIFjWTPPf3qlCQt3GwB2ypuYH1HWrMmUDo64MZH3e4Pekyr6lm0blOqswz7HmrMShzIkhGDyMdiKpwPhIs4+R/mx7/wCNWceVdJtbjPIz196AEO6IgNjkdfXFaNviSEkfMw5+uaz0b5l8wZUtsz25FXNLcxPGfUFD9RTS1JkyZflYE8r0+oqSeJLqPEhZWGMMP4D2IpJ4ijyRp3O5c/qKOVdc9GHHvTaEnchW4Z90UnE8TYzjn/6496f5mSQ4A9z/AAn0+lQXyjerjh1whb27E0scy5CTja46H19qlFiPsnYsBtbqRUDwmNw/Kt1V1/kaW5gMb+bEx8vOSvp9KkgmaVCrL84HIbvTB7EkUokXDja3qvRvp/hViJdp2MNwI7nqKpmP+OIZAGSPWrdnc+dCI2wQG+ZW6p9KaSZDuiYwxhcfwdjj+lRFBGcMBs7EHI/GrLFUAMjrhvlD84PsfSoZ43QZ2gg8fQex707W2BO4r2pZWKfuz1DLyKdbzTwvtnSOVDxuX/CooGkwGyyMvoMg1cDpIoYD5WHY4IPtQmD8xQisDJZENk/NA3AP+BqWFUnP7vcjp96Nh0/xH0pNkTFN+c54YnB/OpDHltsnzY+6T8rj6djVozehVeJfM2OgOe69qguLYW+ySIHHY4O36VoyK7DEibvfoSKQBouJDkHgNnrScRqRVtp45kENxEyg8lW6fUUTxSQBWVybfGFYDJX2PqKbLbAu3lyyIDyf/wBX+FSwvLFGqzBJUY/eU9vemuwX6lJ1kiIuLY7OfmQ8g/StO2uknQNjac4weqn1pZLaJo28kb4X4KHgqfUVTkhe3AUkPEW4k7g+hH9aa0JepZvbP7QC6kLcbcEjo69qwpInhnKsvJOMf7X/ANetpLhxEELL5oPyMemfSobjF0VZuH6YI6UNJjjJrRnPTXRRWcDaVwfmOOKsi5JtJ5EAypD5ByKl1O1USIQoYOOn8xUGnlHS7s2QoyRngnOR2rJx1sa82gNNnbJ5gBDZGferkMsaqrZLMT1APFUrCVvITBQgDAytX7SVDblWCBs9cVKVymy/DIUAKI4/4DSyXAIGWwfoQadDLHKMscg90PSpUER6mUKOAQAwquUnmK/DcqWPuDSsTx8zLj1xU7xIwzmMAd2UqaryW5+9GFZf9h6XKx8yGnqCGOfUrQC5J2lT9DTciMfMZE/3lz/Kk855FG3bKvtgmlYXmIWKqfNU8fSkR1YYP3T0GcU5boMxUqPpUMqxsQBGQD6cc0rMfqEseB97Gfp/KqstrGMsCVb1AOKlVMnChjjrnBFMkgbPy+Yv1FJIq5TGYmbMaMO+08kfSngRzNmFjkH7pbOPw603bIr5kwSDwcU11jdgzKA6ngg4OaeoEkztHGolyU5yfSoJEDx7opMHvz0FPe5dTglZV9zgn6+tQMylSYwAfpjbTAYHnjJDNuj7elPYBcFAEJ6oeVb/AAqu25WBRyT3GelMaSQksyspxjPrQA+VEmclBzjGM8iqyb0bBy6Djj7woEiyNj+P1B5pjzbGClpFcc8rkGjqUTyXGziNyR1z/npUMEgbzZETaT1wSPzqjcO25pSYix6lTgn601b4xqqMJAOhGMYoCxoNEojVnZY2Jz84yT7Y71Lpzx5kIjQN3I7j6VjXF3E7bIyTjoDwR+dXrJlW1G9ipPzFVHIoBrQs3NwzNlEUsPbpWpHJcSamgvraMG6iAlj8zaGOflY/3TxXPC8RUcgHeWyOOCBWtcyafdu14b823n/M8ckZLA4wdpHWhCkip4inkN/KZo/JZMJ5fXaAMAe9FZeuX4v79pIAwiVVRd/UhRjJ9zRTKiklqR6FMqX0TSdcsG3dgw4H51cSPZdbcEiDLY9eKw7Z3E7H7xliDDjuK3WnPkG6wMzIFxj86bRn1HwSF4ZImwAxDKfQ+tMn2vcPkEqQFcDrken8/wAaprOobGSCp4qWeVTfBACsjfd5/LH+elSVbU1bFTN5kdwoKzp5WR2YdCfqKmgYyRAMMTFTGQe7L/8AWqnZ3Ba5MaqBITvQnsw6j6EZFXjL5GpxLLjy5cESep7fpVx1Rk1YgliKtICchHDKSOxHb8aufJLMq4GJo9xz+RFMuF3XBg3cMuFz2I6ipLcKYEJOJrdyCT2B6/WnYObuUT5lrFKr/wDLJwwyf4avSMGIdGXdnAOevcc0t7Awd427gqTjIIqMp5sKxswQvGrIR0Vl4/I1NirloOJIcp3O9fYjqKuQKGluFQ/vCgnU+vqKo27goWPDDkj9GqzbgwtaS5BMEhjJXujdKEJ6mvdDzNkin/WKGUe//wCqqiyEuYtql+qD+lWj8+nvCoPmW7blHfis7UAWeOaH5ldRIh7j1A981b8iIMfKFkRiMnsfp/8AWrNlVwm0vnYcbj0NWZpXDrcpllcfvAPWmtKqv5idOhPqKye5qmVTLJtAbJ9MHpT47pclSwDgfMDx+IqSWGMtlAUYD7y9Pyqu67yS5AIxlvQdjStYovxTJIAC2OnI/nmpJNrSBj8rsNoZRw31rM3fNsdcOD26H6+1XYHUwmKUHZ2PdfpTTIaNO0lMhMUqhpMcg/xD+oqaIFQXtHDKOsUnT/61ZrCSIpESHzgDccFh9fWrCiYt5sbYdeobqPYitEzNonEatJ+5yvZkfqp69PSmYDnYVCv1G4cfgamNzFKiRXSCOYco6nn8D6Uhj+RXSUSZOQV4x9aGroFLuU/OePIdXeNuDxz7YNXobgFdisWVukcnGD7HsaYWPl4UBsenAqENG52sqoT94P0/OknbYejNVJJFj3xNn1jcYxTYbgscEEY4KyDp/wDWqhulttwi3BfUjcCPeportZVOVVXPUbuMf0q+clwsSSxP8jQZXcchf8D/AEqAySBmCsqP/Ep4Df4U1GntuOJE7qT1HqPepXkhuEBOTx36j/GjcnUZHcsJMBWQjgq3b/63vVnzwOOBkcow4I9VNZr74zgZeLORg5xT0uCshSXb5R6f7PtQmNokOx2KF1AfjZnr7ioid/yscSDoRSTKgODwM8cjg0xlY/MrbuemOn0phYk2rdQupOJozuyPUUgiEdwsinhgVLY6GobOTbcZKnLdP9oZ/nV5V8xQuCPM/mDTtcm9jFt45EKqBnaxBGcE1IkZNw65ZW4Ycdac48uUAnqzHHTvULsyagFQHOzIX1rKRtFl+3LmPy3CADnIwPzFXYwxYiOWHbis1Jdz7pFXdjGT1z71ZGyVCzqY2HpzUoZd8tgAzFCo54emtJlTtDqR6c1VIcHcJVA9UNNNzIgxKDx3PU/lRcOUsecx+6fM9j1FRO4ycjYR0LDP601bgNuKEqcd+ajMsirgsJAfTrRzDsEm9xw4kA7jt+NVjM6jIfcnTD8/rSNIBj5nT1ZOKheQsSWXzIx1cHDCkPYlS8GQrIV9CvKmppJVRfmUjvlOaopIjoSRv9SODj3FNVAgJhYup6KTxilqFkaUOyXmKRjnkjdmobgDa2dqnpyOapJLGxAYbcdBnB/CrAFyiNs/ep26HH1FVcViBocLgKGA5wwx+RqqxIPAlGOnPI+hq39pfA+QbcfdHBHv71GXSZWXaykdx3/KgaZRe4h2kTAgdCQPu/UdqryMYyoUh4yeGUnP/wBerd3Ehx5m4OBgP6j6is6ZJIgpi2sg6p0/EUholwkhJPzbjjOOQailVSCMsuOckcj6URziRRvOCDjr82f61VvJ5IwoBOAfrmgpakUxfzwittbOeRkEVHNJM9zvCLkcDbnn61KsrSb2cZUcLxk5qNQyhsDDn2yKAvYqXBErogil3EAEitC5uFjhUFmVV4yB/SqoSSOTexIAXHFN80RyblYY7lqYyw2o5gNrAwEcuBIy4PQ5+o/CujvLu/geOCTXbBJcA7Wh5wemfl4/GuQby97XW1dw6nHWtO9tLfWnbUmg1VFb5pRbwb1fjB2t2pxJdiPXbK6S4u7x7y3unjKJcKgKtH2XK4HB9RRVK+1iCRL94raYXF0I4FV+kUKYwSepY4/Cim4sFfqQ2jM9ym0HCMFb8Rn8q0YHzZTwZ+aFvMQd9veue0SaSbR1kBO8xYLD+Jlbj9K00uW82O6wAh+X3ZSOR+eabVyXuOuMqwnUfu2A3VNeIZYo5lJBj5Ug9PSolmSF5beQK0Tn5CaZaMymWMktGDnHcA9R7+1Z2NL9TWR2lIkVgLiJRJjuV9R9Oc1tyLFqVgJAhaaEBlAPOM5B/A1zwVhFHNG4E8JKnI7Z4zWvpzAliqsmCS0Y7euPbvVxMJdyzK+5Ua4Yqjn7+M7D71JESLr9+uyRh5cmemezD6im3MQYyQ5yrrkegYf4iqdrdEFIZzuVV2x+p9s/TpVErXQ2QhCqm794nyr/ALWOh/Liq4JT5euxty454Pb86kCbYg+4vkHaw6kjnGPU0yIefHtPSQblxwRSauCYuMOMfOJASQOqn/CrlsS1vLFkuNvyOO+OQPqKz7pW8lJ4s+ZGf3g749cfzp1rceTKsgYeWzAshPrx+FA3qjetbne0Mwblh5bHHX2NRSRmOKaNEzGj+bH6gdx/WoHVQ1wi5UsN2R0Y9fwIqeG6PnA7+HUMGXpnoaaZNrEO0DJBBjkG4Y7moipVSMh4+xI6H6+lWSkcUhUkrG5BDKOB6H2plypjCspLcYJB+8PT6+9IpMrxwmRSIl9SFJ/PFQMQGIMZDLwc/wBfapwwPzEso6ZB/mPWtCIC5X5uWHBb0NTyp7FczRkiKOeNogSu0cEtnH/1qj+eB1VyTkdev4/StptPLgvFtaVeg/ve1RG2HkgSKSoPfgqfY0OIudEcEsUieVMCUzkHPKn1B9KsBJI8ebJsnT/VzqOGU+vqKqSWrIQ2MEHnHQ++Ku20m+PyLhflK/Lg8Z9V/wAKaE2SNCLk7VQLIoyYweD/ALSf4VWSV4zhld4+zp95PqKshCkm0sGU8oRwfwPvSSxbJvOVSCxwwH9R2+tVYm/cmjO8B0YMp7D+L/Ci5ihnQfwuOjY3L9D6VRdpoGyrDZnnHUZ9asEYhWQDYSMgjof/AK/tRdC1Wo0xtZLveEiM9JI2JU/WhWgmw22NscEN8pX6eoq1aTuqkr8g7qOVPvii4WKTErRxg/3gvH4ijlK5iP5YyYwB5bfw9x9D6VVlWRSx4H+0aup5ahfmDxcAgHgU1rOJyREwBPOD0pCRFbbXzjAfGWj6fiKbsVjtVSGB5UnPFVpLORdxhGNvbIxn2PbNJFc8BZCY3xgFgflPue4ov3G11Qs0YUMeQnXHdTUTORu2jLAZHHDD2FWpC00QBwswBxt5DVlzo0TKynPTevb60mCJY5wzBkYrnlTnkGtWGVnkjkHRyJFwehHUVjM52AxsskRzt45WrtlKTHCF5Afj3HFXB9xTRNqXF3G5AKCYrn0zzzVLUVH2zIjViOCB1rUvYM+apwyGRc/j3rK1dMXRIK4BAOT1pTQQepPa3ECqPlbKep6Gpj5EkjNFKySH1yM1Tt41kBEbq3HIJzUgj80/dU7eMbuVPv7VndmtkWFSYqRuVh6DqKiaVosKdwGfulc0rwlFDQ71Qf7W7n6U3cJVKl2UjrxkUtxDopUkDYl+bPOegpWyBlGU+6nH6VWmtSG3AgnHVOo/CokZ1fYwXHXAGM/gaB+hZlLAFjCJE9UNVHaHdnOyQDqc81KzqCdrnjuOCPpmony23jzs9W6MPqO9Fhplc5LO/TGCGT+opvmhCpwDu9OhP9KlOwvhlOB35BPtVCZXikMiHKN95ex/w+tAy0THcoduDzgjHINRRXDQvgkq2cDjg1Sd3VvMhAJ6Mf6H/Gpo5UuEWTy2ViORnOD60AXludzpE44z8rDkGj5FOTGNpGQ8bEYI9R2rPDYZgWJYHlRjp6ipS4ABicEjnPO4fWgXoW/tEZV45BkH5iMcn3FZ1zbysw8lN69fTinLduWBS33ZOc8ce3FSpOzbtzdP4SMEH/CgFcynQhgV2pJ2U9D7VGs8brmTEcnQpndVu6X5y7sVYnKtnKtVAxmSQSRjEydAehHpxTRVh7SGNgqquevBzmoW3zKxdJMnuvHH0p2RKhaBypU4weAfX6Gi3/eyZwMLgEEnJoCw6No9gTymU4/jboaquieZ5WUOTnIOavTYQk5yT0pkUaCNixKg9T3B9KAsVJyFZVaTzAp+6On/AOutrW7LWb3UDcaW8kloVX7M8UwCRDA4x/CRWLcIcF+mOCAKrStsRssVGCcAmmmEl2I/GF7DHqUzJIsspRElkX7ryBQHYfU0VT8fWKC+CRKIY/Ihb5PdASfxNFbJCWxmeH5Ws7aaNiSsdyCc/wBw8E/qK1dNcm8vNPnmATO6HHcN0OfY/wA6z7uJZbUS228eapX35HX8CKjE2+xs7sYE8Q8t2HtwT/I1LXQN9TWExZxDcqCygMGA+8P7w/qKmieS3nViQ2cc/wCzVS5uWhuoZXGUIPzdME89fxNTRyLE8cc3+rYhkI7A+n+FQ0NOyOhtyskIdf8AVMSN2eMH/Cp7SZ7S5xKhLJw6/wB5MdR9KqWSm0coSGhmPynqoatDyhKh3HaFOY5AeY2/un296djNs0XkUI4XBeIjH+72IqqTGJ5IZeVb542A+760zL2syPICSeGGOMdse1PaAbjLDk2ud4DYyrdD+BFMlaFy0DRTLBO22NhgODkP6HPqKuvAVkDAAMOWQdCfUVl2zM3yWw84L86ox5A9R6+4q9BcCUYBbCfdTOGx6U0yWWRKpG+UASLwXAONp9f8aoPH5ayrIuGiOGx0YHocf4VbhuNsQKoWO4gnufXinyJHcIksYWVV+Q7SMoe2fTmk1cBLMymFC7ZUD5JE5yPf3qWbClNihQnJ2nse4qHT5DF5ij5UU5HHT1yKsBY3DR8LIx3ALyG/3T/Si2gN6kiMZVaKUHenHpkf1p6KYEbjfB6kfd9iKigJ8lehYcbT1B+vf6VdtAgQuH5b9faiwXKM1r5colgYGNxgqehz2/8Ar0uCFDwhl2jBC9R9fWrVxCy/vIwEXoVUZB/wquy7fLcMY5P73VX9vY1LRSehatbvcAZCG44dOGU+4qy00ZfMxAZhgnHDD1+tZStEXY3ERDn+JeCff/61WlJRAsj/AGm3bjcF+ZfqvpTTsJxRYuYkjRQGKRv9yQ8hT6H61GsIki8t1KP7fwn+8DTTLJaRAkebaE4LDnZ9farDxIxi8t9meFB6fQ0bi6WCz3GN7e74PUNj/wAeFEjTKrI+1iRtDdM+xoZHwMg7hwRnPP1p7RnYXyN2NpUnGTV9BFZZC4BcfNjHzcFT6e9QSM9uAYmwmQCjDjFTxlWdo3Xa2Mr/ALX19xUZfYXQrlT/AAkZ4rNlqxFcShCzxO2ByPUCmR30iNkB3X+7ipHUZypHln+EjDLULQlAA/zqDgMDyPwqbvcpJFqCRJSxi5b+JXFJ52X2qUV+6N90j2P+NUHEiHerkgHr6j61NDMkoaORSH9xTT6A11JJLkqzfKPL6YA+77e9EkiNEcEoAcFf/r1XcNbfdQPEeSAeR9KPMXaGBLKB1HXHoaLiJJreWKIEMr46n+VErpOm2QHI5z6H0NRO21kVG91JPUUOgdAxDZHOQQc0XBoqMDBIysWKHkADofrU1q2ZImhYgcMPz6VDMTEuJclCeGxjn3FOsAi6gq5wueaa3E9tTorhsJy3BkQY9eaxdcjZr662nKxsjqp7joRWnGyuvB3MjqOPcmsa9cHV71P9w9fetJmcN7hbM8csmFwAflIb9KtxMrOJCFL4wef51h28zK08RJ3Gc+UM9QByKuQ3DlskMQ6nG7rx71gdC1NOaOJm8yOXDDtnGKgZX37opEOevOPwpguh5ayMdgI5D8gfjTmnj5BjTLfxK3X3pDHBn6qyuAM7cYI/HvSyN5qlXIcehHT8aiRgqloxhW4Yg9T600txuDldv8SdqYhJyiYE4KA9JE5x9ai2kEhX8xfUHkfhUjXCyoVdlkGePlxn6+9VmaInKEhOwZTkH696YIWVd4yzMCvcD/JqnNcBdo3AbuAy88+4q2A/3gd0Z4Ow9PwqpMUZ9jxDnpxjNICqztEoMMhjY9MHg+1VrvcALqMbT0dV4x+FWZYY/LYW7MhPVW+YZrK3tG/zMQX42joaBrUttIssW6M8pxj1FNM3yDGcjv1zWaJ2s7nodj/xj19xTzNsJ2r056/p9KB7MuCXa4ZDtYdicA//AF6ZLcK6/Jnep5U8Z9s1Vml3Y4yOn4elReZgAgn5ecnn8KCtDRN6PLSGTLwufvr1T2NFy5tkMq4aPoCOQ1ZsblJpGHLv1TPI9xUdrM0UsrBj5Cn5oz39x70BYtzSrHllbiUAuByR7j3FaEvyRoUw0ij7wHDVnWwVgzuqMhPyleMfWrUM4RzG6kZ5j5/T6UCsSWoEhbP8HLE+tPmQI+5jwPvY9PWm7fKfcOFIz7E1XmnwwGM88j1oHuXLS/ubB5JLSQJvwGBUNwOnWoL3xVqqLIBcIG2nnyVwP0pNNWB4L6e8eT7PaKGIjxuck8KD2+tZ3iOygudGm1HRpHaFQDcQyHLwj146r79q0gjJtX2MDxDq0l/Zm51CQSXUi7QVG3JUdOPaisH4iQLZeJbCy05mWBfKmyzZwTEGb8OtFb2Kiro3bWVpRLFH80ikSIF65z8wHv3p8yCOJ5LVfNSUligGMg9T9faueiuJbVg9uSGZcqQO47H2IFb28iI3lt81tMQzA9FY+lZtCtYtWoTUdIWPcJIgNi9iw/u+xFVbAS2x+yXbGWNhlHI5WrOjSGOWUhd1rL+8Cgcq3Q/Q1bv4UE3kzsTHIwaCccEH2/qKlofNbQ29Bud0WyUiRcYBP8m9PrW3DC6OBBtWXGNjHAdfQ1xtuZLG6T5duODs/n9DXQ2+pIkAWZCi7+GXkIe2PQe1BlKPY1bpTJaFQQBGQdhHzKe+PaoIFaJn2jdEcZC+nqR61rgRXf3yAzL8kqn5W46NWPHE3nPDllkAPQccdKbRMX0YxN0c6GJghU70YdR9PY1oiaO4KuVENznJ2ngnsRWUXlLPBcDy5wd0eOM/T61NYzrLKAQVYdz0OO4PYjuKRTRpyM6Tq86JvGAHx949vxqwVMskixtslkX5gOC/v6H+dU5rsQqq3hV4X+USAcc9j6H3pFY267AQ8Kngnt7g0Mkk+1lbxbjAyRsdezH0PpVxrlI8AxsIerHrsP8AUVkXc/lTCUDdlhkqOenOauCQSRoU4Q5VSOPwIouOxbidY53WQ5jcBs5zVs5jZVEmQeVkIwfpWK8pSWIyps5KgjkZq3b3o2LnBIOVB53D2p3JNyC5KyjzG+Yj5mH3W/z60+eGKdJOBtYZGOmayhJLGxltRvQHDwN1A77adazMkjz2Lr5ZPzwtwRSuFuwsWYpjFJ84xxu5Ofap1hwnnWspGeAQcFfr6fSkdoLgAH5MnkZ6fQ1CC0G3dgr08wDhh6MPWk0WmWvNkic7/kdhg4HyPTyUSQFVIjJww7L/APWpj3HlugdQ8LAY74+ntTJbmJlfy28pyceqt7ZoJaLDs1sQQwaBz8uTz/u/1pwuNxwih2AOUc8svf8AKoNpYMh2hWAwByB/jUExZNqsCsin5WHUYPf8Pzp3sCVy1ejzkW4hIdMBSOmf/rio1ZdpjMfzDpk4J/GmwXO+ZiV2IVIcD1/vUlwyyKnmBXdejA4yPWm9QJFlcN5c8OSeFJPDD69jUiRQkHdGwIOMiqDbZoyCd4U4IzylMR2iYK7DaTg56Ef41BVi7NBGUIw/meg6N/8AXqs0a7isgl2qM79uSnsfb3pODyXkX0A5/AUCNGV8MwDHB7Y9vpSYyRtuDyWTpnGCKi8pQny9OoI9aeheBNpOYz3zyKYSAcqGKkZZccGgRWeKVcorDcPu5+63sfSn2xeZSfKTcnUglcim7sjcrblz8h9PY1Gty9vIsqFRk4KE4/GgoLiOTftlEiKemeQfbNR2PyXrSNhgDgj09K0ba9V4hkjdyemR75HY0yMKzs20ZJx0xTSJk3bUs2ThS5GMEjOKw7yQjUrp0II80Yz3A7VpWzrGrM/3S4OK58vvkJByfNkJ+gNXJ6ExGX0oiZHRPmUNKp75J5H5VbsZ0ukjAjlJBxlWyOe1ZEs4kJ3EBeufTBxRpzxQ3QAf9ywwCDxnsayNlax1EaR7Svl/LjnPX6VJG0Pl7Hj5Q4yDgkVQhVFlIZ05+4xy3NTu/lSKzF242tigTsLcW9ugEkMjR54Ic4FRLIIsj5QB1J+YVMbhXUqSrg/Lg9/fBqkWETuIkVe+B/hSGidkdldowMHgkGqcjtE43EeXj7rHg06aYyDchWMgYOB/Oo3leSEA+SwwfmXg/lTGRtKiOzxSgEnG0Hn9ab9o3gqVYg9CW71A81vImyZQSONwBzjtmqkrRxOPLZinT5hgg/1oCxblkIcMcHb0wMHPvVa6eOX5HGDjnjIP0qJpkyP3hLg8hlwR7+9NeXyzjKujcnIOfz9KLBsZlwTGRGCMAcOTgEehphkZ1Kt+8jHOT8rL7e9Wr2FbiAtwY85BXqp9v8K5+ed9OnSIkyQy8B+d2fQ0WLjrobEc+1fKO5ZFXPzfxD1BprEqpKcKeuKyIL6O7h+zl/Luo2OwScZI6irEc7tGSilJUHzK3UHvTsJqxbZ8Rglgy/wv3H/1qhgmE7bHO0DoTUT3CuUH3SRn6HuKVp1iG1lG4/MG9/WlYdzZEyL97GMY+UYI98VJCPtC4Ljzc/Kw6A9jWJDcSyAlsI64JJOQfQ1c+QJu3EORncOKQzVu7pUgXPoQVJ5zWOl2rmTcTvPH4iqEk9wJykv7xHHmIw4IxwciqEt2C8vkMGcsM+mMc1SiD0NS28SSafdosdulxaOpjuYZFLI65746YPesrxHrt/4ftbW70+MrN82VMZZJEbqjDuCKop4qufDPiC2Fof3DoPtaZx5iH09COoPrVzx14x8Qi60+20zVL6OOaJXXKDedx43ds4rdIyadzlte1WbW1uNbntktLmeERJBHnaiooTIzyAaKp+Kdek1LVpfMuGnJjWEzMcl1Rcc/U5NFddOi2rs5p4qNN8p0suUUSY2KOW75+lXdOYWYaINusrn5ot3KjPUfnyKLmIs2NpSRx0X7u71AqtYSS3NvOkmRIGymBj5uvA7fSuVo6L3L7Ttp1wJCCUHB/uMK6iN47mx2uI3gkQlDnp9f8a5i1kXU9OaB22y/dO4YIb1NT6BM9oktrLHzG3IByMjrj0qAaT1W5uwpMqx29zkpgbH6N/8AXrTMewF3UyEALIyc7h2yKrB0mtmj5e2cgq3dOP4T2+lLb3DRNB50oaVG2rKBgOD0DDuKLEXOj0W+MMWwBZYgeAf5VLq22KeOaB9rZGAxx+GfSsCbfbXAeIOYCxLopyR7qfT2rSF2l5YSQSsD8uVcdGxQRbXQu3cJvFPBFxFyIz95c9we4rD3FHcuj7w37xBxz/eHv61q6ZdfaLZYnLK8ZwkoGdo9D/jTNUg3qd2A+fmB/iFJoqLEs75XJtrsfPztPGGX1PvVlQygKpXHYdiPSsCQeSAC5aHGUk252H3/AK1oQXBSIxzowYYyqnp7j2PWlYbRdu1jlhJPySRsNx5GO2cdxVS3aa0Yo5YEjIZTkNUtxMQok3KyZ55wVPuPeo7ohIwyKAv8Wemf8aVhotG6llt8QsqZ5MLjALDkY9KsmKOcgRFlZsnyyPmB9qy1w6ZiPlyqu0h/0NT2Mxlt1RvmlTgg9T7g96BNdjRtpZI5FDud5H4/Wr0M0d5u2KEuk4YdN49RWOl3HOqxNhyDgITh/wDgJ7/SnsMSqwkLEH/WD+o9aAtoaCzdUJKyhto3DH4H/Gp1uQJNkqlMjOM8mqvmLdLGLlljuPurKp4b2P8AniqzSAnZKDuTuOo/2lP9KASNZGHn7Sy4YDAzw4z/ADqOWHl1XAVmPyf1qpbSrNuimPIG9WX/ANCH9atQylo1iuNglzwwPDjtikFxIZ3WNFclgBgHoRVsyefEQ7BnXIyeA47D61SA8tpI2yD97nndS5aJ1ypKsvI9aB2FBZh5gbA6HHUYpGBkVo87XzuXHT8Pamqxkm/dtsmx1JwGHv61TmkaI7JAVIbnJ6f/AK6BWuWYyRMsqALOo2uOcSD0P+NSG4gmcZfZICQNw4z6VXEhjVXVy2Oh9fY0s6k7ZBtbdwSO/saGUXY9rI6S4OB1WoyqxspBP4Hiqib3jyJBxwP4WFSpKHgy6lDn73bNIC7Ip2ZRlYHjIPWqglntnMbANCOVz1HtUQdlmAZgARxk8Z/pUlyJXHzqvpy3H50h2GiUPuMJIXPzKeQR6iq9xKyngEoeff8ACoPMeBypjZgT8wVunv8ASpJcSc7jgcgnnH0p7itYryzknzUOWbllJzn3q9BM0SR5XJ2FnGeB6H61m7sSFH2kSHAOOntU7yiOF5WOBEMGmkKRcmuESxR88kgY96wHkFrBI+QS3GPQsc4rTuPnit0PHylyPfrWLqIDJGr8b2ycenTP4VRMSobr7PdIo/1ciY5H3T3zVxZIWIXYORnBH5gfzrOu8Sk71+dSDj+8uMBh9aW3KsArsPMUBlYd6zZrujopES5h3Wp2yIeUB4J7H6UW91JG5BV2XPdfbnpWRaTwhi+9jIo7HG5fSrcV3CyI63P7tx/EDwaAWhpQ3cbF4QUbaeM4HH4025UgxybsBD/CKovIhYF9koLbfQj8e9NfD71incADBXdnFAXLzt+8Jyq4x1BUH61DO1u0jbEVHHXD1mCWbaDIobsT15HFMlnDDdtBI7Y60DsSXIlDZIEkZPJwM1TklIBDMFx1R6S4kRkI3lCQOnP6VEXMihDIpbHQ80DGy482MvhSRhW7D0+oppeRTywYg9en5j0qLeUyCnyngjqDUQxyoclOoDfwn39qEA4TOkhAxCWOWC9Py9Kju4ra7hw/GDgoTkZ/oaiuhuO0hv3Z5APOPUHvVSWRxLFJCVRgcEHjd/h+NUFrlW6tF82VJCJmPIkjO4uuPzBFI7SxuZEkLuoActxx2bPf0NF3Gs6XBg3RTqodwOqH29qqadqVz5ggllYKMhUOGD+q5P5ihIvctC7cHOAgzny242/4igSm+yyoGYHIwOCPQ0y0vrk3DQztE+f9WWUZK9v8KXz7u2ulO6R4SNrIePLX1+lOwF6OVrdAsuA2CU54P19PpU7XG4DeiKwGCoY5yfWs/eqPGQqmINuZj0xg8j61nzXWLmHynfcxOVAyRjnn1pWDc0vtiu+SSjoCCDz2wPwrO1PMZS6YblAwig4Eh9T7D1qVUfdunGJH2hY8YbBPVvQe1c54pvze3TW7SmGyTO+TbjPsPatYxvsS2up0PggrqeqapNY21vd6wkaG2+0gOFy2HKKeCwXoK19Z1vxwmqvJb21/NIsQhgtnsgytJ3J+XAAFcp4AsrK5mutXu7yS203SYjMBAvzbumVJ6sf7xpni28vtQ0ubWvD2v6lf6OhEU9vLIVltD23qDgq394fjXTSpe9qcVev/ACmL8Qo7S08WXCWscER8qMzxQHMcUxQGRVPoGzRWT4506DRde+x2ryvF9mhmzIQTl41Y/qaK6nXhHRHD7K+rPR1vGjkSS7yVH3wf4G7Ee1R6ufs91HeQkgsoZ1H3JB6+xrUMSXkO5NrMy8e496z7SVYtM8m4JIVtm3HzIf8ACvPZ6q7lizaO8t2vLUiO7B2yIenXjNaVpMLy5dEjNvep1UjkkdR7g1zRhn03UIzE+bdxyTyD9a6KG7E00SOALgfNE2eWx6GlYb0L9nffZHmhUboSAWhYfMvuPWtWZRLaJLEy7QQRIB+hFU7m3S/8t7hWWdTmOdeMn0NUomvNNLi6jdoXyBLH0IHt61LJ8zZtZds2ISRcD5mTP3l9R61dTy5mbyt1u5PK4+U+/tWXBPb3NsrRqJYcZDKPmj9fcfSrBiukgEsUolT1zy31FAmWpBcaZIGChkfh16j61aW637REzBUw2xvvp7j1FZ0t+Wh8yRRHcJxjs34GrltLa3EUbnAUcJt5KmkTYYrCSMlQDHkglf4eagZ5IGVosSIRgKfT0/wp7Q4kcqV3ElUdc7X9QR61FFOfPNreKUc8jPf6fSkaXNQSR3Fss0KrNC0ZyAcMv4VWgmcsVB8yGZeM9iPUVkvNJp94QGJhc5YAZAb29iKnEgS3SZF37DjKn+GiwI0I2jAT52R0JGeo2+lOs3KMscbjefmAHAb0wapfaAMyfeQjLKeCc/1pkxCWxjy5jC5T6f4ikM2CAzZkiCzNyAx4LD39asxXHmA+YHSReCknJHtnvWbBL9ptRvZZVIBRh95T3Bqa3nKJtl/fRj7hz8y+3uKAepqxrHOdsLDOMtG3Bz6rThlgqvJukB+U9M47H3rNnf7s0BDFRlWB5A9Km+1x3Cfvgx6ZZeo9xSsTZk6tsl3IpQo2cZ6E9vp+lTTMAA8WCoOcH+EHuKiQs4EsTCRui7R8rjuPY1F5yhC0QLxAnIHBQ9xSsC1NGKQswJbDD/OakW63Aq64xyVI6e4rJVjNbF4GLleFOefXFWLO9F5Hu3YfkHIwyn0NBRekRJELEcjkZPSo9n2hTHIQT1G4dfY/41CriP5jj0PtUzRkrlD0GR/hTAqKHt4nR9xCnnPVfrUkUzbGQH5gMn39xT/tDMCTwcZ3DnPqDVGXcJD9mZVcdARkD0qQLULurBo5CGPAz8wI7A1NHdFf3uz5G+VwTjB9azVmG7d0Un51YZKN/hT+Wy7KvmZ5x0ceopjsa8sf2uP/AFaBsZ9x+VV7Z2iBJZfNXjYVwMe9V7eeUxnbskjTuh5x/WnyP/y1ByV4AAP4g09BC3VxKwU4Al5K4Ixj0qo82V3KrKrfMV9auMqSpv8AK3xkZxgjmsu+MtoWlSJtnQ46Z+lISdxA6iZ5FB29uPu1BJKwihjLZM79xn8DUi7Xj2rgdvvdKpvKsupITjZbrkg9M/WmMvX875ldjhY49gI7Gs+6cGOCTJXYNoG3JORRcXBMQ7+YS7A9xniqd8WwiKzNgbyF7nvigS8xk4IUeWGLRHdtxyQeo/8ArVWjnCIfLYEZyuOSR6fWnPJMsaMrN5oHB/vClxBIp2BGB4G09D1xSLH5ADbXK8blx6nrS21xEZ2AaIAn51JwwPqO2KztymWS3yVKjIPIx/iKmieKMsHXacbCVXOM9DSaGX2lkUZPKh+hYfMPUCpnmUAMyumeQ46Z965+6heEw4k81CwGTwV98elLbySxs3mGSOTHDA8H2NKw7GuL14pXLZxu6qMgintPHMuMhh+RFY32qUTZlCyhxyYzk8e3WnzzwecN6hWxlQCefzqrWAuSs6tsDcejDNQFh8oeI7gThk6CoLa6jdSFfeo6qTyKkhWSSMSQsHQE5TuOaAJi8bjY8ilGODu4Oagu0VosrkSjIViccVBPMSzny8bR86kc/UdjVaK7YjGV56g8hh9OlNCASyrGwYASx4zG+Rj/AOtVTKO4EUhj3DpKMg+oNaMTQlSsg2qeOpI/A/0qtqJubdFZT5tup5UgFQPUe9OwX1Mk3L215G+9d0QIZSeSD3H95aTVbVRtvLIK8UxAcbshXHQ47GknhhvYZUbCb2Gw55XHbnpVPTJ1sTLEFWWKTImjHDsvdl9xRYsmQRxMkrz/AHyGWMHlG6EH2yK0XuFu7dnQYfo6Z/i9vWuX1Kya1ncQykiM795HJRhkEjvmr2lSun74cwKBvU9+ysp7Z7imh26liWe5t7JVkYhLhsZIz5fP9ake4+xNvUyzXEjYhiUADPr+VQTXkMl7NvBecYwuOV9vSpdOJkgYxBTcNldw/h55Ofek2o6sHroY+ueIJYENvbkfaN+6STOST61xUmbqdjc3hZieDgkn8K7zXNJigs2IHzsMlmHJNcfpCQx6mj3Az5ZBVf7zZ4p0cVu7bGdbD8yR2+lz/wBiRyaelhHeWNzAIL2CUlTIoO4AMPusDk5HrWJp6X/h6/a806NSjK0ctvKN0c0TdY3HcYr0fwho6alLJc3YdoY8F9n35nY4VF9ye/YCuln0qwnkurWXRrVVgUlzbzHzQB1KkkhyO4xXK8XVbbWxSpUo6NHzv431b+3Nde/W0FmpijiEIfcFCIF4J7cUVs/EPRhpOsyQB1kjIDxyKMB0YZVse4NFddKpzxuzmq4Xll7r0Or0e+EDb45A1vMA0QH8J7itfWrdVh/tOBTJEwAuIgcH3P1rzrwQ7SR3UTsTGgJVT2Ndtos8rWUu5ydwO7PetXsCZlmSVXWNZS8KjfGD0df8R0rXso/OhUwgukh3xnqY5R/Dn0NYdkMXKRj7gdgB6CtLTnaNrkRsVGRwD70jVnU6DqwltpIb3CSL8rbuA3sfQ1swxsLfCN59u5LNGeSnv7j3rkvEPy6nZMuAZceZx976+tbPheaQLKu9sRsQuTnFJkNdSX7KgIlsZQk2T8pON3t7/jV2Hzo1UJuVjxsYdalniTAO0AyctjjNQ6JcTSh4pZC6I5ChucfjUiY9St0jbNjFR80RGDkH0/qKpRSi1uJY5YiiuQxTP6g0/UUWK+SSMbXY8kHrVpiZjaNJ8zDcMn0pDemhJbyzRgyRSLc2rMRhjh1PrReEXEBdkZtn3ZAOVb/aH9azYkDQFCPlyeAcVbQlYoZFZg5IBOev19aGgSK0jmVfLI3J0Vs+nOCf5UwLLHG8kLEwOOVIyF9QaS9Hl3A2fLuznHfFVoppF1iNVchWXJA6E0FIm+0NsiWPCyHBXJyGHfFWo5x9nByHUHO0n88VlmNTHtKghJXK+1WbYlmbcc5Jz+VFgNGzkAJMRaPByo6j6EVZjmXeYZzs3H5XB6f4isGxZlnOCfuGtC8/eWQL8nYG/H1pMDUaeS0bM6gxZwZUPCn0I9KW3ZdrSxbmUNllBzj3HtWNY3M0lgjySFnXgE+nv6/jVkExGdoyVKxLIMcYbPWkBppeS2V1+7ceW3zDtu96sCQyzSTwBlB5lj7qezD1BqpdgC2U45wG+hPXHpTIZHivLcxsVOccemOlJiLhbyJVeAlVk6YPGRU0j78zxHbMp5XoD7GotTVY2jVBtUnOBUCMQ8DZO51IY+oFIq2hpRXzuwGcsOoI5Iq9Ddk43uFU85HIrGk4nixxk81LZuwuJIwfkDcDtzTTJaL8ixMzFsq/UYHy/hVYyLG6iRgFPCk/wH/A1LMAt3sUYUYIAqvIoNs2Rnn+tIY2VminAccMMBz0I9KkV/KUhmIjPTIyMf0NQxMXtUD/ADYYqM+npUYJ8kr/AA7jwaBtkjbYZg8JOScq6nj6YHarFnfyTki4WMA8FlI5FUU4bjiklUeY5xzhTQBalumhcIJ2CHgEdB71Wup2dly5cnIwOhpJRlG6/nVe2YgMeM4xnFCGkOkkjVSgAIQZyex9KpxoUsz2llYK3pjualu3Zohk9GGOKgvWYRxAEgeX/M00SyK7mYKoiJDMRszyMDoKrXBwbcyMirgq25sYPrUd8S2pohJ2IQFHQAYpLpVLAbRgjB460F9CzHGysUkmgcjABD8kf/WqsiNazbnB8t+GA547H6g1Wv3ZF3oSGEfBFJqMrqwZWwxUEkfSgT7ElwxkiuJHIWdBhwOnXhh7GhZ0uLcLIMOMnch5x0DVLpbGVT5nzZGDn0rnLqeW215EgdkTZjA7DJ4ptCT0NiRHkUQy8yY3RuGxn3/+tToZLhNjrGzn+KLGMeuP8KSZFaK6hYZjjAdAf4T7elVtJkeXzhKxfZgqTyR+NIu5ba4glTLh19mj/qKebqJlEE80a9lEnI/AmqWpDAyMgkHoaxEuJWdYXcvGR91vm/nTQJX1Nu7j8oNJHsjbBwXiGPwINV7fULqAq0nkomQu9D7c59ar6bdTGcwl8xA42kAjFT6nEkIZYlCruBwOmabBauzNZJBPAWZN/OVMZGSPX6iqMtms4YwBnVj869GHbOP51FbyMWhbOG8wrkccYqvkxamixkqAVk4P8ROCadhbbC6ek8c5triOTdsOGySpI6c1bszOsJV7aYw9GDnOOvPuKr3HEsjgkMjS7SD04NZDuxEYLNg4B59etBNzZvtIYOBCioVG5AWH5daxtYso2nia6MaZAI2yDcGPfHar+tkqbMqSCqjFZ+uorThiPm8snNGw4u5BNC82m2rC/sllgkMTPnzMp2HTOaralc2dpZiaeWTyc7IvKjIGcc/X603w/bxTaZCJUD+ZcHdnqeR3rD18eZ4gltnJNvGCEjzwuD2ralBSZFSo4rQYmr2AlVYoJnQcfvZSBj8Oa6XTdcii3qioEYA7Yx37815sOJTj1qzFcSru2yMO3FZ4zDq2jDDVnLdHaeINcE0LINqjHHc1xNvd7LwP1w2aZcMWQkkk1TXqKwo0VGLReIxEoySR738O/EUJgaBp4oJXeOaCSVsIJUOQrHsGBIz2rsJn+zvLcxafdWj7W/fXcqC2g3DBbeOWABOBXzXYyyRoDG7KfY1du7qdowrTSFfQscVzOjZ2udPKpe8avxL1m31HWibJi1pbxpbwserqgxuP1OTRXG3hJOSc0V3UoKMbHn4itJTsj//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A marked reduction in terminal hair density is present on the crown of the scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_10_3238=[""].join("\n");
var outline_f3_10_3238=null;
var title_f3_10_3239="Transjugular intrahepatic portosystemic shunt";
var content_f3_10_3239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Transjugular intrahepatic portosystemic shunt",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 664px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A transjugular intrahepatic portosystemic shunt (TIPS) is created by passing a needle catheter via the transjugular route into the hepatic vein and wedging it there. The needle is then extruded and advanced through the liver parenchyma to the intrahepatic portion of the portal vein and a stent is placed between the portal and hepatic veins. A TIPS functions like side-to-side surgical portacaval shunt, but does not require general anesthesia or major surgery for placement. (A) Passage of a guidewire between the hepatic vein and the portal vein. (B) Inflation of a balloon catheter within the liver to dilate the tract between the hepatic vein and the portal vein. (C) Deployment of the stent. (D) Stent in its final position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_10_3239=[""].join("\n");
var outline_f3_10_3239=null;
var title_f3_10_3240="Minocycline: Drug information";
var content_f3_10_3240=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Minocycline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/53/17237?source=see_link\">",
"    see \"Minocycline: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/20/43334?source=see_link\">",
"    see \"Minocycline: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F196900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dynacin&reg;;",
"     </li>",
"     <li>",
"      Minocin&reg;;",
"     </li>",
"     <li>",
"      Minocin&reg; PAC;",
"     </li>",
"     <li>",
"      Solodyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F196901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Minocycline&reg;;",
"     </li>",
"     <li>",
"      Arestin Microspheres;",
"     </li>",
"     <li>",
"      Dom-Minocycline;",
"     </li>",
"     <li>",
"      Minocin&reg;;",
"     </li>",
"     <li>",
"      Mylan-Minocycline;",
"     </li>",
"     <li>",
"      Novo-Minocycline;",
"     </li>",
"     <li>",
"      PHL-Minocycline;",
"     </li>",
"     <li>",
"      PMS-Minocycline;",
"     </li>",
"     <li>",
"      ratio-Minocycline;",
"     </li>",
"     <li>",
"      Riva-Minocycline;",
"     </li>",
"     <li>",
"      Sandoz-Minocycline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F196940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Tetracycline Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F196905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Initial: 200 mg, followed by 100 mg every 12 hours (maximum: 400 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Initial: 200 mg, followed by 100 mg every 12 hours; more frequent dosing intervals may be used (100-200 mg initially, followed by 50 mg 4 times daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acne:",
"     </b>",
"     Oral: Capsule or immediate-release tablet: 50-100 mg  twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acne, inflammatory, non-nodular, moderate-to-severe (Solodyn&reg;):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45-49 kg: 45 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-59 kg: 55 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60-71 kg: 65 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     72-84 kg: 80 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     85-96 kg: 90 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     97-110 kg: 105 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     111-125 kg: 115 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     126-136 kg: 135 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Therapy should be continued for 12 weeks. Higher doses do not confer greater efficacy and may be associated with more acute vestibular side effects. Safety of use beyond 12 weeks has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cellulitis (purulent) due to community-acquired MRSA (unlabeled use):",
"     </b>",
"     Oral: Initial: 200 mg; Maintenance: 100 mg twice daily for 5-10 days (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chlamydial or",
"     </b>",
"     <b>",
"      <i>",
"       Ureaplasma urealyticum",
"      </i>",
"     </b>",
"     <b>",
"      infection, uncomplicated:",
"     </b>",
"     Oral, I.V.: Urethral, endocervical, or rectal: Oral: 100 mg every 12 hours for at least 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gonococcal infection, uncomplicated (males):",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Without urethritis or anorectal infection:",
"     </i>",
"     Initial: 200 mg, followed by 100 mg every 12 hours for at least 4 days (cultures 2-3 days post-therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Urethritis:",
"     </i>",
"     100 mg every 12 hours for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Meningococcal carrier state (manufacturer's labeling):",
"     </b>",
"     Oral: 100 mg every 12 hours for 5 days.",
"     <b>",
"      Note:",
"     </b>",
"     CDC recommendations do not mention use of minocycline for eradicating nasopharyngeal carriage of meningococcal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Mycobacterium marinum:",
"      </i>",
"     </b>",
"     Oral: 100 mg every 12 hours for 6-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nocardiosis, cutaneous (non-CNS) (unlabeled use):",
"     </b>",
"     Oral: 100-200 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prosthetic joint infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Staphylococci (oxacillin-sensitive or &ndash;resistant) oral phase treatment (after completion of pathogen-specific I.V. therapy) following 1-stage exchange:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Total ankle, elbow, hip, or shoulder arthroplasty: 100 mg twice daily for 3 months;",
"     <b>",
"      Note:",
"     </b>",
"     Must be used in combination with rifampin (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Total knee arthroplasty: 100 mg twice daily for 6 months;",
"     <b>",
"      Note:",
"     </b>",
"     Must be used in combination with rifampin (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Chronic oral antimicrobial suppression (unlabeled use):",
"     </i>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Propionibacterium",
"     </i>",
"     spp (alternative to penicillin or amoxicillin): 100 mg twice daily (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Staphylococci (oxacillin-resistant): 100 mg twice daily (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis (unlabeled use):",
"     </b>",
"     Oral: 100 mg twice daily (O&rsquo;Dell, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syphilis:",
"     </b>",
"     Oral, I.V.: Initial: 200 mg, followed by 100 mg every 12 hours for 10-15 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F196925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/20/43334?source=see_link\">",
"      see \"Minocycline: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     Children &gt;8 years: Oral, I.V.: Initial: 4 mg/kg followed by 2 mg/kg/dose every 12 hours (maximum: 400 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inflammatory, non-nodular, moderate-to-severe acne",
"     </b>",
"     (Solodyn&reg;): Children &ge;12 years: Oral: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cellulitis (purulent) infection due to community-acquired MRSA (unlabeled use):",
"     </b>",
"     Oral: Children &gt;8 years: Initial: 4 mg/kg (maximum: 200 mg); Maintenance: 2 mg/kg/dose (maximum: 100 mg) every 12 hours for 5-10 days (Liu, 2011);",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F196906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F196907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; monitor BUN and creatinine clearance. Consider decreasing dose or increasing dosing interval (extended release).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;80 mL/minute: Do not exceed 200 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15035749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, hepatotoxicity has been reported. Use with caution in patients with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F196875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 50 mg, 75 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, pellet filled, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minocin&reg;: 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minocin&reg; PAC: 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minocin&reg;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg, 75 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dynacin&reg;: 50 mg, 75 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 45 mg, 90 mg, 135 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solodyn&reg;: 45 mg [DSC], 55 mg, 65 mg, 80 mg, 90 mg [DSC], 105 mg, 115 mg, 135 mg [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F196861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes injection, pellet-filled capsule",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15237430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ximino&trade; extended-release capsules: FDA approved July 2012; anticipated availability currently unknown. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F196879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Infuse slowly; avoid rapid administration. The manufacturer&rsquo;s labeling does not provide a recommended administration rate. The injectable route should be used only if the oral route is not feasible or adequate. Prolonged intravenous therapy may be associated with thrombophlebitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May be administered with or without food. Administer with adequate fluid to decrease the risk of esophageal irritation and ulceration. Swallow pellet-filled capsule and extended release tablet whole; do not chew, crush, or split.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F9610387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, Ringer&rsquo;s injection, LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Incompatible",
"     </b>",
"     with calcium-containing solutions (except LR)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aztreonam, cisatracurium, cyclosporine, docetaxel, etoposide phosphate, filgrastim, fludarabine, gemcitabine, granisetron, heparin, hydrocortisone sodium succinate, linezolid, magnesium sulfate, melphalan, oxytocin, potassium chloride, remifentanil, sargramostim, teniposide, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amifostine, hydromorphone, meperidine, morphine, pemetrexed, propofol, thiotepa.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F196878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible bacterial infections of both gram-negative and gram-positive organisms; treatment of anthrax (inhalational, cutaneous, and gastrointestinal); moderate-to-severe acne; meningococcal (asymptomatic) carrier state; Rickettsial diseases (including Rocky Mountain spotted fever, Q fever); nongonococcal urethritis, gonorrhea; acute intestinal amebiasis; respiratory tract infection; skin/soft tissue infections; chlamydial infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release (Solodyn&reg;): Only indicated for treatment of inflammatory lesions of non-nodular moderate-to-severe acne",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6762770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rheumatoid arthritis (patients with low disease activity of short duration); nocardiosis; alternative treatment for community-acquired MRSA infection; chronic oral antimicrobial suppression of prosthetic joint infection",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F196948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dynacin&reg; may be confused with Dyazide&reg;, DynaCirc&reg;, Dynapen",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Minocin&reg; may be confused with Indocin&reg;, Lincocin&reg;, Minizide&reg;, niacin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F196938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Myocarditis, pericarditis, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Bulging fontanels, dizziness, fatigue, fever, headache, hypoesthesia, malaise, mood changes, paresthesia, pseudotumor cerebri, sedation, seizure, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, angioedema, drug rash with eosinophilia and systemic symptoms (DRESS), erythema multiforme, erythema nodosum, erythematous rash, exfoliative dermatitis, hyperpigmentation of nails, maculopapular rash, photosensitivity, pigmentation of the skin and mucous membranes, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Thyroid cancer, thyroid discoloration, thyroid dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, dyspepsia, dysphagia, enamel hypoplasia, enterocolitis, esophageal ulcerations, esophagitis, glossitis, inflammatory lesions (oral/anogenital), moniliasis, nausea, oral cavity discoloration, pancreatitis, pseudomembranous colitis, stomatitis, tooth discoloration, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Balanitis, vulvovaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia, hemolytic anemia, leukopenia, neutropenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Autoimmune hepatitis, hepatic cholestasis, hepatic failure, hepatitis, hyperbilirubinemia, jaundice, liver enzyme increases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction (I.V. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthritis, bone discoloration, joint stiffness, joint swelling, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing loss, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure, BUN increased, interstitial nephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, bronchospasm, cough, dyspnea, pneumonitis, pulmonary infiltrate (with eosinophilia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity, lupus erythematosus, lupus-like syndrome, serum sickness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F196882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to minocycline, other tetracyclines, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F196865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune syndromes: Lupus-like, hepatitis, and vasculitis autoimmune syndromes have been reported; discontinue if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Lightheadedness and vertigo may occur; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased BUN: May be associated with increases in BUN secondary to antianabolic effects; use caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: May cause photosensitivity; discontinue if skin erythema occurs. Use skin protection and avoid prolonged exposure to sunlight; avoid use of use tanning equipment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pseudotumor cerebri: Has been (rarely) reported with tetracycline use; usually resolves with discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin rash: Rash, along with eosinophilia, fever, and organ failure (Drug Rash with Eosinophilia and Systemic Symptoms [DRESS] syndrome), may occur; onset of symptoms may be delayed up to several weeks; fatal in up to 10% of cases; discontinue treatment immediately if DRESS syndrome is suspected",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Hepatotoxicity has been reported; use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;80 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: May cause tissue hyperpigmentation, enamel hypoplasia, or permanent tooth discoloration; use of tetracyclines should be avoided during tooth development (children &lt;8 years of age) unless other drugs are not likely to be effective or are contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Do not use during pregnancy. In addition to affecting tooth development, tetracycline use has been associated with retardation of skeletal development and reduced bone growth.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rheumatoid arthritis (unlabeled/investigational): Contraindicated in pregnancy and breast-feeding; Child-Pugh Class C and acute hepatitis B and C. (Saag KG, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F196870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Minocycline may decrease the serum concentration of Atazanavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bismuth: May decrease the serum concentration of Tetracycline Derivatives. Management: Consider dosing tetracyclines 2 hours before, or 6 hours after, bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bismuth Subsalicylate: May decrease the serum concentration of Tetracycline Derivatives. Management: Consider dosing tetracyclines 2 hours before, or 6 hours after, bismuth subsalicylate. The need to separate doses during Helicobacter pylori eradication regimens is questionable.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the serum concentration of Tetracycline Derivatives. Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Tetracycline Derivatives. Only a concern with orally administered products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Tetracycline Derivatives. Management: Administer oral tetracycline antibiotics at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Tetracycline Derivatives may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Tetracycline Derivatives. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines can not be avoided, separate administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Tetracycline Derivatives may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinapril: May decrease the serum concentration of Tetracycline Derivatives. Management: Separate doses of quinapril and oral tetracycline derivatives by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the tetracycline if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: Tetracycline Derivatives may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: May decrease the serum concentration of Tetracycline Derivatives. Management: In order to minimize any potential impact of strontium ranelate on tetracycline antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during tetracycline therapy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Tetracycline Derivatives. Management: Administer the tetracycline derivative at least 2 hours prior to sucralfate in order to minimize the impact of this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tetracycline Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the absorption of Tetracycline Derivatives. Only a concern when both products are administered orally.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Zinc Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F196895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Minocycline serum concentrations are not significantly altered if taken with food or dairy products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai, St John's wort (may also cause photosensitization).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F196872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F196885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tetracyclines cross the placenta and accumulate in developing teeth and long tubular bones. Rare spontaneous reports of congenital anomalies, including limb reduction, have been reported following maternal minocycline use. Due to limited information, a causal association cannot be established. Tetracyclines may discolor fetal teeth following maternal use during pregnancy; the specific teeth involved and the portion of the tooth affected depends on the timing and duration of exposure relative to tooth calcification. As a class, tetracyclines are generally considered second-line antibiotics in pregnant women and their use should be avoided (Mylonas, 2011). Minocycline should not be used for the treatment of acne in pregnant women, or in males or females attempting to conceive a child.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F196912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F196886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Minocycline is excreted in breast milk (Brogden, 1975). According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Oral absorption is not affected by dairy products; therefore, oral absorption of minocycline by the breast-feeding infant would not be expected to be diminished by the calcium in the maternal milk. Nondose-related effects could include modification of bowel flora. There have been case reports of black discoloration of breast milk in women taking minocycline (Basler, 1985; Hunt, 1996).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F196887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F196884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Minocin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $615.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (50): $615.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Minocycline HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $169.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $197.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (50): $169.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Minocin Combination)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $370.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $740.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Minocin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $71.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Minocycline HCl ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45 mg (30): $605.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (30): $605.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     135 mg (30): $605.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Solodyn Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45 mg (30): $846.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     55 mg (30): $1042.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     65 mg (30): $1042.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (30): $1042.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (30): $846.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     105 mg (30): $1042.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     115 mg (30): $1042.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     135 mg (30): $846.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Dynacin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $1051.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $1543.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (50): $921.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Minocycline HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $343.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $504.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (50): $300.98",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2934391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     LFTs, BUN, renal function with long-term treatment; if symptomatic for autoimmune disorder, include ANA, CBC",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F196888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Akamin (AU);",
"     </li>",
"     <li>",
"      Bagomicina (EC);",
"     </li>",
"     <li>",
"      Borymycin (MY, SG, TW);",
"     </li>",
"     <li>",
"      Cyclimycin (ZA);",
"     </li>",
"     <li>",
"      Cynomycin (IN);",
"     </li>",
"     <li>",
"      Klinomycin (LU);",
"     </li>",
"     <li>",
"      Lederderm (DE);",
"     </li>",
"     <li>",
"      Melicin (TW);",
"     </li>",
"     <li>",
"      Mestacine (FR);",
"     </li>",
"     <li>",
"      Micromycin (MX);",
"     </li>",
"     <li>",
"      Mino-50 (LU);",
"     </li>",
"     <li>",
"      Minocin (AR, BE, BO, BR, CH, CL, CN, CR, DO, EC, ES, GB, GR, GT, HK, HN, ID, IT, KP, LU, MX, NI, NL, PA, PE, PH, PK, PR, PT, PY, SV, UY, VE);",
"     </li>",
"     <li>",
"      Minocin SA (IE);",
"     </li>",
"     <li>",
"      Minoclin (IL);",
"     </li>",
"     <li>",
"      Minocyclin (CZ);",
"     </li>",
"     <li>",
"      Minocyclin 50 Stada (DE);",
"     </li>",
"     <li>",
"      Minogran (CO);",
"     </li>",
"     <li>",
"      Minoline (TW);",
"     </li>",
"     <li>",
"      Minomax (BR);",
"     </li>",
"     <li>",
"      Minomycin (AU, NZ);",
"     </li>",
"     <li>",
"      Minostad (AT);",
"     </li>",
"     <li>",
"      Minot (PE);",
"     </li>",
"     <li>",
"      Minotab (LU);",
"     </li>",
"     <li>",
"      Minotab 50 (BE, NZ, ZA);",
"     </li>",
"     <li>",
"      Mirosin (TW);",
"     </li>",
"     <li>",
"      Mynocine (FR);",
"     </li>",
"     <li>",
"      Parocline (FR);",
"     </li>",
"     <li>",
"      Periocline (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F196864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial protein synthesis by binding with the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria; cell wall synthesis is not affected",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Rheumatoid arthritis: The mechanism of action of minocycline in rheumatoid arthritis is not completely understood. It is thought to have antimicrobial, anti-inflammatory, immunomodulatory, and chondroprotective effects. More specifically, it is thought to be a potent inhibitor of metalloproteinases, which are active in rheumatoid arthritis joint destruction.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F196881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 70% to 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: 15-23 hours; Oral: 16 hours (range: 11-22 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Capsule, pellet filled: 1-4 hours; Extended release tablet: 3.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine, feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Basler RS and Lynch PJ, \"Black Galactorrhea as a Consequence of Minocycline and Phenothiazine Therapy,\"",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 1985, 121(3):417-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/10/3240/abstract-text/4038862/pubmed\" id=\"4038862\" target=\"_blank\">",
"        4038862",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brogden RN, Speight TM, and Avery GS, \"Minocycline: A Review of Its Antibacterial and Pharmacokinetic Properties and Therapeutic Use,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 1975, 9(4):251-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/10/3240/abstract-text/1173232/pubmed\" id=\"1173232\" target=\"_blank\">",
"        1173232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghislain PD and Roujeau JC, \"Treatment of Severe Drug Reactions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis and Hypersensitivity Syndrome,\"",
"      <i>",
"       Dermatol Online J",
"      </i>",
"      , 2002, 8(1):5. Available at file://dermatology.cdlib.org/DOJvol8num1/reviews/drugrxn/ghislain.html",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/10/3240/abstract-text/12165215/pubmed\" id=\"12165215\" target=\"_blank\">",
"        12165215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goulden V, &ldquo;Guidelines for the Management of Acne Vulgaris in Adolescents,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2003, 5(5):301-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/10/3240/abstract-text/12716217/pubmed\" id=\"12716217\" target=\"_blank\">",
"        12716217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt MJ, Salisbury EL, Grace J, et al, \"Black Breast Milk Due to Minocycline Therapy,\"",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 1996, 134(5):943-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/10/3240/abstract-text/8736342/pubmed\" id=\"8736342\" target=\"_blank\">",
"        8736342",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu C, Bayer A, Cosgrove SE, et al, &ldquo;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant",
"      <i>",
"       Staphylococcus Aureus",
"      </i>",
"      Infections in Adults and Children: Executive Summary,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(3):285-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/10/3240/abstract-text/21217178/pubmed\" id=\"21217178\" target=\"_blank\">",
"        21217178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mylonas I, \"Antibiotic Chemotherapy During Pregnancy and Lactation Period: Aspects for Consideration,\"",
"      <i>",
"       Arch Gynecol Obstet",
"      </i>",
"      , 2011, 283(1):7-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/10/3240/abstract-text/20814687/pubmed\" id=\"20814687\" target=\"_blank\">",
"        20814687",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O&rsquo;Dell JR, Haire CE, Palmer W, et al, &ldquo;Treatment of Early Rheumatoid Arthritis With Minocycline or Placebo: Results of a Randomized, Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1997, 40(5):842-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/10/3240/abstract-text/9153544/pubmed\" id=\"9153544\" target=\"_blank\">",
"        9153544",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O&rsquo;Dell JR, Blakely KW, Mallek JA, et al, &ldquo;Treatment of Early Seropositive Rheumatoid Arthritis: A Two-Year, Double-Blind Comparison of Minocycline and Hydroxychloroquine,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2001, 44(10):2235-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/10/3240/abstract-text/11665963/pubmed\" id=\"11665963\" target=\"_blank\">",
"        11665963",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/10/3240/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(5):625-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/10/3240/abstract-text/22473917/pubmed\" id=\"22473917\" target=\"_blank\">",
"        22473917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smilack JD, Wilson WR, and Cockerill FR 3d, &ldquo;Tetracyclines, Chloramphenicol, Erythromycin, Clindamycin, and Metronidazole,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1991, 66(12):1270-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/10/3240/abstract-text/1749296/pubmed\" id=\"1749296\" target=\"_blank\">",
"        1749296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strauss JS, Krowchuk DP, Leyden JJ, et al, &ldquo;Guidelines of Care for Acne Vulgaris Management,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2007, 56(4):651-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/10/3240/abstract-text/17276540/pubmed\" id=\"17276540\" target=\"_blank\">",
"        17276540",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9653 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-FBD0C7583D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_10_3240=[""].join("\n");
var outline_f3_10_3240=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196900\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196901\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196940\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196905\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196925\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196906\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196907\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15035749\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196875\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196861\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15237430\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196879\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9610387\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196878\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6762770\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196948\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196938\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196882\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196865\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299717\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196870\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196895\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196872\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196885\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196912\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196886\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196887\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196884\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934391\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196888\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196864\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196881\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9653\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9653|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/53/17237?source=related_link\">",
"      Minocycline: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/20/43334?source=related_link\">",
"      Minocycline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_10_3241="Treatment of premenstrual syndrome and premenstrual dysphoric disorder";
var content_f3_10_3241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of premenstrual syndrome and premenstrual dysphoric disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/10/3241/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/10/3241/contributors\">",
"     Robert F Casper, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/10/3241/contributors\">",
"     Kimberly A Yonkers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/10/3241/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/10/3241/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/10/3241/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/10/3241/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/10/3241/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/10/3241/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The premenstrual syndrome (PMS) and the more severe variant of premenstrual dysphoric disorder (PMDD) (also called late luteal phase dysphoric disorder in previous versions of the Diagnostic and Statistical Manual: DSM) are characterized by the presence of physical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    behavioral symptoms that occur repetitively in the second half of the menstrual cycle and often the first few days of menses. The symptoms of PMS or PMDD are severe enough that they interfere with some aspects of the woman's life (eg, family or other social relations, work in or outside the home, etc). The most common physical manifestation is abdominal bloating, which occurs in 90 percent of women with this disorder; breast tenderness and headaches are among the other symptoms that can be seen, occurring in more than 50 percent of cases (",
"    <a class=\"graphic graphic_table graphicRef55312 \" href=\"UTD.htm?15/16/15628\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39751?source=see_link\">",
"     \"Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Premenstrual dysphoric disorder (PMDD), as defined by the American Psychiatric Association DSM-IV, can be differentiated from PMS by the presence of at least one affective symptom, such as anger, irritability,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    internal tension. Premenstrual symptoms are common, affecting up to 75 percent of women with regular menstrual cycles. However, clinically significant PMS occurs in 20 to 30 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], while true PMDD affects a much smaller subset of this group. The diagnosis of PMDD is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39751?source=see_link\">",
"     \"Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of medications are beneficial to women with either PMS or PMDD (",
"    <a class=\"graphic graphic_table graphicRef59712 \" href=\"UTD.htm?14/43/15035\">",
"     table 2",
"    </a>",
"    ). These treatments have largely supplanted earlier prescriptions which had little or no scientific evidence to support their efficacy. This review will discuss the major aspects of the medical therapy of PMDD. The pathogenesis of this disorder, which provides the rationale for some of the therapeutic options, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28935?source=see_link\">",
"     \"Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SEROTONIN REUPTAKE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic reviews of SRIs for PMDD conclude that these drugs are effective [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The utility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    has been demonstrated in a variety of studies when given in a daily dose of 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. The overall response rate is 60 to 75 percent. A Canadian multicenter study randomized 313 women to placebo or to fluoxetine in doses of 20 or 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/9\">",
"     9",
"    </a>",
"    ]. Both doses of fluoxetine were more effective than placebo; the higher dose was associated with significantly more side effects while not providing more benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/9\">",
"     9",
"    </a>",
"    ]. In this daily dosing study, fluoxetine was superior to placebo in relieving both common physical symptoms and mood symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An uncontrolled study of the long-term follow-up of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    suggests that the beneficial response is maintained for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/11\">",
"     11",
"    </a>",
"    ]. The most common reasons for failure to continue the treatment are headache, anxiety, and nausea, the combined incidence of which is approximately 15 percent. The United States Food and Drug Administration approved use of fluoxetine for women with PMDD. However, European drug regulators (Committee for Proprietary Medicinal Products) have not given approval, citing lack of evidence that PMDD is a well-established entity and the poor quality of trials evaluating the drug's effectiveness. In particular, they felt women with mild premenstrual symptoms might receive this, or other, antidepressants inappropriately.",
"   </p>",
"   <p>",
"    Other SRIs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    (50 to 150",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/12,13\">",
"     12,13",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    (20 to 30",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/14\">",
"     14",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    (20 to 30",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/15\">",
"     15",
"    </a>",
"    ], have also been shown to be effective. In a randomized placebo controlled study of 200 women, for example, total daily symptom scores decreased more in the patients treated with sertraline compared to placebo (64 to 44 versus 62 to 54) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/16\">",
"     16",
"    </a>",
"    ]. Sertraline was also associated with a greater reduction in rating scale depression scores (44 versus 29 percent) and a higher incidence of much or very much improvement in end-point global ratings (62 versus 34 percent). Similar findings were noted in another controlled study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other antidepressants that inhibit serotonin reuptake (but are not SRIs), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    (given either throughout the menstrual cycle or restricted to the luteal phase) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/20\">",
"     20",
"    </a>",
"    ] may be effective in PMS.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     Venlafaxine",
"    </a>",
"    , a drug that selectively inhibits the reuptake of both serotonin and norepinephrine, is also more effective (50 to 200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Luteal phase therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent therapy given during the luteal phase only (starting on cycle day 14) is effective for some drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/15,19,22,23\">",
"     15,19,22,23",
"    </a>",
"    ]. This regimen has the advantages of being less expensive and having fewer side effects. In some preliminary studies, a treatment interval as short as three days appears to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Therapy is typically discontinued at the onset of menses, although it may be continued for several additional days in women with a history of persistent symptoms during menses.",
"   </p>",
"   <p>",
"    Higher doses of the SRI are needed in some women to adequately treat physical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Intermittent therapy beginning at the point of symptom onset until the first few days of menses may also be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of 29 trials of SRIs, intermittent dosing (luteal phase) trials (n = 9) had a smaller estimate of treatment effect size (OR 0.55) when compared to the continuous dosing trials (OR 0.28) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANTIDEPRESSANTS AND LITHIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the well-documented efficacy of serotonin reuptake inhibitors, antidepressants outside of this class (eg, tricyclic antidepressants, monoamine oxidase inhibitors), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , are not effective in the treatment of PMS or PMDD. As an example, in a study that randomly assigned 189 women with",
"    <span class=\"nowrap\">",
"     PMS/PMDD",
"    </span>",
"    to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    , desipramine, or placebo, sertraline significantly reduced symptoms compared to the other agents (65 versus 36 and 29 percent, respectively), with no significant difference between desipramine and placebo therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/17\">",
"     17",
"    </a>",
"    ]. Based upon current evidence, there is no rationale for use of these agents in PMS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ALPRAZOLAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benzodiazepine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    (0.25 mg three or four times daily) has been shown in double-blind, placebo-controlled crossover studies to be beneficial in PMS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. In one report, the efficacy of alprazolam appeared to be limited to women who met strict criteria for PMDD; women who also had anxiety and depression at other times in the menstrual cycle did not benefit from alprazolam [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/31\">",
"     31",
"    </a>",
"    ]. A second study suggested that it may only be effective for depressive symptoms of PMS. Alprazolam is currently considered a second-line treatment for PMS, particularly in view of the addictive potential of the drug if its use is not limited to the luteal phase of the menstrual cycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GnRH AGONISTS AND DANAZOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contributory role of ovarian steroids in the pathogenesis of PMDD has led to the evaluation of gonadotropin-releasing hormone (GnRH) agonists and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    in this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28935?source=see_link\">",
"     \"Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    .) Pulsatile secretion of GnRH normally stimulates the release of gonadotropins (follicle-stimulating hormone and luteinizing hormone). However, when GnRH or its agonists are given continuously, gonadotropin secretion and gonadal function are suppressed (",
"    <a class=\"graphic graphic_figure graphicRef51212 \" href=\"UTD.htm?19/58/20398\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=see_link\">",
"     \"Physiology of gonadotropin-releasing hormone\"",
"    </a>",
"    .) Danazol also inhibits gonadotropin secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     GnRH agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first demonstration of benefit of \"medical oophorectomy\" with a GnRH agonist in the treatment of PMS was made in a crossover study of eight patients in 1984 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/32\">",
"     32",
"    </a>",
"    ]. This finding has subsequently been replicated by several other investigators [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some reports, GnRH agonists may be less effective for depressive symptoms than for irritability or physical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. However, in one of the author's experience with GnRH agonists, this is not the case. The side effects with GnRH agonist alone are related to hypoestrogenism and are substantial (in particular, hot flashes and loss of bone mineral density) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/36\">",
"     36",
"    </a>",
"    ]. The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    is maintained when low-dose exogenous estrogen and a progestin are added back [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. However, it is essential that estrogen and progestin be given in a continuous regimen, and not in a cyclic fashion, which may reproduce PMS. The long-term use of GnRH agonists is possible with estrogen-progestin addback with no loss of bone mineral density and with continued resolution of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Danazol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     Danazol",
"    </a>",
"    is a 19-nortestosterone derivative with progestin-like effects. It inhibits pituitary gonadotropin secretion, and when given in sufficient doses to inhibit ovulation, is an effective therapy for PMS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Doses that lead to anovulation appear necessary for the therapeutic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/42\">",
"     42",
"    </a>",
"    ]. However, the androgenic side effects of danazol limit its use to patients who fail to respond adequately to the above therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENTS WITH POSSIBLE EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of additional drugs have possible efficacy in women with PMS (",
"    <a class=\"graphic graphic_table graphicRef59712 \" href=\"UTD.htm?14/43/15035\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perhaps the simplest method of inducing anovulation is the use of an oral contraceptive. Early studies did not demonstrate that oral contraceptives were more effective than placebo for treatment of PMS or PMDD [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. However, placebo-controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/46,47\">",
"     46,47",
"    </a>",
"    ] and a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/48\">",
"     48",
"    </a>",
"    ] suggest that an oral contraceptive containing the progestin, drospirenone, and use of a four rather than seven day pill-free interval, is more effective than placebo for symptom relief in women with PMDD. The long-term safety and efficacy of this compound for treating",
"    <span class=\"nowrap\">",
"     PMS/PMDD",
"    </span>",
"    are not known.",
"   </p>",
"   <p>",
"    Dydrogesterone administration during the luteal phase was slightly better than placebo in one study, but the difference was not likely to be clinically important [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Exercise and relaxation techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not demonstrated in rigorous controlled studies, there is suggestive evidence that exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/50,51\">",
"     50,51",
"    </a>",
"    ], relaxation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/52\">",
"     52",
"    </a>",
"    ], and reflexology [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/53\">",
"     53",
"    </a>",
"    ] may help to alleviate PMS symptoms. It is not clear that benefits from these techniques are any more than a placebo effect. The placebo response in this condition is typically high and it is difficult to test these techniques in an adequately blinded manner. Exercise is beneficial in general and may be recommended on this basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Spironolactone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     Spironolactone",
"    </a>",
"    , the diuretic with the most theoretical likelihood of demonstrating therapeutic usefulness because of its structural similarity to steroid hormones, has not been consistently shown to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/54-57\">",
"     54-57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Agnus castus fruit extract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fruits of Vitex agnus castus (the chasteberry tree) have been used to treat the symptoms of PMS. It is thought to antagonize prolactin. In a placebo-controlled trial of 170 women with PMS (using earlier DSM-III criteria), agnus castus (one dry extract tablet daily for three cycles) resulted in a significant decrease in irritability, anger, headache, and breast fullness when compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/58\">",
"     58",
"    </a>",
"    ]. No differences in adverse events were seen between the groups. While this appears to be a potential therapy for",
"    <span class=\"nowrap\">",
"     PMS/PMDD,",
"    </span>",
"    it requires replication. Further, caution should be used when using herbal preparations, as they are not regulated by the Food and Drug Administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Vitamin supplements and diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several vitamin supplements including vitamin B6, vitamin E, calcium, and magnesium may have some efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/59-63\">",
"     59-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several placebo-controlled trials have evaluated the therapeutics of calcium treatment. In a trial of 466 women with PMS randomly assigned to receive 600 mg of elemental calcium, twice daily or placebo reported a reduction in overall luteal symptoms with calcium supplementation compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a nested case-control study within a prospective cohort study reported that high dietary intake of calcium or vitamin D reduced the risk of developing PMS over a 10-year follow-up period [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/64\">",
"     64",
"    </a>",
"    ]. The relative risk of PMS for women with the highest calcium intake (median 1283",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    compared to low intake (median 529",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was 0.70 (95% CI 0.50-0.97). For vitamin D, the relative risk of PMS in women with high intake (median 706",
"    <span class=\"nowrap\">",
"     IU/day)",
"    </span>",
"    compared to low intake (median 112",
"    <span class=\"nowrap\">",
"     IU/day)",
"    </span>",
"    was 0.59 (95% CI 0.40-0.86).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of the currently available data suggests that doses of vitamin B6 up to 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      may be effective, but the evidence is derived from poor quality studies, making definitive conclusions difficult [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/65\">",
"       65",
"      </a>",
"      ]. In addition, high doses of vitamin B6 (greater than",
"      <strong>",
"       100",
"      </strong>",
"      mg",
"      <strong>",
"       per",
"      </strong>",
"      day) have been linked with peripheral neuropathy.",
"     </li>",
"     <li>",
"      Smaller trials have described modest relief of premenstrual symptoms with 200 to 360 mg of magnesium administered up to three times per day [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/61,62\">",
"       61,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A small, randomized trial reported a significant improvement in certain affective and physical symptoms in women treated with 400 IU of d,alpha-tocopherol (vitamin E) compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, several placebo-controlled trials of specially-formulated, complex carbohydrate-rich beverage demonstrated a reduction in psychological and appetite symptoms in those consuming the carbohydrate-rich beverage [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/66\">",
"     66",
"    </a>",
"    ]. These findings are notable because such beverages increase the availability of the amino acid, tryptophan, in the periphery. Tryptophan is actively transported into the central nervous system and is the rate limiting step in serotonin synthesis. Dysphoria can be induced by peripheral reductions in tryptophan. Thus, the efficacy of these beverage supports the notion that serotonin is involved in the pathophysiology of premenstrual disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Bright light therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of four crossover trials studying a total of 55 subjects concluded that the impact of bright light therapy for this indication remains uncertain and may be attributable to a placebo response [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22936?source=see_link\">",
"     \"Seasonal affective disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     INEFFECTIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other drugs, dietary supplements, and vitamins, have been evaluated for use in PMS without demonstrable benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Progesterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progesterone and progestins, which once constituted the most common therapies for PMS, do not appear to be more effective than placebo in most studies and systematic reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/68-72\">",
"     68-72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Dietary and vitamin supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of dietary and vitamin supplements have been tried in the treatment of PMS and have generally been found to be no better than placebo. These include evening primrose oil&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/73\">",
"     73",
"    </a>",
"    ], essential free fatty acids [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/74\">",
"     74",
"    </a>",
"    ], and ginkgo biloba extract [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/75\">",
"     75",
"    </a>",
"    ]. We do not advocate their use in the treatment of PMS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     APPROACH TO THE MANAGEMENT OF PMS/PMDD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should not be considered unless a clear diagnosis of PMS or PMDD has been established. In particular, women must be symptom-free during the follicular phase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39751?source=see_link\">",
"     \"Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    .) This can be best discerned by having a patient chart her mood and physical symptoms daily over the course of at least one menstrual cycle.",
"   </p>",
"   <p>",
"    In the absence of substantial distress or socioeconomic dysfunction, the patient should be advised to consider exercise and an attempt at management with moderate vitamin (B-6) supplementation. She should be advised that these therapies are",
"    <strong>",
"     possibly",
"    </strong>",
"    &nbsp;",
"    <strong>",
"     effective",
"    </strong>",
"    and have virtually no adverse effects unless the dose of B-6 exceeds 100 mgs per day. Pharmacologic intervention should be considered if these therapies do not provide sufficient relief.",
"   </p>",
"   <p>",
"    In comparison, women who meet the criteria for PMS or PMDD",
"    <strong>",
"     including",
"    </strong>",
"    socioeconomic dysfunction are best served by pharmacologic intervention. Because of the proven efficacy and safety profile, serotonin reuptake inhibitors (SRIs) are the first line therapy. The effective dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    is 20",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     Sertraline",
"    </a>",
"    is beneficial in doses of 50 to 150 mgs daily and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    -controlled release is most effective in a dose of 25 mgs daily. SRIs can be administered as a daily therapy or luteal phase-only treatment. While most women prefer luteal phase therapy, clinicians who plan to use this platform should ensure that the patient is asymptomatic during the follicular phase of the cycle, since otherwise, she will be undertreated. If the patient has severe physical symptoms and would like intermittent therapy, higher doses may be required.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 15 percent of patients will experience significant side effects from an SRI, including nausea, jitteriness, and headache. In such patients, a trial of either a lower starting dose or a second SRI is warranted. The most problematic side effect of an SRI may be sexual dysfunction including anorgasmia and diminished sexual interest. A dose reduction may not alleviate this side effect. Women should be informed that this complication may arise.",
"     </li>",
"     <li>",
"      Approximately 30 to 40 percent of women do not respond to an SRI over several menstrual cycles. Lack of response should not be diagnosed if response is not evident during the first cycle of treatment. Some women who do not respond to one SRI may respond to a second SRI and it is worth attempting this switch in non-responders. Additionally, women who do not respond completely to intermittent therapy may benefit from daily therapy and some women who undergo daily treatment may do better with intermittent treatment. If these interventions are not sufficiently beneficial, women may be tried on low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      treatment (0.25 mg BID or TID), although sedating side effects can be problematic with this compound.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women who desire contraception in addition to treatment of PMS or PMDD can consider an oral contraceptive with a shortened pill-free interval. One of these (Yaz&reg;), a combination of 3 mgs of the progestin, drospirenone and 20 micrograms of ethinyl estradiol appears to be effective. Other pills with a shortened pill-free interval may also be effective, although they have not yet been studied.",
"   </p>",
"   <p>",
"    When patients do not respond to several SRIs, an attempt should be made to augment treatment using compounds, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    , calcium, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    . It is also reasonable to review the patient's symptoms to ensure that another illness, such as major depression, a substance use disorder or another condition has not been missed. If the patient is suffering from severe PMDD, not complicated by other illnesses and is not responsive to prior treatment, she is a candidate for ovulation suppression agents. A GnRH agonist with estrogen and progestin addback is preferable to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    because of the more favorable side effect profile. In patients who respond well to GnRH agonists and estrogen-progestin addback, therapy may be extended beyond six months without loss of bone density.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical therapy of PMDD is usually successful. As a result, surgery is considered only in the rare refractory cases with severe, disabling symptoms. Three observational studies found bilateral oophorectomy, usually with concomitant hysterectomy, to be effective for such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/76-78\">",
"     76-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following guidelines should be considered before resorting to a surgical approach to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3241/abstract/79\">",
"     79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of PMDD must be confirmed with prospective symptom recording",
"     </li>",
"     <li>",
"      GnRH agonist therapy must be the only medical approach that has been effective, and it must have been continuously effective for a minimum of six months",
"     </li>",
"     <li>",
"      Tolerance of estrogen (or estrogen-progestin) replacement therapy has been tested during the GnRH agonist therapy",
"     </li>",
"     <li>",
"      Childbearing is complete",
"     </li>",
"     <li>",
"      The need for several more years of therapy is anticipated based on the woman's age",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42146?source=see_link\">",
"       \"Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/12/13510?source=see_link\">",
"       \"Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/1\">",
"      Borenstein J, Chiou CF, Dean B, et al. Estimating direct and indirect costs of premenstrual syndrome. J Occup Environ Med 2005; 47:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/2\">",
"      Deuster PA, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 1999; 8:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/3\">",
"      Dimmock PW, Wyatt KM, Jones PW, O'Brien PM. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000; 356:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/4\">",
"      Brown J, O' Brien PM, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2009; :CD001396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/5\">",
"      Stone, AB, Pearlstein, TB, Brown, WA. Fluoxetine in the treatment of premenstrual syndrome. Psychopharm Bull 1991; 26:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/6\">",
"      Stone AB, Pearlstein TB, Brown WA. Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1991; 52:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/7\">",
"      Wood SH, Mortola JF, Chan YF, et al. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet Gynecol 1992; 80:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/8\">",
"      Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995; 332:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/9\">",
"      Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993; 328:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/10\">",
"      Steiner M, Romano SJ, Babcock S, et al. The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. BJOG 2001; 108:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/11\">",
"      Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatry 1997; 9:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/12\">",
"      Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997; 278:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/13\">",
"      Freeman EW, Rickels K, Sondheimer SJ, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 1999; 56:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/14\">",
"      Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995; 12:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/15\">",
"      Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998; 18:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/16\">",
"      Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry 1997; 58:393.",
"     </a>",
"    </li>",
"    <li>",
"     Congress. Women's Health Equity Act: House of Representatives. February 27, 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/18\">",
"      Sundblad C, Modigh K, Andersch B, Eriksson E. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand 1992; 85:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/19\">",
"      Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 1993; 9:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/20\">",
"      Freeman EW, Rickels K, Sondheimer SJ, et al. Nefazodone in the treatment of premenstrual syndrome: a preliminary study. J Clin Psychopharmacol 1994; 14:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/21\">",
"      Freeman EW, Rickels K, Yonkers KA, et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001; 98:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/22\">",
"      Steiner M, Korzekwa M, Lamont J, Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull 1997; 33:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/23\">",
"      Halbreich U, Bergeron R, Yonkers KA, et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002; 100:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/24\">",
"      Yonkers KA, Holthausen GA, Poschman K, Howell HB. Symptom-onset treatment for women with premenstrual dysphoric disorder. J Clin Psychopharmacol 2006; 26:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/25\">",
"      Land&eacute;n M, Erlandsson H, Bengtsson F, et al. Short onset of action of a serotonin reuptake inhibitor when used to reduce premenstrual irritability. Neuropsychopharmacology 2009; 34:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/26\">",
"      Cohen LS, Miner C, Brown EW, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002; 100:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/27\">",
"      Miner C, Brown E, McCray S, et al. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002; 24:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/28\">",
"      Shah NR, Jones JB, Aperi J, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol 2008; 111:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/29\">",
"      Smith S, Rinehart JS, Ruddock VE, Schiff I. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol 1987; 70:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/30\">",
"      Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam. A controlled study. Arch Gen Psychiatry 1990; 47:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/31\">",
"      Berger CP, Presser B. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study. Obstet Gynecol 1994; 84:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/32\">",
"      Muse KN, Cetel NS, Futterman LA, Yen SC. The premenstrual syndrome. Effects of \"medical ovariectomy\". N Engl J Med 1984; 311:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/33\">",
"      Freeman EW, Sondheimer SJ, Rickels K. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull 1997; 33:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/34\">",
"      Brown CS, Ling FW, Andersen RN, et al. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 1994; 84:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/35\">",
"      West CP, Hillier H. Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome. Hum Reprod 1994; 9:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/36\">",
"      Hussain SY, Massil JH, Matta WH, et al. Buserelin in premenstrual syndrome. Gynecol Endocrinol 1992; 6:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/37\">",
"      Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 1991; 72:252A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/38\">",
"      Mezrow G, Shoupe D, Spicer D, et al. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril 1994; 62:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/39\">",
"      Wyatt KM, Dimmock PW, Ismail KM, et al. The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta analysis. BJOG 2004; 111:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/40\">",
"      Mitwally MF, Gotlieb L, Casper RF. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause 2002; 9:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/41\">",
"      Bedaiwy MA, Casper RF. Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain. Fertil Steril 2006; 86:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/42\">",
"      Halbreich U, Rojansky N, Palter S. Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndromes. Fertil Steril 1991; 56:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/43\">",
"      Hahn PM, Van Vugt DA, Reid RL. A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 1995; 20:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/44\">",
"      Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992; 36:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/45\">",
"      Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001; 10:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/46\">",
"      Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/47\">",
"      Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/48\">",
"      Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2009; :CD006586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/49\">",
"      Khajehei M, Abdali K, Parsanezhad ME, Tabatabaee HR. Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome. Int J Gynaecol Obstet 2009; 105:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/50\">",
"      Steege JF, Blumenthal JA. The effects of aerobic exercise on premenstrual symptoms in middle-aged women: a preliminary study. J Psychosom Res 1993; 37:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/51\">",
"      Aganoff JA, Boyle GJ. Aerobic exercise, mood states and menstrual cycle symptoms. J Psychosom Res 1994; 38:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/52\">",
"      Goodale IL, Domar AD, Benson H. Alleviation of premenstrual syndrome symptoms with the relaxation response. Obstet Gynecol 1990; 75:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/53\">",
"      Oleson T, Flocco W. Randomized controlled study of premenstrual symptoms treated with ear, hand, and foot reflexology. Obstet Gynecol 1993; 82:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/54\">",
"      Burnet RB, Radden HS, Easterbrook EG, McKinnon RA. Premenstrual syndrome and spironolactone. Aust N Z J Obstet Gynaecol 1991; 31:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/55\">",
"      Hellberg D, Claesson B, Nilsson S. Premenstrual tension: a placebo-controlled efficacy study with spironolactone and medroxyprogesterone acetate. Int J Gynaecol Obstet 1991; 34:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/56\">",
"      Wang M, Hammarb&auml;ck S, Lindhe BA, B&auml;ckstr&ouml;m T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand 1995; 74:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/57\">",
"      O'Brien PM, Craven D, Selby C, Symonds EM. Treatment of premenstrual syndrome by spironolactone. Br J Obstet Gynaecol 1979; 86:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/58\">",
"      Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ 2001; 322:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/59\">",
"      Stewart A. Vitamin B6 in the treatment of the premenstrual syndrome--review. Br J Obstet Gynaecol 1991; 98:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/60\">",
"      Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol 1998; 179:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/61\">",
"      Facchinetti F, Borella P, Sances G, et al. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol 1991; 78:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/62\">",
"      Walker AF, De Souza MC, Vickers MF, et al. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health 1998; 7:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/63\">",
"      London RS, Murphy L, Kitlowski KE, Reynolds MA. Efficacy of alpha-tocopherol in the treatment of the premenstrual syndrome. J Reprod Med 1987; 32:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/64\">",
"      Bertone-Johnson ER, Hankinson SE, Bendich A, et al. Calcium and vitamin D intake and risk of incident premenstrual syndrome. Arch Intern Med 2005; 165:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/65\">",
"      Wyatt KM, Dimmock PW, Jones PW, Shaughn O'Brien PM. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ 1999; 318:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/66\">",
"      Sayegh R, Schiff I, Wurtman J, et al. The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. Obstet Gynecol 1995; 86:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/67\">",
"      Krasnik C, Montori VM, Guyatt GH, et al. The effect of bright light therapy on depression associated with premenstrual dysphoric disorder. Am J Obstet Gynecol 2005; 193:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/68\">",
"      Freeman E, Rickels K, Sondheimer SJ, Polansky M. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome. JAMA 1990; 264:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/69\">",
"      Wyatt K, Dimmock P, Jones P, et al. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 2001; 323:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/70\">",
"      Magill PJ. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. progesterone Study Group. Br J Gen Pract 1995; 45:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/71\">",
"      Vanselow W, Dennerstein L, Greenwood KM, de Lignieres B. Effect of progesterone and its 5 alpha and 5 beta metabolites on symptoms of premenstrual syndrome according to route of administration. J Psychosom Obstet Gynaecol 1996; 17:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/72\">",
"      Ford O, Lethaby A, Roberts H, Mol BW. Progesterone for premenstrual syndrome. Cochrane Database Syst Rev 2009; :CD003415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/73\">",
"      Khoo SK, Munro C, Battistutta D. Evening primrose oil and treatment of premenstrual syndrome. Med J Aust 1990; 153:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/74\">",
"      Collins A, Cerin A, Coleman G, Landgren BM. Essential fatty acids in the treatment of premenstrual syndrome. Obstet Gynecol 1993; 81:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/75\">",
"      Tamborini A, Taurelle R. [Value of standardized Ginkgo biloba extract (EGb 761) in the management of congestive symptoms of premenstrual syndrome]. Rev Fr Gynecol Obstet 1993; 88:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/76\">",
"      Casson P, Hahn PM, Van Vugt DA, Reid RL. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 1990; 162:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/77\">",
"      Casper RF, Hearn MT. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am J Obstet Gynecol 1990; 162:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/78\">",
"      Cronje WH, Vashisht A, Studd JW. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod 2004; 19:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3241/abstract/79\">",
"      Johnson SR. Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: a clinical primer for practitioners. Obstet Gynecol 2004; 104:845.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7382 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_10_3241=[""].join("\n");
var outline_f3_10_3241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SEROTONIN REUPTAKE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Luteal phase therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANTIDEPRESSANTS AND LITHIUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ALPRAZOLAM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GnRH AGONISTS AND DANAZOL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GnRH agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Danazol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENTS WITH POSSIBLE EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Exercise and relaxation techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Spironolactone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Agnus castus fruit extract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Vitamin supplements and diet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Calcium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Bright light therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      INEFFECTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Progesterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Dietary and vitamin supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      APPROACH TO THE MANAGEMENT OF PMS/PMDD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7382\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7382|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/58/20398\" title=\"figure 1\">",
"      Continuous GnRH LH and FSH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7382|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/16/15628\" title=\"table 1\">",
"      UCSD criteria for PMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15035\" title=\"table 2\">",
"      Treatment of PMS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39751?source=related_link\">",
"      Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28935?source=related_link\">",
"      Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/12/13510?source=related_link\">",
"      Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42146?source=related_link\">",
"      Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=related_link\">",
"      Physiology of gonadotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22936?source=related_link\">",
"      Seasonal affective disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_10_3242="Presentation, diagnosis, and clinical course of vesicoureteral reflux";
var content_f3_10_3242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/10/3242/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/10/3242/contributors\">",
"     Gordon McLorie, MD, FRCSC, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/10/3242/contributors\">",
"     John T Herrin, MBBS, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/10/3242/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/10/3242/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/10/3242/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/10/3242/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/10/3242/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/10/3242/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vesicoureteral reflux (VUR) is the retrograde passage of urine from the bladder into the upper urinary tract. It is the most common urologic finding in children, occurring in approximately 1 percent of newborns, and as high as 30 to 45 percent of young children with a urinary tract infection (UTI) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current management is based upon the premise that VUR predisposes patients to acute pyelonephritis by transporting bacteria from the bladder to the kidney. Pyelonephritis itself is a morbid event that requires acute medical care and possible hospitalization in young infants. In addition, the resulting infection may lead to renal scarring, which is the loss of renal parenchyma between the calyces and the renal capsule. Extensive scarring may progress to further renal injury with subsequent hypertension, decreased renal function, proteinuria, and sometimes end-stage renal disease (ESRD) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/1,4-6\">",
"     1,4-6",
"    </a>",
"    ]. However, this long-held belief that reflux may lead to progressive chronic kidney disease and potentially ESRD has been increasingly questioned. As a result, the clinical impact of VUR and its management remain uncertain and controversial. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Role in renal scarring and chronic kidney disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The diagnosis, presentation, and clinical impact of VUR will be reviewed here. The management of VUR is discussed elsewhere in the program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/62/41961?source=see_link\">",
"     \"Management of vesicoureteral reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vesicoureteral reflux (VUR) is divided into two categories; primary and secondary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Primary VUR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary VUR, the most common form of reflux, is due to incompetent or inadequate closure of the ureterovesical junction (UVJ), which contains a segment of the ureter within the bladder wall (intravesical ureter). Normally, reflux is prevented during bladder contraction by fully compressing the intravesical ureter and sealing it off with the surrounding bladder muscles.",
"   </p>",
"   <p>",
"    In primary VUR, failure of this anti-reflux mechanism is due to the shortening of the intravesical ureter (",
"    <a class=\"graphic graphic_figure graphicRef54236 \" href=\"UTD.htm?9/22/9569\">",
"     figure 1",
"    </a>",
"    ). The intravesical ureter length may be genetically dictated, which may explain the increased incidence in family members of patients with VUR.",
"   </p>",
"   <p>",
"    Spontaneous resolution of primary VUR can occur with growth [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/7\">",
"     7",
"    </a>",
"    ]. As the bladder grows, the intravesical ureter increases in length, improving the function of the anti-reflux mechanism. This is especially true in infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Secondary VUR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary VUR is a result of abnormally high pressure in the bladder that results in failure of the closure of the UVJ during bladder contraction. Secondary VUR is often associated with anatomic (eg, posterior urethral valves) or functional bladder obstruction (eg, dysfunctional voiding and neurogenic bladder) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/8\">",
"     8",
"    </a>",
"    ]. The degree and chronicity of obstruction can influence the severity of VUR. The management of secondary VUR is focused on treating the primary abnormality with the rare need for direct surgical correction of the VUR. None of the data subsequently discussed are applicable to patients with secondary vesicoureteral reflux.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vesicoureteral reflux (VUR) is present in approximately 1 percent of newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The risk of VUR is increased in children with febrile UTIs, with a reported incidence that ranges from 30 to 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. In neonates with prenatal hydronephrosis, the prevalence of VUR is about 15 percent. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Prenatal presentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The incidence for primary VUR varies based on ethnicity, gender, and age. This was shown in a retrospective study from a single urban center in the United States that diagnosed VUR in 3661 children from 15,504 children who were screened by a voiding cystourethrogram (VCUG) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/12\">",
"     12",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ethnicity &ndash; White children were three times more likely to have VUR than black children. The maximal grade of reflux was significantly lower in black children.",
"     </li>",
"     <li>",
"      Gender &ndash; Girls were twice as likely to have reflux as boys [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/13\">",
"       13",
"      </a>",
"      ]. However, this ratio is reversed in patients who present with antenatal hydronephrosis with a male predominance [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical findings and course'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Age &ndash; Young children and infants (younger than two years of age) were more likely to have VUR than older children. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Genetics'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a strong genetic predisposition for primary vesicoureteral reflux (VUR) as documented by a systematic review of the literature that reported prevalence rates of 27.4 percent for siblings of a patient with VUR, and 35.7 percent for children of an affected parent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/15\">",
"     15",
"    </a>",
"    ]. The risk of VUR decreased as the age of the screened family member increased at an estimated annual resolution rate of 4 percent. The prevalence rate for grade III to V VUR was lower than grade I to II VUR (9.8 versus 16.7 percent).",
"   </p>",
"   <p>",
"    Support for a strong genetic component was also demonstrated by a study of siblings from multiple gestation births that found a higher VUR rate in identical twins (12 out of 15 twin sets, 80 percent) compared with fraternal twins (11 out of 31 twin sets, 35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genetic loci underlying these associations as well as the mode(s) of inheritance are unknown. There is speculation that the length of the intravesical ureter may be genetically dictated. In mice, primary VUR directly results from genetic deletion of the uroplakin III genes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/17\">",
"     17",
"    </a>",
"    ]; however, this gene does not appear to have a causative role in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/18\">",
"     18",
"    </a>",
"    ]. Genes that may play a role in familial VUR include those that encode SLIT2 protein and its receptor ROBO2, which play key roles in the formation of the ureter [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In one study, whole genome linkage and association in 320 families with at least two affected siblings failed to detect any association with six candidate genes (AGTR2, HNF1B, PAX2, RET, ROBO2, and UPKA3) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/21\">",
"     21",
"    </a>",
"    ]. The authors conclude that a major locus may not be associated with VUR within affected European families.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of vesicoureteral reflux (VUR) is based upon the demonstration of reflux of urine from the bladder to the upper urinary tract by either contrast voiding cystourethrogram (VCUG) or radionuclide cystogram (RNC). The VCUG provides greater anatomic detail but there is increased radiation exposure with VCUG compared to RNC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Grading",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Reflux Study Group (IRSG) developed a classification system that grades the severity of VUR based upon the degree of retrograde filling and dilation of the renal collecting system demonstrated by VCUG [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/22\">",
"     22",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef67039 \" href=\"UTD.htm?11/1/11280\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade I &ndash; Reflux only fills the ureter without dilation.",
"     </li>",
"     <li>",
"      Grade II &ndash; Reflux fills the ureter and the collecting system without dilation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58470 \" href=\"UTD.htm?5/57/6047\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Grade III &ndash; Reflux fills and mildly dilates the ureter and the collecting system with mild blunting of the calyces.",
"     </li>",
"     <li>",
"      Grade IV &ndash; Reflux fills and grossly dilates the ureter and the collecting system with blunting of the calyces. Some tortuosity of the ureter is also present.",
"     </li>",
"     <li>",
"      Grade V &ndash; Massive reflux grossly dilates the collecting system. All the calyces are blunted with a loss of papillary impression and intrarenal reflux may be present (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53390 \" href=\"UTD.htm?17/7/17535\">",
"       image 2",
"      </a>",
"      ). There is significant ureteral dilation and tortuosity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The severity of reflux is classified as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild &ndash; Grades I and II",
"     </li>",
"     <li>",
"      Moderate &ndash; Grade III",
"     </li>",
"     <li>",
"      Severe &ndash; Grades IV and V",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A system based upon RNC findings utilizes three grades and correlates with the IRSG VCUG grades as follows (",
"    <a class=\"graphic graphic_picture graphicRef74445 \" href=\"UTD.htm?16/53/17247\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade 1 for mild reflux &ndash; VCUG grades I",
"     </li>",
"     <li>",
"      Grade 2 for moderate reflux &ndash; VCUG grades II and III",
"     </li>",
"     <li>",
"      Grade 3 for severe reflux &ndash; VCUG IV and V",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PRESENTATION, DIAGNOSIS, AND COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The remainder of this discussion focuses on primary vesicoureteral reflux (VUR). The clinical course and outcome vary depending upon whether VUR presents prenatally or postnatally. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Prenatal presentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prenatal presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of VUR is suggested by the finding of hydronephrosis on prenatal ultrasonography. In fetuses with prenatally diagnosed hydronephrosis, the reported prevalence of VUR ranges from 10 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. This variability is primarily due to differences in the definition of prenatal hydronephrosis and the indications for and timing of postnatal evaluation. Systematic reviews of the literature have reported estimated prevalence rates of 15 to 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/15,25\">",
"     15,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the larger of the systematic reviews conducted by the American Urological Association (AUA), prenatal hydronephrosis was defined as a renal pelvic diameter (RPD) &ge;4 mm during the second trimester and &ge;7 mm during the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/15\">",
"     15",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the 34 studies included in this analysis, the VUR prevalence rate was 16.2 percent.",
"     </li>",
"     <li>",
"      RPD was not predictive of VUR.",
"     </li>",
"     <li>",
"      In nine studies in infants with a normal renal ultrasound, the prevalence rate was 17 percent demonstrating that a normal renal ultrasound does not exclude the presence of VUR.",
"     </li>",
"     <li>",
"      The severity of VUR was equally distributed with one-third of patients with grades I to II, a third with grade III, and the remaining third with grades IV to V.",
"     </li>",
"     <li>",
"      Renal damage increased with the grade of reflux; 6.2 percent in patients with grades I to III and 47.9 percent in those with grades IV to V.",
"     </li>",
"     <li>",
"      Data were insufficient to determine the rate of UTI and the efficacy of prophylactic antibiotics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The extent of the neonatal evaluation required for infants prenatally diagnosed with hydronephrosis is controversial. Some experts in the field recommend a full diagnostic evaluation in",
"    <strong>",
"     all",
"    </strong>",
"    infants, which includes a postnatal renal ultrasound and voiding cystourethrogram (VCUG) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. However, one of the reservations for a full diagnostic evaluation is that the diagnosis of VUR is made only by VCUG or radionuclide cystogram (RNC). Neither test is a benign procedure because of the need for catheterization, and risk of post-procedure urinary tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In addition, both procedures are costly and require skilled personnel to perform these studies in infants. Performing these studies in all neonates with antenatal hydronephrosis would subject a large number of patients without VUR to an invasive and costly procedure.",
"   </p>",
"   <p>",
"    A sensitive and less invasive screening test for VUR is therefore desirable. Although postnatal renal ultrasound is a noninvasive screening test, it remains unclear whether the test is sufficiently sensitive. The following examples illustrate this controversy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one retrospective study, almost 90 percent of patients with known VUR (previously detected by VCUG) had one of the following abnormalities on postnatal renal ultrasonography: increased diameter of the renal pelvis of greater than 7 mm, caliceal or ureteral dilatation, pelviureteral wall thickening, absence of renal corticomedullary differentiation, or findings suggestive of renal dysplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/31\">",
"       31",
"      </a>",
"      ]. It was concluded that a VCUG is",
"      <strong>",
"       unnecessary",
"      </strong>",
"      in infants with a normal postnatal ultrasound, as the risk of VUR is low and, if detected, may not be clinically significant.",
"     </li>",
"     <li>",
"      A second case series of 121 infants with prenatal hydronephrosis also reported that the risk of VUR increased as the postnatal diameter of the renal pelvis increased with a cut-off of 7 mm demonstrating a fair ability to predict VUR [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other studies, principally observational, have reported that 17 to 25 percent of neonates with a normal postnatal renal ultrasound have VUR detected by VCUG [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/15,26,27\">",
"       15,26,27",
"      </a>",
"      ]. These authors therefore recommended VCUG be performed on",
"      <strong>",
"       all",
"      </strong>",
"      infants with prenatal hydronephrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies, although flawed, provide the rationale for the following two approaches for evaluation of prenatal hydronephrosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postnatal renal ultrasound and VCUG are performed for",
"      <strong>",
"       all",
"      </strong>",
"      patients with prenatal hydronephrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/26-28\">",
"       26-28",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      Postnatal renal ultrasound alone is performed initially in",
"      <strong>",
"       all",
"      </strong>",
"      patients with prenatal hydronephrosis. A VCUG is performed only in patients with abnormalities on a postnatal renal ultrasound or who develop a UTI during observation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/15,31,33\">",
"       15,31,33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our practice, we use the second two-step approach with an initial screening ultrasound for all patients with prenatal hydronephrosis consistent with the AUA and the European Association of Urology guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/15,34\">",
"     15,34",
"    </a>",
"    ]. VCUG is reserved for those with an abnormal ultrasound, those who develop a UTI on observation, or those who have a family history of VUR [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/15,31,33\">",
"     15,31,33",
"    </a>",
"    ]. VCUG is performed if there are other prenatally detected renal anomalies that increase the risk of VUR, such as ureteropelvic junction obstruction, ureteral duplication, bladder diverticulum, renal agenesis, renal ectopia, and multicystic dysplastic kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/25,27,35,36\">",
"     25,27,35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link\">",
"     \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a VCUG is to be performed, the procedure needs to be done in referral centers that have expertise both in catheterization and determination of radiation exposure in infants. In these settings, the complications of the procedure can be minimized [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Our diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed previously, the extent of the evaluation for infants prenatally diagnosed with hydronephrosis is controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34119?source=see_link&amp;anchor=H10#H10\">",
"     \"Postnatal management of antenatal hydronephrosis\", section on 'Approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our practice, we use the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repeat renal ultrasonography postdelivery. The timing is dependent upon whether there is bilateral or unilateral involvement and the severity of hydronephrosis. In most circumstances, renal ultrasound is optimally performed after the first week of delivery, when urine output is well-established (",
"      <a class=\"graphic graphic_algorithm graphicRef74670 \" href=\"UTD.htm?14/15/14591\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef69172 \" href=\"UTD.htm?5/2/5166\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34119?source=see_link&amp;anchor=H10#H10\">",
"       \"Postnatal management of antenatal hydronephrosis\", section on 'Approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If there is persistent moderate or severe hydronephrosis (increased diameter of the renal pelvis more than 7 mm),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ureteral dilatation on postnatal ultrasonography, a VCUG is performed. If the VCUG is normal and the hydronephrosis is grade 3 or 4 or greater that 12 mm, a functional renal scan with Tc99mMAG3 is suggested to detect possible obstruction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34119?source=see_link\">",
"       \"Postnatal management of antenatal hydronephrosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the postnatal renal ultrasonography is normal or demonstrates mild hydronephrosis, we repeat renal sonography two or three months later. If hydronephrosis persists, a follow-up renal sonogram is performed six months late. If the hydronephrosis worsens at any state, we proceed to a radionuclide cystogram [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If there is a strong family history of VUR or an anomaly associated with VUR without persistent hydronephrosis on renal ultrasound, we suggest proceeding to a VCUG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Clinical findings and course",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a male predominance in patients with VUR who present prenatally. In one study of 155 consecutive infants with VUR, 75 percent were males and patients with grade V reflux were almost exclusively male [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/14\">",
"     14",
"    </a>",
"    ]. In 54 percent of refluxing ureters, the reflux was mild to moderate, defined as grades I to III.",
"   </p>",
"   <p>",
"    The rate of spontaneous resolution of reflux among those diagnosed prenatally appears to be related to the severity of reflux, however, even cases of high-grade reflux may resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. This was illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 43 patients diagnosed prenatally were followed prospectively for at least two years with VCUG evaluations before six weeks of age, at one year of age, and if VUR persisted at two years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/38\">",
"       38",
"      </a>",
"      ]. VUR spontaneously resolved in 29 of 32 patients (91 percent) with low-grade reflux (grades I to III). In patients with high-grade reflux (grades IV and V), VUR resolved in 2 of 11 patients.",
"     </li>",
"     <li>",
"      In a second study of 25 patients diagnosed prenatally, VUR resolved in 3 of 10 patients with grade IV or V reflux and in 10 of 15 patients with grade I to III reflux [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third study of 115 infants (median age 2.7 months) with high-grade VUR (grades III to V), VUR resolved in 26 percent of these high-grade cases [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/40\">",
"       40",
"      </a>",
"      ]. In this cohort of patients, 26 percent were diagnosed prenatally and 71 percent after a urinary tract infection. Multi-variate analysis identified renal abnormality, bladder dysfunction, and breakthrough urinary tract infection as independent negative predictive factors for VUR resolution.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Decrease renal parenchyma (scarring)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants who present prenatally, decrease renal parenchyma formation (eg, renal hypoplasia and dysplasia) is often associated with severe reflux. In the literature, primary (congenital) renal scarring refers to decrease formation of normal renal parenchyma and acquired renal scarring refers to the loss of renal parenchyma due to injury after birth.",
"   </p>",
"   <p>",
"    Primary renal scarring has been reported in 30 to 60 percent of patients detected prenatally with grades IV and V reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/14,38\">",
"     14,38",
"    </a>",
"    ]. As an example, in the previously mentioned study, 3 of the 11 patients with grade IV and V reflux had evidence of primary renal scarring detected by radionuclide renal scan at a median age of three months (range two to eight months) before any clinical evidence of UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In these patients, it has been proposed that chronic kidney disease (CKD) results from decreased formation of normal renal parenchyma (ie, primary renal scarring) due to abnormal development (ie, hypoplasia and dysplasia). In these cases, VUR may only be a marker of abnormal development and play no role in renal scar formation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. These data have led to questioning the results of the prior retrospective studies that attributed renal scarring in children presenting with UTI to acquired morphologic changes rather than developmental abnormalities, which were present at birth prior to the presentation of any UTI. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Role in renal scarring and chronic kidney disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Postnatal presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postnatal diagnosis of VUR usually is made after a UTI, and less commonly, it is detected after screening of family members (eg, a child or sibling) of an index case.",
"   </p>",
"   <p>",
"    Children with a febrile UTI have a higher risk for abnormalities of the genitourinary tract, including VUR and obstructive uropathy. As previously mentioned, the diagnosis of VUR is made only by demonstrating reflux of urine from the bladder to the collecting system either by a VCUG or radionuclide cystogram (RNC). Among children with VUR who present after an initial UTI, 95 percent will have mild or moderate reflux (ie, grades I to III) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approach including indications, timing, and choice of modality for imaging in children with UTI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=see_link&amp;anchor=H15#H15\">",
"     \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with VUR diagnosed after an initial UTI are also more likely to have dysfunctional voiding [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/62/41961?source=see_link&amp;anchor=H25152771#H25152771\">",
"     \"Management of vesicoureteral reflux\", section on 'Voiding dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies that examine the natural course of VUR include both patients diagnosed prenatally (or would have been with universal prenatal ultrasound) and those diagnosed postnatally. These largely reflect the clinical course of those who would have been diagnosed postnatally as the number of patients diagnosed prenatally is much smaller than those diagnosed after delivery. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Prenatal presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the majority of cases, VUR will spontaneously resolve, as illustrated by a retrospective study from a single tertiary center that reviewed the outcome of 2462 patients with primary VUR diagnosed between 1998 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/45\">",
"     45",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VUR resolved spontaneously in 1257 patients (51 percent) at a mean duration of two years. Factors associated with spontaneous resolution included age of diagnosis under one year of age, lower grades of VUR, prenatal hydronephrosis, and unilateral involvement.",
"     </li>",
"     <li>",
"      Rates of spontaneous resolution were 72, 61, 49, and 32 percent for grades I, II, III, and",
"      <span class=\"nowrap\">",
"       IV/V,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      Surgical correction was performed in 634 patients (26 percent). Indications for surgery included breakthrough febrile UTI, renal scarring detected by renal radionuclide scan, nonresolution, and parent preference.",
"     </li>",
"     <li>",
"      At the time of publication, 571 patients (23 percent) were still being observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data from this study were used to construct nomogram tables that predict the rate of cumulative annual VUR resolution one to five years after diagnosis (",
"    <a class=\"graphic graphic_table graphicRef74719 \" href=\"UTD.htm?35/37/36446\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62958 \" href=\"UTD.htm?35/31/36350\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The association between the severity of reflux and spontaneous resolution was also supported by a review of 26 studies of 1987 patients (",
"    <a class=\"graphic graphic_figure graphicRef50469 \" href=\"UTD.htm?29/16/29952\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/4\">",
"     4",
"    </a>",
"    ]. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grades I and II &ndash; By five years of age, spontaneous resolution occurred in 80 percent of patients. The likelihood of resolution was not dependent upon age at presentation or whether the reflux was unilateral or bilateral (laterality of reflux).",
"     </li>",
"     <li>",
"      Grade III &ndash; Age at presentation and laterality of reflux had major effects on resolution of reflux. The oldest group of children (5 to 10 years of age) with bilateral reflux had less than 20 percent resolution over five years. In contrast, there was a 70 percent resolution rate in the youngest group of children (one to two years) with unilateral disease.",
"     </li>",
"     <li>",
"      Grade IV &ndash; There was a 60 percent resolution rate for unilateral disease and less than 10 percent resolution rate for bilateral reflux over five years regardless of age at presentation.",
"     </li>",
"     <li>",
"      Grade V &ndash; Spontaneous resolution rarely occurred.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A follow-up report of one of the reviewed studies demonstrated continued resolution of grade III and IV reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/46\">",
"     46",
"    </a>",
"    ]. This study of 149 children found that resolution of reflux increased from 15 percent at five years to 52 percent at 10 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Renal scarring and severity of reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal scarring is associated with VUR. Studies have reported 30 to 60 percent of patients at initial diagnosis of VUR have evidence of renal scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/47-52\">",
"     47-52",
"    </a>",
"    ]. The risk of scarring increases with the severity of reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/44,49,51-53\">",
"     44,49,51-53",
"    </a>",
"    ]. Renal scarring may be congenital or appear to occur early or after recurrent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/51,54\">",
"     51,54",
"    </a>",
"    ], although it is unusual for new scars to form after the age of five years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/55\">",
"     55",
"    </a>",
"    ]. Evaluation of scarring by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/26/12709?source=see_link\">",
"     dimercaptosuccinic acid",
"    </a>",
"    (DMSA) renal scan is more sensitive than ultrasonography.",
"   </p>",
"   <p>",
"    These points were illustrated in a retrospective review of 303 Swedish children younger than two years of age diagnosed with their first documented urinary tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/51\">",
"     51",
"    </a>",
"    ]. VUR was found in 26 percent of the entire group (80 patients), and in 22 percent of the boys (36 of 163) and 31 percent of the girls (44 of 140). Boys compared to girls presented at an earlier age (median age 3.1 versus 8.5 months) and those with scarring had a higher grade of reflux. A follow-up DMSA scan performed one to two years later demonstrated renal scarring in 26 percent of the patients including 43 without VUR (19 percent) and 37 with VUR (46 percent). As the grade of VUR increased so did the likelihood of renal scarring as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade I, RR 1.20, 95% CI (0.43-3.35)",
"     </li>",
"     <li>",
"      Grade II, RR 2.17, 95% CI (1.33-3.56)",
"     </li>",
"     <li>",
"      Grade III, RR 2.5, 95% CI (1.55-4.01)",
"     </li>",
"     <li>",
"      Grade IV to V, RR 4.61, 95% CI (3.23-6.57)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another Swedish study of 115 infants (median age at diagnosis 2.7 months) with high grade VUR (ie, grades III, IV and V), renal parenchymal damage detected by either DMSA or MAG3 renal scan was observed in 98 patients (85 percent) at study inclusion; 90 percent of patients with grade IV and V VUR and 75 percent of those with grade III [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/56\">",
"     56",
"    </a>",
"    ]. All patients received antibiotic prophylaxis. At a median follow-up of 5 years, renal parenchymal abnormalities were demonstrated in 103 patients (90 percent). GFR was decreased in one-third of the 108 patients who underwent GFR measurement by 51 chromium edetic acid (51Cr EDTA) clearance. During the follow-up period, renal status (defined as increase parenchymal scarring",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decrease in GFR) remained unchanged in 84 patients (78 percent), improved in 5 (5 percent), and deteriorated in 19 (18 percent). The risk of deterioration increased with the grade of reflux, a prenatal versus postnatal diagnosis, and febrile breakthrough UTI.",
"   </p>",
"   <p>",
"    A Finnish study assessed long-term outcome (median follow-up time of 11.1&plusmn; 3.2 years) of a stratified random sample of 228 patients from a cohort of 1185 children with a history of UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/53\">",
"     53",
"    </a>",
"    ]. Ninety-one of the 193 patients who participated in the follow-up evaluation had VUR with grades III through V. Overall, 22 unilateral renal parenchymal defects were detected in 15 percent of 150 patients who underwent ultrasound testing at follow-up: 18 of the defects occurred after the episode of UTI, and all but one of the 22 defects occurred in patients with grade III-V VUR. In addition, kidney growth retardation was detected by renal ultrasound in five patients (3 percent of tested patients), all of whom had VUR with grade III-V VUR. At the last follow-up visit, all patients had normal renal function and blood pressure, and no patients had hematuria or proteinuria. However, because most patients with grade III-V VUR received medical intervention (eg, antimicrobial prophylaxis) and 45 percent underwent antireflux surgery, it remains uncertain whether or not the favorable clinical outcome was a result of, or despite, active therapeutic measures.",
"   </p>",
"   <p>",
"    In contrast, a retrospective study of 389 Korean children with first febrile urinary tract infection (mean age 14.9 months) did not find an association between reflux grade and scar formation based upon follow-up DMSA scan performed 6 months (range 5 to 7 months) after the urinary tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/57\">",
"     57",
"    </a>",
"    ]. However, other findings in this study were similar to those of the first Swedish study including a 32 percent risk of VUR and an increased likelihood of scarring in patients with VUR compared to those without VUR (50 versus 18 percent).",
"   </p>",
"   <p>",
"    As a result, it still remains unclear whether VUR and its severity have a causative role in the formation of renal scars or whether it is a marker for congenital maldevelopment such as renal hypoplasia, dysplasia, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/41\">",
"     41",
"    </a>",
"    ]. The controversial role of VUR in renal scarring and the development of chronic kidney disease are discussed in the next section.",
"   </p>",
"   <p>",
"    If VUR does play a causative role in renal scarring, the best approach towards managing affected children remains unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/62/41961?source=see_link\">",
"     \"Management of vesicoureteral reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ROLE IN RENAL SCARRING AND CHRONIC KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previously, it was a consensus opinion that reflux of infected urine, but not sterile urine, into the renal parenchyma (called intrarenal reflux) resulted in renal scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Patients with vesicoureteral reflux (VUR)-induced scarring were considered to be at risk for the late development of hypertension, proteinuria, focal segmental glomerulosclerosis, and if bilateral VUR, progressive renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/1,58-61\">",
"     1,58-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, this long-held belief that reflux alone can lead to progressive chronic kidney disease due to renal scarring and potentially ESRD, has been increasingly questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/42,60,62-65\">",
"     42,60,62-65",
"    </a>",
"    ]. Another view, as noted previously, is that VUR is",
"    <strong>",
"     not",
"    </strong>",
"    an important risk factor for renal scarring and potential chronic kidney disease (CKD) but is a marker for abnormal renal development, which results in decreased formation of renal parenchyma referred to as primary renal scarring.",
"   </p>",
"   <p>",
"    Support for this view that VUR does not play a role in renal scar formation but is a marker for abnormal renal development is provided by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A population-based cohort study of children with first recognized febrile UTI demonstrated that an increased risk for \"renal scarring\" was principally found in young boys with VUR [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/41,43\">",
"       41,43",
"      </a>",
"      ]. These boys did not have a previous history of recurrent UTI and their kidneys were globally small, with smooth renal outlines on radiologic imaging consistent with renal hypoplasia or dysplasia. The authors concluded that children with VUR could be divided into those with primary \"scarring\" due to due malformation (who are predominately male) and those with acquired scarring.",
"     </li>",
"     <li>",
"      Data from a population-based chronic kidney registry from Italy suggested the primary cause of renal failure in children with VUR was congenital renal hypoplasia or dysplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prospective studies that compared prophylactic antibiotics alone with combined antibiotics and surgery demonstrated a reduction in febrile illness with combination therapy but no difference in reduction of renal scarring over five years [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Candidate genes have been identified in animal models that may play a role in the regulation of ureteric and renal development [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/66\">",
"       66",
"      </a>",
"      ]. Dysregulation of this process due to gene mutation leads to reflux and renal malformations such as dysplasia and hypoplasia.",
"     </li>",
"     <li>",
"      Data demonstrating that VUR is associated with progressive chronic kidney damage and potentially ESRD were primarily from studies of patients diagnosed in the 1970s, prior to the routine use of prenatal ultrasonography.",
"     </li>",
"     <li>",
"      The rate of reflux-related ESRD has not changed in Australia and New Zealand over the four decades from the 1960s to 1990s despite the change in general clinical practice of proactively identifying children with VUR and treating them with either surgical correction or antibiotic prophylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The viewpoint that CKD results from renal maldevelopment (hypoplasia and dysplasia) associated with VUR has led to questioning the utility of any regimen directed at identifying or treating VUR [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/60,63\">",
"     60,63",
"    </a>",
"    ]. Although there are limited data comparing the outcome of children with VUR who receive treatment (either medical or surgical) to those who receive no directed intervention, the results do not conclusively demonstrate whether or not therapeutic interventions affect long-term renal outcome.",
"   </p>",
"   <p>",
"    Because of the severity of the potential poor outcome and the paucity of conclusive evidence, we continue to regard VUR as a risk for recurrent pyelonephritis and possible renal scarring. As a result, until large clinical studies show similar renal outcomes (chronic kidney disease and renal scarring) in children who do not receive treatment for VUR compared to those who do, we continue to suggest imaging studies to detect possible VUR in at-risk children and intervention in those diagnosed with significant VUR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/62/41961?source=see_link\">",
"     \"Management of vesicoureteral reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H630866720\">",
"    <span class=\"h1\">",
"     FURTHER EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the association between vesicoureteral reflux (VUR) and renal scarring, which may lead to chronic kidney disease (CKD), 2010 revised guidelines from the American Urological Association state that an initial evaluation of the child&rsquo;s renal status, growth parameters, and blood pressure should be performed in any child with VUR [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/67\">",
"     67",
"    </a>",
"    ]. The guidelines were based on a systemic review of the available literature; however, the strength of these guidelines was limited because of the lack of well-designed clinical trials.",
"   </p>",
"   <p>",
"    In our practice, we incorporate these guidelines in our evaluation of a child with VUR as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A careful medical evaluation is performed, which includes measurement of height, weight, and blood pressure.",
"     </li>",
"     <li>",
"      Laboratory assessment includes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serum creatinine, which is used to estimate glomerular filtration rate.",
"     </li>",
"     <li>",
"      Urinalysis to detect proteinuria or pyuria. Since proteinuria may be an indication of significant CKD, further evaluation (eg, measuring the urine",
"      <span class=\"nowrap\">",
"       protein/creatinine",
"      </span>",
"      ratio) should be performed if the urinalysis is positive for protein. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=see_link&amp;anchor=H8#H8\">",
"       \"Evaluation of proteinuria in children\", section on 'Measurement of urinary protein'",
"      </a>",
"      .). If pyuria or bacteria is present, a urine culture should be obtained to screen for urinary tract infection (UTI). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Urine culture'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal imaging should be performed to assess the status of the kidneys. Although renal ultrasound may not detect all renal scarring and does not provide a quantitative assessment of relative renal function, it is the preferred modality for initial renal imaging because it is the most widely available modality, inexpensive, and free of radiation exposure.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/26/12709?source=see_link\">",
"       Dimercaptosuccinic acid",
"      </a>",
"      (DMSA) renal scan is superior in detecting renal cortical abnormalities; however, it is more expensive, requires sedation, has radiation exposure, and is not as readily available. DMSA renal scan may be obtained in patients who are at-risk for scarring. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Renal scarring and severity of reflux'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bladder and bowel (voiding) dysfunction is associated with VUR and recurrent UTI. Voiding dysfunction also prolongs the time to spontaneous VUR resolution. As a result, the initial evaluation should identify if there are symptoms indicative of voiding dysfunction (eg, urinary frequency and urgency, daytime wetting, constipation, and encopresis), so that interventions to improve bladder and bowel function can be initiated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25384?source=see_link\">",
"       \"Evaluation and diagnosis of bladder dysfunction in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41785?source=see_link\">",
"       \"Management of bladder dysfunction in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28793?source=see_link&amp;anchor=H16#H16\">",
"       \"Etiology and clinical features of bladder dysfunction in children\", section on 'Vesicoureteral reflux'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/62/41961?source=see_link&amp;anchor=H25152771#H25152771\">",
"       \"Management of vesicoureteral reflux\", section on 'Voiding dysfunction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H630866948\">",
"    <span class=\"h2\">",
"     Screening of family members",
"    </span>",
"    &nbsp;&mdash;&nbsp;The screening of family members is controversial, with debate concerning the risk and benefits of screening because there are no data on the outcome of treated versus untreated first degree family members (ie, offspring or siblings) of a patient with VUR [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/34\">",
"     34",
"    </a>",
"    ]. However, there is a rate of renal damage of 14 percent in asymptomatic siblings.",
"   </p>",
"   <p>",
"    Unfortunately, a prospective randomized trial that could determine the optimal approach to managing siblings of patients with VUR is highly unlikely. As a result, the use of decision analysis modeling based on published data is being used to determine whether screening of these individuals is cost-effective. In one study, hypothetical modeling demonstrated a relatively high cost of universal screening with limited benefits in reducing the number of febrile UTI in siblings of children with VUR [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/68\">",
"     68",
"    </a>",
"    ]. In addition, universal screening resulted in a 10-fold greater radiation dose per child compared to symptomatic screening. This analysis did not include the risk of subsequent hypertension and renal impairment. The estimated costs and effectiveness of averting febrile UTIs was heavily dependent on the screening age (screening was most cost-effective for children less than one year of age) and the assumption that antibiotic prophylaxis was effective in reducing the risk of UTI. These observations are not supportive of routine screening of siblings of patients with VUR.",
"   </p>",
"   <p>",
"    There appears to be a significant risk of renal scarring in siblings of patients with high grade VUR. In an observational study of 300 siblings of 259 patients with VUR (ie, grades between III and V), almost a quarter of the 212 siblings who underwent DMSA renal scan had evidence of renal scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, we screen siblings and children of patients with VUR because of the increased familial incidence of VUR. Our approach, which is consistent with the AUA guidelines, is to selectively screen younger siblings with a renal and bladder ultrasound (RBUS) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/10/3242/abstract/15\">",
"     15",
"    </a>",
"    ]. A VCUG is only performed in patients with an abnormal ultrasound (eg, renal cortical abnormalities or asymmetry) or if there is a history of UTI. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Genetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/45/3794?source=see_link\">",
"       \"Patient information: Prenatal hydronephrosis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/19/38193?source=see_link\">",
"       \"Patient information: Vesicoureteral reflux in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vesicoureteral reflux (VUR) is the retrograde passage of urine from the bladder into the upper urinary tract (",
"    <a class=\"graphic graphic_figure graphicRef54236 \" href=\"UTD.htm?9/22/9569\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Current management is based upon the long-held belief that VUR, when associated with febrile urinary tract infection, is a risk factor for renal scarring that can result in an increased risk of hypertension and chronic kidney disease. However, this premise has been increasingly questioned with data supporting an alternate viewpoint that VUR does not play a causative role in renal scarring but merely is a marker for abnormal renal development. This disruption in renal development leads to a decrease in the formation of normal parenchyma (eg, renal hypoplasia and dysplasia) and results in an increased risk of poor renal outcome. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Decrease renal parenchyma (scarring)'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18\">",
"     'Role in renal scarring and chronic kidney disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conclusive evidence demonstrating whether or not directed therapeutic interventions towards VUR affect long-term renal outcome is lacking. Until such data are available, we continue to regard VUR as a risk factor for recurrent pyelonephritis and possible renal scarring.",
"      <br/>",
"      <br/>",
"      As a result, we suggest diagnostic evaluation to detect possible VUR in at-risk children and therapeutic intervention in those with clinically significant VUR. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Role in renal scarring and chronic kidney disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/62/41961?source=see_link\">",
"       \"Management of vesicoureteral reflux\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      VUR occurs in approximately 1 percent of newborns. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of VUR is based upon the demonstration of reflux of urine from the bladder to the upper urinary tract by either contrast voiding cystourethrogram (VCUG) or radionuclide cystogram (RNC). The severity of VUR is dependent upon the degree of retrograde filling and dilation of the renal collecting system demonstrated by VCUG or RNC. Well-established grading systems based upon imaging findings are used to measure the severity of VUR (",
"      <a class=\"graphic graphic_figure graphicRef67039 \" href=\"UTD.htm?11/1/11280\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two clinical presentations of VUR are currently recognized based upon when the diagnosis was made (prenatal versus postnatal); they differ in gender predisposition and clinical course.",
"     </li>",
"     <li>",
"      Patients that present prenatally are identified by prenatal ultrasound with the finding of antenatal hydronephrosis. Approximately 10 to 40 percent of fetuses with antenatal hydronephrosis will be diagnosed with VUR postnatally. Severe reflux is common, but it has a reasonable rate of spontaneous resolution. Renal hypoplasia and dysplasia, referred to as primary scarring, are frequently observed. These patients, who are predominantly male, are at increased risk for developing chronic kidney disease and hypertension. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prenatal presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The extent of the neonatal evaluation of antenatal hydronephrosis to detect VUR is controversial. In our practice, postnatal renal ultrasound alone is performed initially in",
"      <strong>",
"       all",
"      </strong>",
"      patients with prenatal hydronephrosis. A VCUG is performed only in patients with abnormalities on a postnatal renal ultrasound or in those with a strong family history of VUR. An alternate approach is performing postnatal renal ultrasound and VCUG for",
"      <strong>",
"       all",
"      </strong>",
"      patients with prenatal hydronephrosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prenatal presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients that present postnatally generally are diagnosed after an initial febrile illness or urinary tract infection. These patients are predominantly female. The rate of spontaneous resolution is dependent upon age, grade of reflux, and whether the reflux is unilateral or bilateral. In these patients, the risk of renal scarring increases with the severity of VUR. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Postnatal presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that the following 2010 American Urologic Association guidelines be used in the initial evaluation of children with VUR (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H630866720\">",
"       'Further evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Medical evaluation including measurements of height, weight, and blood pressure and identifying any patient with symptoms indicative of voiding dysfunction.",
"     </li>",
"     <li>",
"      Serum creatinine and urinalysis.",
"     </li>",
"     <li>",
"      Renal imaging with either renal ultrasound or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/26/12709?source=see_link\">",
"       dimercaptosuccinic acid",
"      </a>",
"      (DMSA) renal scan.",
"     </li>",
"     <li>",
"      We suggest initial screening with sonography for VUR in siblings and children of any patient with VUR (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/1\">",
"      Dillon MJ, Goonasekera CD. Reflux nephropathy. J Am Soc Nephrol 1998; 9:2377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/2\">",
"      Shah KJ, Robins DG, White RH. Renal scarring and vesicoureteric reflux. Arch Dis Child 1978; 53:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/3\">",
"      Smellie JM, Normand IC, Katz G. Children with urinary infection: a comparison of those with and those without vesicoureteric reflux. Kidney Int 1981; 20:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/4\">",
"      Elder JS, Peters CA, Arant BS Jr, et al. Pediatric Vesicoureteral Reflux Guidelines Panel summary report on the management of primary vesicoureteral reflux in children. J Urol 1997; 157:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/5\">",
"      Blane CE, DiPietro MA, Zerin JM, et al. Renal sonography is not a reliable screening examination for vesicoureteral reflux. J Urol 1993; 150:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/6\">",
"      Willi U, Treves S. Radionuclide voiding cystography. Urol Radiol 1983; 5:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/7\">",
"      Ramage IJ, Schuckett B, McLorie GA, Geary DF. Primary vesicoureteric reflux diagnosed in the 1st month of life. Pediatr Nephrol 1999; 13:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/8\">",
"      Willemsen J, Nijman RJ. Vesicoureteral reflux and videourodynamic studies: results of a prospective study. Urology 2000; 55:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/9\">",
"      Hiraoka M, Hori C, Tsukahara H, et al. Vesicoureteral reflux in male and female neonates as detected by voiding ultrasonography. Kidney Int 1999; 55:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/10\">",
"      Ransley PG. Vesicoureteric reflux: continuing surgical dilemma. Urology 1978; 12:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/11\">",
"      Hoberman A, Charron M, Hickey RW, et al. Imaging studies after a first febrile urinary tract infection in young children. N Engl J Med 2003; 348:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/12\">",
"      Chand DH, Rhoades T, Poe SA, et al. Incidence and severity of vesicoureteral reflux in children related to age, gender, race and diagnosis. J Urol 2003; 170:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/13\">",
"      Vates TS, Shull MJ, Underberg-Davis SJ, Fleisher MH. Complications of voiding cystourethrography in the evaluation of infants with prenatally detected hydronephrosis. J Urol 1999; 162:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/14\">",
"      Yeung CK, Godley ML, Dhillon HK, et al. The characteristics of primary vesico-ureteric reflux in male and female infants with pre-natal hydronephrosis. Br J Urol 1997; 80:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/15\">",
"      Skoog SJ, Peters CA, Arant BS Jr, et al. Pediatric Vesicoureteral Reflux Guidelines Panel Summary Report: Clinical Practice Guidelines for Screening Siblings of Children With Vesicoureteral Reflux and Neonates/Infants With Prenatal Hydronephrosis. J Urol 2010; 184:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/16\">",
"      Kaefer M, Curran M, Treves ST, et al. Sibling vesicoureteral reflux in multiple gestation births. Pediatrics 2000; 105:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/17\">",
"      Hu P, Deng FM, Liang FX, et al. Ablation of uroplakin III gene results in small urothelial plaques, urothelial leakage, and vesicoureteral reflux. J Cell Biol 2000; 151:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/18\">",
"      Jiang S, Gitlin J, Deng FM, et al. Lack of major involvement of human uroplakin genes in vesicoureteral reflux: implications for disease heterogeneity. Kidney Int 2004; 66:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/19\">",
"      Bertoli-Avella AM, Conte ML, Punzo F, et al. ROBO2 gene variants are associated with familial vesicoureteral reflux. J Am Soc Nephrol 2008; 19:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/20\">",
"      Zu S, Bartik Z, Zhao S, et al. Mutations in the ROBO2 and SLIT2 genes are rare causes of familial vesico-ureteral reflux. Pediatr Nephrol 2009; 24:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/21\">",
"      Cordell HJ, Darlay R, Charoen P, et al. Whole-genome linkage and association scan in primary, nonsyndromic vesicoureteric reflux. J Am Soc Nephrol 2010; 21:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/22\">",
"      Medical versus surgical treatment of primary vesicoureteral reflux: report of the International Reflux Study Committee. Pediatrics 1981; 67:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/23\">",
"      Jaswon MS, Dibble L, Puri S, et al. Prospective study of outcome in antenatally diagnosed renal pelvis dilatation. Arch Dis Child Fetal Neonatal Ed 1999; 80:F135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/24\">",
"      Brophy MM, Austin PF, Yan Y, Coplen DE. Vesicoureteral reflux and clinical outcomes in infants with prenatally detected hydronephrosis. J Urol 2002; 168:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/25\">",
"      van Eerde AM, Meutgeert MH, de Jong TP, Giltay JC. Vesico-ureteral reflux in children with prenatally detected hydronephrosis: a systematic review. Ultrasound Obstet Gynecol 2007; 29:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/26\">",
"      Herndon CD, McKenna PH, Kolon TF, et al. A multicenter outcomes analysis of patients with neonatal reflux presenting with prenatal hydronephrosis. J Urol 1999; 162:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/27\">",
"      Zerin JM, Ritchey ML, Chang AC. Incidental vesicoureteral reflux in neonates with antenatally detected hydronephrosis and other renal abnormalities. Radiology 1993; 187:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/28\">",
"      Marra G, Barbieri G, Moioli C, et al. Mild fetal hydronephrosis indicating vesicoureteric reflux. Arch Dis Child Fetal Neonatal Ed 1994; 70:F147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/29\">",
"      Elder JS. Imaging for vesicoureteral reflux--is there a better way? J Urol 2005; 174:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/30\">",
"      Wosnitzer M, Shusterman D, Barone JG. Bladder rupture in premature infant during voiding cystourethrography. Urology 2005; 66:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/31\">",
"      Avni EF, Ayadi K, Rypens F, et al. Can careful ultrasound examination of the urinary tract exclude vesicoureteric reflux in the neonate? Br J Radiol 1997; 70:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/32\">",
"      Grazioli S, Parvex P, Merlini L, et al. Antenatal and postnatal ultrasound in the evaluation of the risk of vesicoureteral reflux. Pediatr Nephrol 2010; 25:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/33\">",
"      Yerkes EB, Adams MC, Pope JC 4th, Brock JW 3rd. Does every patient with prenatal hydronephrosis need voiding cystourethrography? J Urol 1999; 162:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/34\">",
"      Tekg&uuml;l S, Riedmiller H, Hoebeke P, et al. EAU guidelines on vesicoureteral reflux in children. Eur Urol 2012; 62:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/35\">",
"      Guarino N, Casamassima MG, Tadini B, et al. Natural history of vesicoureteral reflux associated with kidney anomalies. Urology 2005; 65:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/36\">",
"      Cascio S, Paran S, Puri P. Associated urological anomalies in children with unilateral renal agenesis. J Urol 1999; 162:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/37\">",
"      Hafez AT, McLorie G, Bagli D, Khoury A. Analysis of trends on serial ultrasound for high grade neonatal hydronephrosis. J Urol 2002; 168:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/38\">",
"      Ismaili K, Hall M, Piepsz A, et al. Primary vesicoureteral reflux detected in neonates with a history of fetal renal pelvis dilatation: a prospective clinical and imaging study. J Pediatr 2006; 148:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/39\">",
"      Upadhyay J, McLorie GA, Bolduc S, et al. Natural history of neonatal reflux associated with prenatal hydronephrosis: long-term results of a prospective study. J Urol 2003; 169:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/40\">",
"      Sj&ouml;str&ouml;m S, Sill&eacute;n U, Jodal U, et al. Predictive factors for resolution of congenital high grade vesicoureteral reflux in infants: results of univariate and multivariate analyses. J Urol 2010; 183:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/41\">",
"      Patterson LT, Strife CF. Acquired versus congenital renal scarring after childhood urinary tract infection. J Pediatr 2000; 136:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/42\">",
"      O'Donnell B. Reflections on reflux. J Urol 2004; 172:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/43\">",
"      Wennerstr&ouml;m M, Hansson S, Jodal U, Stokland E. Primary and acquired renal scarring in boys and girls with urinary tract infection. J Pediatr 2000; 136:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/44\">",
"      Silva JM, Santos Diniz JS, Marino VS, et al. Clinical course of 735 children and adolescents with primary vesicoureteral reflux. Pediatr Nephrol 2006; 21:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/45\">",
"      Estrada CR Jr, Passerotti CC, Graham DA, et al. Nomograms for predicting annual resolution rate of primary vesicoureteral reflux: results from 2,462 children. J Urol 2009; 182:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/46\">",
"      Smellie JM, Jodal U, Lax H, et al. Outcome at 10 years of severe vesicoureteric reflux managed medically: Report of the International Reflux Study in Children. J Pediatr 2001; 139:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/47\">",
"      Smellie JM, Normand IC. Bacteriuria, reflux, and renal scarring. Arch Dis Child 1975; 50:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/48\">",
"      Skoog SJ, Belman AB, Majd M. A nonsurgical approach to the management of primary vesicoureteral reflux. J Urol 1987; 138:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/49\">",
"      Caione P, Ciofetta G, Collura G, et al. Renal damage in vesico-ureteric reflux. BJU Int 2004; 93:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/50\">",
"      Szlyk GR, Williams SB, Majd M, et al. Incidence of new renal parenchymal inflammatory changes following breakthrough urinary tract infection in patients with vesicoureteral reflux treated with antibiotic prophylaxis: evaluation by 99MTechnetium dimercapto-succinic acid renal scan. J Urol 2003; 170:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/51\">",
"      Swerkersson S, Jodal U, Sixt R, et al. Relationship among vesicoureteral reflux, urinary tract infection and renal damage in children. J Urol 2007; 178:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/52\">",
"      Shaikh N, Ewing AL, Bhatnagar S, Hoberman A. Risk of renal scarring in children with a first urinary tract infection: a systematic review. Pediatrics 2010; 126:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/53\">",
"      Hannula A, Perhomaa M, Venhola M, et al. Long-term follow-up of patients after childhood urinary tract infection. Arch Pediatr Adolesc Med 2012; 166:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/54\">",
"      Lenaghan D, Whitaker JG, Jensen F, Stephens FD. The natural history of reflux and long-term effects of reflux on the kidney. J Urol 1976; 115:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/55\">",
"      Coulthard MG, Lambert HJ, Keir MJ. Occurrence of renal scars in children after their first referral for urinary tract infection. BMJ 1997; 315:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/56\">",
"      Sj&ouml;str&ouml;m S, Jodal U, Sixt R, et al. Longitudinal development of renal damage and renal function in infants with high grade vesicoureteral reflux. J Urol 2009; 181:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/57\">",
"      Oh MM, Jin MH, Bae JH, et al. The role of vesicoureteral reflux in acute renal cortical scintigraphic lesion and ultimate scar formation. J Urol 2008; 180:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/58\">",
"      Jacobson SH, Ekl&ouml;f O, Eriksson CG, et al. Development of hypertension and uraemia after pyelonephritis in childhood: 27 year follow up. BMJ 1989; 299:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/59\">",
"      el-Khatib MT, Becker GJ, Kincaid-Smith PS. Reflux nephropathy and primary vesicoureteric reflux in adults. Q J Med 1990; 77:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/60\">",
"      Cla&euml;sson I, Jacobsson B, Jodal U, Winberg J. Compensatory kidney growth in children with urinary tract infection and unilateral renal scarring: an epidemiologic study. Kidney Int 1981; 20:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/61\">",
"      Lahdes-Vasama T, Niskanen K, R&ouml;nnholm K. Outcome of kidneys in patients treated for vesicoureteral reflux (VUR) during childhood. Nephrol Dial Transplant 2006; 21:2491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/62\">",
"      Marra G, Oppezzo C, Ardissino G, et al. Severe vesicoureteral reflux and chronic renal failure: a condition peculiar to male gender? Data from the ItalKid Project. J Pediatr 2004; 144:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/63\">",
"      Wheeler D, Vimalachandra D, Hodson EM, et al. Antibiotics and surgery for vesicoureteric reflux: a meta-analysis of randomised controlled trials. Arch Dis Child 2003; 88:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/64\">",
"      Craig JC, Irwig LM, Knight JF, Roy LP. Does treatment of vesicoureteric reflux in childhood prevent end-stage renal disease attributable to reflux nephropathy? Pediatrics 2000; 105:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/65\">",
"      Moorthy I, Easty M, McHugh K, et al. The presence of vesicoureteric reflux does not identify a population at risk for renal scarring following a first urinary tract infection. Arch Dis Child 2005; 90:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/66\">",
"      Murawski IJ, Gupta IR. Vesicoureteric reflux and renal malformations: a developmental problem. Clin Genet 2006; 69:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/67\">",
"      Peters CA, Skoog SJ, Arant BS Jr, et al. Summary of the AUA Guideline on Management of Primary Vesicoureteral Reflux in Children. J Urol 2010; 184:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/68\">",
"      Routh JC, Grant FD, Kokorowski P, et al. Costs and consequences of universal sibling screening for vesicoureteral reflux: decision analysis. Pediatrics 2010; 126:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/10/3242/abstract/69\">",
"      Hunziker M, Puri P. Familial vesicoureteral reflux and reflux related morbidity in relatives of index patients with high grade vesicoureteral reflux. J Urol 2012; 188:1463.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6094 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-211.167.112.17-380DEE3FB3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_10_3242=[""].join("\n");
var outline_f3_10_3242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS AND DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Primary VUR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Secondary VUR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Grading",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PRESENTATION, DIAGNOSIS, AND COURSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prenatal presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Our diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Clinical findings and course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Decrease renal parenchyma (scarring)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Postnatal presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Renal scarring and severity of reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ROLE IN RENAL SCARRING AND CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H630866720\">",
"      FURTHER EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H630866948\">",
"      Screening of family members",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6094\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6094|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?14/15/14591\" title=\"algorithm 1\">",
"      Eval uni prenatal hydroneph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?5/2/5166\" title=\"algorithm 2\">",
"      Postnatal evaluation of severe bilateral prenatal hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6094|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/57/6047\" title=\"diagnostic image 1\">",
"      VCUG Grade II reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/7/17535\" title=\"diagnostic image 2\">",
"      VCUG Grade V reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6094|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/22/9569\" title=\"figure 1\">",
"      Normal versus refluxing ureterovesical junctions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/1/11280\" title=\"figure 2\">",
"      Int classification VUR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/16/29952\" title=\"figure 3\">",
"      Probability resolution reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6094|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/53/17247\" title=\"picture 1\">",
"      Moderate VUR on nuclear cystogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6094|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/37/36446\" title=\"table 1\">",
"      Resolution VUR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/31/36350\" title=\"table 2\">",
"      Resolution bilateral VUR girls",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=related_link\">",
"      Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=related_link\">",
"      Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28793?source=related_link\">",
"      Etiology and clinical features of bladder dysfunction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25384?source=related_link\">",
"      Evaluation and diagnosis of bladder dysfunction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=related_link\">",
"      Evaluation of proteinuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41785?source=related_link\">",
"      Management of bladder dysfunction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/62/41961?source=related_link\">",
"      Management of vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=related_link\">",
"      Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/45/3794?source=related_link\">",
"      Patient information: Prenatal hydronephrosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/19/38193?source=related_link\">",
"      Patient information: Vesicoureteral reflux in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34119?source=related_link\">",
"      Postnatal management of antenatal hydronephrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_10_3243="AASLD Rx guidelines HH";
var content_f3_10_3243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of hereditary hemochromatosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        One phlebotomy (500 mL) once every one or two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Check hematocrit (Hct) prior to each phlebotomy; do not allow Hct to fall by more than 20 percent of prior level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Check serum ferritin every 10 to 12 phlebotomies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stop frequent phlebotomy when ferritin reaches 50 to 100 microg/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continue phlebotomies at intervals to keep ferritin between 50 and 100 microg/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid vitamin C and iron supplements; dietary adjustments are unnecessary",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Excerpted from: Bacon BR, et al. Diagnosis and managment of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:328.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_10_3243=[""].join("\n");
var outline_f3_10_3243=null;
var title_f3_10_3244="Therapeutic levels common drugs";
var content_f3_10_3244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly available serum quantitative levels",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug or toxin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Toxic level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acetaminophen",
"       </td>",
"       <td>",
"        &gt;150 mg/L&nbsp;at 4 hours (if later, plot on nomogram)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salicylate",
"       </td>",
"       <td>",
"        &gt;30 mg/dL or 300 mg/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Theophylline",
"       </td>",
"       <td>",
"        &gt;20 mcmol/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenobarbital",
"       </td>",
"       <td>",
"        &gt;50 mg/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"       <td>",
"        &gt;12 mg/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin",
"       </td>",
"       <td>",
"        &gt;20 mg/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valproic acid",
"       </td>",
"       <td>",
"        &gt;150 mg/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digoxin",
"       </td>",
"       <td>",
"        &gt;2.0 ng/L (distribution takes approx. 6 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethanol",
"       </td>",
"       <td>",
"        &gt;100 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethylene glycol",
"       </td>",
"       <td>",
"        &gt;20 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methanol",
"       </td>",
"       <td>",
"        &gt;20 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carboxyhemoglobin",
"       </td>",
"       <td>",
"        &gt;10 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methemoglobin",
"       </td>",
"       <td>",
"        &gt;15 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lithium",
"       </td>",
"       <td>",
"        &gt;2.0 meq/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron",
"       </td>",
"       <td>",
"        &gt;500 mcg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lead",
"       </td>",
"       <td>",
"        &gt;25 mg/dL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_10_3244=[""].join("\n");
var outline_f3_10_3244=null;
var title_f3_10_3245="Drugs affecting cyclosporine";
var content_f3_10_3245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F50343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F50343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs which modify cyclosporine levels",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Cyclosporine levels decreased",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Phenytoin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Phenobarbital",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Carbamazepine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Primidone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rifampin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Nafcillin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Orlistat",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ticlopidine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulfonamides",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulfinpyrazone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Trimethoprim",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Troglidazone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Isoniazid",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          St. John's wort",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Cyclosporine levels increased",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Erythromycin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Clarithromycin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ketoconazole*",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Itraconazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fluconazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diltiazem*",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Verapamil",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Metoclopramide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Nefazodone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Octreotide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Imatinib mesylate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Voriconazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sertraline",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Glipizide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Quinupristin-dalfopristin (Synercid)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Grapefruit juice",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Nicardipine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acetazolamide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Alcohol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Colchicine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ciprofloxacin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Imipenim",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Amiodarone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cimetidine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fluvoxamine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Omeprazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rabeprazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fluoxetine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Allopurinol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Glyburide",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These agents have been purposefully given with cyclosporine in an attempt to reduce cyclosporine dosage and drug costs.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_10_3245=[""].join("\n");
var outline_f3_10_3245=null;
var title_f3_10_3246="Types of chronic diarrhea";
var content_f3_10_3246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of chronic diarrhea classified by typical stool characteristics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Osmotic diarrhea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mg, PO4, SO4 ingestion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbohydrate malabsorption",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Fatty diarrhea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Malabsorption syndromes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mucosal diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Short bowel syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Postresection diarrhea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Small bowel bacterial overgrowth",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mesenteric ischemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Maldigestion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pancreatic exocrine insufficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Inadequate luminal bile acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Inflammatory diarrhea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Inflammatory bowel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ulcerative colitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Crohn's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Diverticulitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ulcerative jejunoileitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Infectious diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pseudomembranous colitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Invasive bacterial infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Tuberculosis, yersinosis, others",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ulcerating viral infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Cytomegalovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Herpes simplex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Amebiasis/other invasive parasites",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ischemic colitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Radiation colitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Neoplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Colon cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lymphoma",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Secretory diarrhea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Laxative abuse (nonosmotic laxatives)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Post-cholecystectomy (from bile salts)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Congenital syndromes (chloridorrhea)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bacterial toxins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ileal bile acid malabsorption",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Inflammatory bowel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ulcerative colitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Crohn's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Microscopic (lymphocytic) colitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Collagenous colitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Diverticulitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vasculitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drugs and poisons",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Disordered motility",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Postvagotomy diarrhea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Postsympathectomy diarrhea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Diabetic autonomic neuropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hyperthyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Irritable bowel syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Neuroendocrine tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Gastrinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            VIPoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Somatostatinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mastocytosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carcinoid syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Medullary carcinoma of thyroid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Neoplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Colon carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Villous adenoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Addison's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Epidemic secretory (Brainerd) diarrhea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Idiopathic secretory diarrhea",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116:1464.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_10_3246=[""].join("\n");
var outline_f3_10_3246=null;
var title_f3_10_3247="Clinical response to gold RA";
var content_f3_10_3247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Beneficial response to gold in RA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 386px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plots of treatment variables from the start of intramuscular gold to the completion of 12 months therapy in 98 patients with rheumatoid arthritis.",
"    <div class=\"footnotes\">",
"     ESR: erythrocyte sedimentation rate.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Wolfe, F, Hawley, DJ, Cathey MA, J Rheumatol 1993; 20:797.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_10_3247=[""].join("\n");
var outline_f3_10_3247=null;
